var title_f5_38_5728="2D TTE Anteriorly angulated 4-chamber view";
var content_f5_38_5728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from an anteriorly angulated four-chamber view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This view is particularly useful for imaging the wall motion of other portions of the septum and for obtaining Doppler flow signals from the left ventricle outflow tract.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5728=[""].join("\n");
var outline_f5_38_5728=null;
var title_f5_38_5729="Dydrogesterone: International drug information";
var content_f5_38_5729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dydrogesterone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1978632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dabroston (HR);",
"     </li>",
"     <li>",
"      Dufaston (IT);",
"     </li>",
"     <li>",
"      Duphaston (AT, AU, BE, CH, CZ, DE, ES, FR, GB, HU, IE, IN, LU, NL, PT, SE, ZA);",
"     </li>",
"     <li>",
"      Terolut (DK, FI, NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Progestin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of progesterone deficiencies; counteract unopposed estrogen in hormone replacement therapy",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 5-40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 10 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10373 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.14-B56043E255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5729=[""].join("\n");
var outline_f5_38_5729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978632\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978626\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978629\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978624\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821178\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978628\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10373\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10373|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_38_5730="Intertrochanteric hip fracture";
var content_f5_38_5730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intertrochanteric hip fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 498px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHyASwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poorwDwP4SvvHeq+Ob7UPHPjew+xeJr6wgt9O1dooUiRlKgKVbGN5HGBgDigD3+ivKv+FN/9VH+JP/g8/wDsKP8AhTf/AFUf4k/+Dz/7CgD1WivKv+FN/wDVR/iT/wCDz/7Cj/hTf/VR/iT/AODz/wCwoA9Voryr/hTf/VR/iT/4PP8A7CmD4PZJ/wCLjfEjH/Yc/wDsKAPWKK8pPwdwB/xcf4k/+Dz/AOwph+EGOT8RviTj/sOf/YUrges0V5J/wqE/9FG+JH/g8/8AsKcvwfJHPxG+JH/g8/8AsKLges0V5R/wp7j/AJKN8Sf/AAef/YUf8Ke44+I/xI/8Hn/2FFwPV6K8o/4U7/1Ub4k/+D3/AOwpR8HM/wDNR/iR/wCDz/7CncD1aivKv+FN/wDVR/iT/wCDz/7Cj/hTf/VR/iT/AODz/wCwoA9Voryr/hTf/VR/iT/4PP8A7Cj/AIU3/wBVH+JP/g8/+woA9Voryr/hTf8A1Uf4k/8Ag8/+wo/4U3/1Uf4k/wDg8/8AsKAPVaK8q/4U3/1Uf4k/+Dz/AOwo/wCFN/8AVR/iT/4PP/sKAPVaK8q/4U3/ANVH+JP/AIPP/sKP+FN/9VH+JP8A4PP/ALCgD1WivKv+FN/9VH+JP/g8/wDsKP8AhTf/AFUf4k/+Dz/7CgD1WivKv+FN/wDVR/iT/wCDz/7Cj/hTf/VR/iT/AODz/wCwoA9Voryr/hTf/VR/iT/4PP8A7Cj/AIU3/wBVH+JP/g8/+woA9Voryr/hTf8A1Uf4k/8Ag8/+wo/4U3/1Uf4k/wDg8/8AsKAPVaK8q/4U3/1Uf4k/+Dz/AOwrF8b/AAwn0HwXr+r2nxE+Ij3On6fcXcSy62SjPHGzAMAgOMgZwRQB7fRXNfDK5nvPht4TuryaWe5n0m0klllcs8jtChLMTySSSSTXS0AFeVfAL/mo/wD2Oepf+069Vryr4Bf81H/7HPUv/adAHqtFFFABRRRQBDcPgBQcE0RfdyRUJIlk3dg22p+BhR0PFTcYx34II6c0xjx71VMwDspI4OM08SbjwRzSuOw/PGeKkU9AKrM3GfSpIfvUgsS7qQOOKjZupqF5AoI7jmncLFrzMDNSo+aqwsrKO/FPXKgE9KLhYuBqC1V9+Fz70wyYOPSncVi4GFLVZJOfrUgf3ouFiWim7qXdTuIWim7qUHNFwFopCaNwxRcBaKKKYBRRRQAUUUUAFFFFABXK/Fj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD0AHwn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QldVQAV5V8Av+aj/9jnqX/tOvVa8q+AX/ADUf/sc9S/8AadAHqtFFFABUV1J5NtLL/cUt+QqWqGu7jpNwEGWYBR+JApMEVtJeSZOOFHP41PfkqAsRbef7vU1BpivFEArDG4oRj0qC/MyXRkWTAUgqpGRWdzS2pUWTJfk8HmrkMhDc81m7zJK7OfmLEsfepVlwzAdaVx2L/mFmB6cYIqWFzjjPBxVENwfanpL1APai4rFx2wjHp6VVZjx7dab5uepJ5zSDnIJzRe40izZsQSnJ+tWs5Tp0qgp2kOuM4q0sm6PPSmmJokUjJ57Zqq0mWyD+FIXwG9+Kr5IcA9M4pNjSL8Unuc4qyrcDms6Nsg49cVcDEKD2ppiaJwxAPNOBJqAMCgPGDUqc44zTuTYdu9/anK+ehpjj5sDpTTleaYh7vjBzihZQwI71C5LAg+nXNIjFm45J4GO9A7FxDmn0xRtUCniqRIUUUUwCiiigAooooAK5X4sf8ks8Zf8AYFvf/RD11Vcr8WP+SWeMv+wLe/8Aoh6AD4T/APJLPBv/AGBbL/0QldVXK/Cf/klng3/sC2X/AKISuqoAK8q+AX/NR/8Asc9S/wDadeq15V8Av+aj/wDY56l/7ToA9VooooAKz9fbZpcrHOAyE49N4rQqlrUTT6TeRoPnMTbR6kDIpPYa3MbTrz5/KJZlRz+pqI3Cm7Cys7IWyVfg1R0l/Me3aE7d5Epyev8A+rFaF61u13CXXGSNwB5Fc6ZtYz4n3CU9CWNIJMM30zVGK5VLy6twQTE5Gc9eT/hUjviT8KGwsa8L5ZRn74x1pGk2tknoaprKBAhB6VJM+9QwPDDNFwsSCXEhWrEUmT6A1lNKQwYjnrU8cwGOfakpBY11GVbnp2ojkx8lVI7jBDdQaQyD7Rtbt6GruKxb3kjkk80dXz26iqqv8uVOSDg1ZicMAR1xikA+IMrD/aq6wKIVJ71SDcAVN5jSQqzfeHXnpTuDJVB2H25qzbkHH5VFB8yZJ+U8H2pYxscrVEsmYFSfTrTGIPFTrg1XOAzNzgUySNvmkHcY5qW1CiTCjgDP51ED+9Yg84p9mf3swGDjaP0oQMuKSX57Cn1DE2WPvUmePeqJHUUzPPtT+1NAFFFFMAooooAK5X4sf8ks8Zf9gW9/9EPXVVyvxY/5JZ4y/wCwLe/+iHoAPhP/AMks8G/9gWy/9EJXVVyvwn/5JZ4N/wCwLZf+iErqqACvKvgF/wA1H/7HPUv/AGnXqteVfAL/AJqP/wBjnqX/ALToA9VooooAKKKKAPPrgCw1u5tEJVVkygHQI/zD9cirmpZ+1pcujL5qgquR8oI6/XPNV/HQ+y+JtImBwLxGgP1QhlP/AI81aOtbodNt/lDzRAjDc5JxiuV6No6Fqkzi7l3tNcuYCM5GCcc565+lS/at0qgnBI7+tM1+1lh01tTLpvhdfMVj85U8H8KyJrgAh1J/vDHOaxlJo1SudPbT/eUnoQat28pKle6niuWt7newZXx3rXhuMSZyCDQpicTRk+YNj6inRENH9KiMmdrA8H0pYW2ORniqvqSXI2+Qr260skgIjfncvDfSoVcZIAOB0oVgWwejVaYi8hCyvz1GaswEbgeR9KzY3wVyecbTVpJcDliCDTTFYtvJg7iMr0YenvVmMhGXd91+CcfrWfG6OuM5wOfersAPkhSwYDofaqTEy1EDG2Dyp4NWFHQZ6frVQMcfKTxwwqWKQlRz0qkyGWlbaO5qFjgAHjPHShnOO1QSysXjwQeeaYkiYjHOcdRUOmhszA9Q5Gc+wp00w2DjnOahsZ8RzueolYZH4Uw6GjCc/XNTZHPHNVbVwy4HPpU+fm6dadyWPwMZpV6UAZ+lIp4poQ+ik3UoqgCiiigArlfix/ySzxl/2Bb3/wBEPXVVyvxY/wCSWeMv+wLe/wDoh6AD4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISuqoAK8q+AX/NR/wDsc9S/9p16rXlXwC/5qP8A9jnqX/tOgD1WiiigAooooA4D4xoyaRpN3GDvgv0XI7B1Zf5lRWhb3sN9bxxQB2RUyjPzzjnn61d+IWmHV/B+p2sakziLzoQvXzEO9QPqVx+NcR8JdYbUNHkDzxtBFDvUHhjvwfxxgfnXHVfLUt3X5HTT1hfsad8RI88ckBlZWKlUbaWTaDgn0JOK87OYY2t1BDQk7UYjIXJx+nFei62rLI+wsjksHwuSB0Neda8s1rrN/Mm9zG5UKgySvBwffqa56srG9NDtOlHmsmSDgkCtyzlDjHQtkfjXMrdwo4ZCCGG5WHSke+aG9B3qYnGVweQ3pWKqJGrhc7exukYNE7c549jVmOcncrfeWuKi1FXbeDhs8joa2LPUVlVGL/MOD7j1rSNVMzlTaOoEn7ncMe+KgS4AfaTweRVK2ugAUJ4xkfSqF5c7HwOo/UVftFuQoHTpKHXcDz3p08uP0OKxtPuxJEJEJJ6MKs3FwSVZTkDqPUVpz3RPKbdkQ2XwcDmtaPacGJhj09DWN4eaOaTYXGCPlrVCeXIyhcofT+dWnoQ9ywMKwVgQzfdNPQkOVx1qKNt4CNjK8qwHUVO20qrkbWHeqUiGSqdykZ6VUmkAf0A9aUy/dGeT+VVbyQYY+3B9aq4rEtxIPLlbP3V4/Gmacxa0vjkcTn8OBVFrhfsUrE9Rg/WrehOjQ6mmQfmD4+qg1UXdDasjRs2Ct2GDV4MP+BVmwArIwJ7Crv4iqIaJw/GB0pw6cVXQ45/n3qRX796aJJaepyKhVs1KppiHUUUVQBXK/Fj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD0AHwn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QldVQAV5V8Av+aj/9jnqX/tOvVa8q+AX/ADUf/sc9S/8AadAHqtFFFABRRRQBFMxUZFeARW6+E/ibdaVKri3Mx1CzAGBJbOSWQY67WLLj2FfQMw3Ia4P4ieFX8U6ZbNp94NP17TpfP0+95wjdGRsc7GHBx3APOMVhiKXtI6bo2o1OSVnsyxqF7awWF/q+R5BJaMt8u9gD1z0HTjuTXj1tqiX0329HleK9bJRk2lGHVj6/Wul/s74g3VjBp2vaY8q2z7mubG5gnjvV/uSJIQ6jPOV64xgVXv8Awzr1stwun+FdSkhctL5Zu7fYWHA/jJH0A9q4asKkrWT+46oShHRs5vVYnjIltYkmRzidXbCqvqD2JpY9PRLmFbiF0BUmJm/iyO3rnpRZ60unX/2bVbGbSr91+e1uoWDE+qMwAbjsCa6/TXt77YtriduuwjGPp7+9c3szfnPONTkudNLzvHIluZWwcbl2DoS2OO9amhavBdIskEiyJuxnNeuW0MGoWUtncwJ5ckflshAwwrzXxD4OXRIpbrSkAPV4AAA49j61nUpSh70TSM1L3WbcEwMYKn3U/wBKg1CXeFdMhl7d/pXO+G9bhvIG2GQbW2SJKNrKfcHv71rXw3oXjYluhx/Omp6EOFmW9MuTDMGXPlt1GOhrWaQmZWU4Q8/SuUsLndLtb5X/AEaun02RWYLIflP6VrTndWInHU6LQoS0u6J/m67f8K6uyxK28A89RiuY02Bk/eRsVkQ569RW9pd2sckqyZA3bq7IM56i7F2SNRMoj4OelRajJsIUfiKdaTLcXLMpyo6ZPasvWdQUSuEG5hnGen41V9DJRbdhlzcYcR7sjq3sKzJ78yyDGTjgVRNyZllO7cc7M/z/AKVCk6Qvknkfzqee5ry2NpVDKI2bCscH8afpdyYdRuImwA0a8/QkVh/2rGXyjZI7U/7Sh1OKVSQrkpz78j9RWsJdCeW52c0nlzAKxOR6083m0YY84rMhkLMvc471JIj7yx6VrcxsaCXTE+oq9E28A9/SsATSRgCPYTnknoK0LYTOufPCtnoBiqQmjXQcDrip061kmSaPBMm4djuFX7abzIgxyDnFUQ0WhRSAgilqhBXK/Fj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD0AHwn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QldVQAV5V8Av+aj/9jnqX/tOvVa8q+AX/ADUf/sc9S/8AadAHZeIfGGm6FqUOn3MWpXV7LCZxDY2M1ywjDBdzeWpwMnHNUP8AhYenf9AfxV/4Ibv/AON1m+IP+Sqj/sX2/wDSqOp9xraFJSV7kOTuW/8AhYenf9AfxT/4Ibv/AON0D4had/0B/FP/AIIbv/43VUE0Zq/YLuLmZa/4WBp5GP7H8U/+CK7/APjdUJ/Hel+YT/ZXilSf+oDdf/EVPn2FUrzjmj2C7hzMf/wnmmY/5Bnin/wRXX/xFL/wnmmdtN8UD/uBXX/xFVFcY/xFO3+mKPYxFzMfqXjDQNVsZbLVtC8Q3tnIMPDP4fuXU/gU/WvJ9YjfwzqEd34UtfEkuiZZ5Ir3S7hDYgDOd7KN0fXrkjA69vU9w+tPjmZG3KMEdCKyq4SFVWb17mtKtOm9Nuxk+C/FWn6+ioHjWd1VlaMcN7+/eun1WBGgkSQBsZUjH615j4g8IyabrKeJPCMSpNGxludOUYSX1aMdj1JUde3PB1tA8Uz6vb200sm4lt3TGAOCuPb/AArx6tOVF8lT5eZ6EJRqLmh/wxxuvaYdG1H7dA/m29w5V1x9w56Ef1rUtLpVTMqoU6M6E8++K6nxX4Zt9ZtnmsHMdyw3HC459eO1edaIzW1zNZzqIr22by54mbh19fQg+/SuDl5JW6HXfmjc2Htw0++LlSc5rpLBSUUkjdjvWTaxRRyAwIY4358otkKf9k+lbsVs7RKUbH1rWnGzInqjotMlOzk4x0q0xbG7kH2NY+mvJEfLmB571uqm6IjHIrpT0MWS2dz9milY91xXNanc+Zc4i/iB3cd8Vev5jCrKSQAD3rHU7pGJ6g9voKly6AktyA3AtbQtIwXOWOeO/wD9auZvdaimJCScFtox1JPYDv8ASs3x1qsshNlZK81xLKtvDGn3nc8AD6k16x8P/AGneErGCa8jjvdfK5lunG4RMf4YgfugdMjk8n2DpQlWlaOyCpKNKPNLd9Dn9D8H65cosj2v2SNuQblwjH/gIyR+NbkHg7Vy4jeWzXawdZBIW5ByOMZrt/ObPzEmnhs4INehGhGJxOvJ6nHzzvZ3Pk3kTQzgA7eoIPcHuKsJeNMuI+RWt4qsmvtK8+IZntcuB/eX+If1/CuW02XK/L0zSfuuxSfMrm3boUlB4OfWtO1Y+aAQpzxyKzLcM656Veh+UZxk+uOtUiWaWxQMgRZ68dafG4YDaNo9KjQLIoLKVbrUqxhWyKoksxnC89qesgJxUK8inRxfNmmST1yvxY/5JZ4y/wCwLe/+iHrqq5X4sf8AJLPGX/YFvf8A0Q9UIPhP/wAks8G/9gWy/wDRCV1Vcr8J/wDklng3/sC2X/ohK6qgAryr4Bf81H/7HPUv/adeq15V8Av+aj/9jnqX/tOgDQ8Qf8lVH/Yvt/6Vx1PUPiD/AJKsP+xfb/0rjqxwa66Pwmb3EpQM0uOaXFaiD0qnqC/ISKuVHcpvhPtSAxg/WnBxVaTKSMKQOakRb30ZqsH4pRIaALSSFWBBrifFG7QtdSeGHdpurk7gg/497tRncPZ0zkeqmut8w/5Nc/48kJ0vShsDbtThznsNr5NcuNipUJX6am+Fk1VSXU6rwxeC6t4hMQQGGDnhge9cD8X/AA7f6XdWviHSmQmOQpMjKWWRf7rY5A9D2Ndz4c00W+mqUfrgDHY9a6O/iivLK8srlN8U0f3T1zjtXgpOcbPc9PmUJXWx4j4d1feg8yPfYSfdwwbyT9TzXd6URceUobG7pzXAaZbf2bqV7pwWPaj5iZxw4/un0I9e4+ldTpkL2wL2zsVBDiIn7h749RUUm7am00uh2jxNEUEwJU/xVsW9vsKkHcrDINVLOVb2zSTA2sBkH+Fvar1i/lymF846jNdaRySbOc8RriWTqFwR07VgyS+TYS3DkgeUxB9wBXVeJEG9snrzXCa/KU8PtGn3mbZnrjnBrnm7NmsdUiH4OaKNU8TXfiC8y8GmsVtww4MzA/N/wFc/iw9K9oL7mJNcb8N7MaX4LsYx9+ctcv8AVjx+gFdVG+RXp4Sn7OlFdXr95wYmpz1H2WhZB9KejYb271XBqRTmugxL0DAPg8g1xer6cdI1bMQ/0OfLJ/snuv8AntXXRNx7il1Oxj1Kxa3kJUnDI4GdpHQ1M48yLhLlZz9k4Yd8Vd+0yLH+72M3HDDge9YcPnWl49rcqVkU4OP0I9jW5bJzyPm/mKzRo0izDNcMnEo3D0AFPgu5VmSOZSQxxnHINJBEd53qCD61eWCNGDKgz6jtVkMkjfnH51ZXkCoI0qdRgVSJYtcr8WP+SWeMv+wLe/8Aoh66quV+LH/JLPGX/YFvf/RD0xB8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVUAFeVfAL/mo//Y56l/7Tr1WvKvgF/wA1H/7HPUv/AGnQBo6//wAlWH/Yvt/6Vx1aPWquvf8AJVh/2L7f+lUdXCOTXVS+Eze4mM0YpaXFaCEA4pcZH1opQPzpgYupWp3blFZxVgcFTmurZFcYYVE1pET0pCsc1tOOlAAIOa6U2URHSqtxpoIJWkFjGHXNc74+Z007SGQA41OIk+g2SZrp5YWjPzA4rm/iICnhGa4U7Ta3EE2cZ4DhT+jVz4pXoTXkzXD6VY+p2mmN/wAS+NIQN6LvXHp/EPzFTT3m9o3UN5jYOVHB7HFcf4Y1cuIpVI2lSBzng/eB/H+ddWjqTI5wsbfMhP8ACw/zj8a8DfVHqWtozyv4hSx6d4kEz58l1O4qOWHXjFWvD+px+WjB/wB0+WQ53YP+BBBqj8Vr37Nq9rcRpnGG2t2weSKr6EwF1NHA6mKRVmRNo+T1A9j+lYX5ZtHRa8Ez1bQdRUloQAQeqnuPUV0M8YQoylg2NyMen0rg/D7obfZz5kPC54IBOR+Fd/bTie13DovDjrtPr9K7YO6OSasyjr6eZbxT7dqsOR6ZrzfxqfsOlyOxIXzADj8K9Xvonn0qWNQPNKfKB2PUY/WvN/iDZm88PTI67XZMkehrKtHRtF0XsmdxpI8rSNPQdraP/wBBFXkbHSsXw5di/wDDGjXYP+ts4ifqFAP6g1qRtXsRs0rHlPRu5eVsipUaqsR7VYRWOMCmBajbB9quxNxjuKoKDU0T9BnB7e9Ayl4mtBJDFeJ/rYTtY+qH/A8/nTLd98aP3xWrLieCSFwMSKVrEsSUjMbA71JBHvmoasy07qxsREbFIBIPY1chyevBrOtZGK7QcY9utXEUj+JvTk00JlxRS1HG+eD1qSqEFcr8WP8AklnjL/sC3v8A6Ieuqrlfix/ySzxl/wBgW9/9EPQAfCf/AJJZ4N/7Atl/6ISuqrlfhP8A8ks8G/8AYFsv/RCV1VABXlXwC/5qP/2Oepf+069Vryr4Bf8ANR/+xz1L/wBp0AaWu/8AJVx/2L7f+lUdXCOaqa5/yVcf9i+3/pVHV3HNdVL4TJ7jQPb8qdj0PFKBxS1oAg9aUUYpaAExS4paKACgUUUgILm1WZTxzXPavpcV7ZXen3in7PcxtE5XqAe49xwfwrqKiuIFlQ5HND13DbVHhHgi8l0m5v8Aw3q48jULKfKlvuzRt911PZWHfoDXd2msWotRBPKFDMMAnHT/APVVnxV4Xsddj2XSeTfIhW2vY+JISfcdVz1U8de/NeNWllcpLJDdXEg1GCVoJAGzllJBA9elfO4ug8LJW1i9j2KFVYhNvRrc7HxeyapYy3Kqsi2jlvl5Jjbgn+RNY8cghggvNP2pMkRjjJOVLYwNw9s/lW14dtbxI0iSErzlvMXCup4IJ78Uuv8AhVLGxSOzuXeMyh0Cn5oz/cJ7qO1ccve942jJL3blrwZfXc+mQT3abbyE+TcRls7G+vcE8g+hr0WyupItsiHORhhjhhXn2kWxgeQSpuMkYDHHLY5rr7SZYUiLZe3YjB9Aa3pSujKdmddbXiz2xtwOSCI2PUHqB+dcz4lTzrV3IO4ffX9DU7TPbXAUHcrdPrVa+vReQuSuyQZDgnqPWtJO+hMY2dyv8PZh/YUtgeDZTsi/7jfOv8yPwrqIgS2AK4Hwhciz8Vy2zn5byLYvPBdMsv6Fq9O0e1Mkm4jjNd+FnzUl5afd/wAA4cTDlqPz1LdhYFgGbgVrJbRoMYqVFCqAOgpa3M7Efkp0xVC7h8ttyjArTqK4jEiEd6AM9G3D3qjdw+Xd+cg+WTqPerPKPjuKnKCVSh7jj69qTVwTsRW/GCKvLjGR0rOt22jHcVfiIMY7E9KENkgODmpd+UyBzUNSwngimIWIsVy1cx8WP+SWeMv+wLe/+iHrqq5X4sf8ks8Zf9gW9/8ARD0AHwn/AOSWeDf+wLZf+iErqq5X4T/8ks8G/wDYFsv/AEQldVQAV5V8Av8Amo//AGOepf8AtOvVa8q+AX/NR/8Asc9S/wDadAGprfPxYX/sX2/9Ko6vEc1R1r/krK/9i+3/AKVR1fPWuql8Jm9wpKM0VoIWijpS4oASinAUo4pANxS4pwoxSAQClxSgUuDigZj62Y7eGW4k+5EjSNjrgDJ/lXHeCtA0+4hm8R6na3l3qGqTvObW3jLrB22r78ctXZ67AtzazQSNtjljZGb0BBBP615VPZX3ji8thLPcw6JYwC1SO2uXiWYqMNIQpGQxyfxrnrYSeLkoppRWrb/rfsb0J8l2tz0+O/8ADflJFPpd/YgfKd0WQPcnJqSx0q01F51spI7iJCCvGC49geeK8wl+FlrGjDStV1SyY8jyrpwM/nRpc3i3wWAl7E3iDTF4Dh/Lu4h/syfx/Rufeuapk0n8Eoy/8lf+X5Gn1nl3v+f/AAT0278Pi3YKNqt1G7sapSWYiUIQuzoAM7aTwb4607XgRb3NxcRxcyw3I2XVmSf4wSdy+4yPftXaKIrweVIqNjjcB970NcEqLpycZKzXR7miqaX6HGXcMotcDBZOUYHris6WVZ1EisqydHTcM59cV3L6T5Ks64Ze6+tc9q2mhUaWACPPcAZB96iUWjaE09DzrXLt9KvLTUIxlreVZOO+DyPxHH4179oD29zp1veWbiS3uI1kjYd1IyK8X1rShqFpKrJskA+ZcfqK0fgz4il0W+PhTWHxBKxfTpWPGerRZ9+o/EelVhavs58r2f5hiaPPHmW6PaqKKK9U84KDRRQBRvYc/OvUDmo7ckFc8dq0WAIqjNGUOR/+qgCpcIYrk8cPyKt2/CCnSRrOoB4Ocg+lNiyuVbgj1pDJqmiGFye9JEvygnrUlMQVyvxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9AB8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVUAFeVfAL/mo//Y56l/7Tr1WvKvgF/wA1H/7HPUv/AGnQBqa3/wAlYH/Yvt/6VR1e71S1n/krC+n/AAj7f+lUdaBHNdNL4TN7jccUoFOxSgVpcBoFLine+KAuT6UrgJjminAdepFOCn3FADQKUDnGaeABR0pCGgAj604KMgdRSipLdd0gBOF7n0FAHBfEe5muo5dC019lzNFmeQDJRW+6g925z6L9a5LQJta8GXEKalbNPp33JAp3rg+mOVPseK0PDusC61PVdVm+YXF48iMB91M7U/IACuytolZGgIQCR/M5HRv8K8j6/WVRyhL3e3R/L9dz1YQjTgouN+/f7zas47DVtNS+0ycSWx6Y+8h/usOxqrLbKFI2+Yp4IIrnLOZvDeoR6lAmy1eQpfRBTgx5wWA/2ev512k+xJQysrQygPHIDlWU9CK9OlV54c8f+G8jlnHlfkeQ/EXwXcRXMXiLwzK1lqtsd0csY+96qw7qehBrsvhn4uh8RaOL+RTAPN+z3tsTlrK4A7f7DdQfw6iunZI5FKMMowwRXkni22v/AAB4g/4SfQohLbNhNRtMZW4hzzn/AGhyQe1a1KSxcFF/GtvPy/yMG/ZO62e/+Z7xgqgBUMg4Ydcj1qhcwqsojZEWJ+RzmqvgvWrfXNLSa1bdazL5tqSeWjP8Pvg8e1bVxCsyFCG+g7V4jVza7i7M4zVrJbdt7DEYP315K+/09a5DxDoiyx5cBZUO+ORD+O5SPz9q9CuCp823O4Mp4LdAfTNZUlgphbKEL1ZBztP94CuWcVsdtOempe+Hfi/+11Ol6m23VrdM7j0uEH8Y9/Ufj9O4rwfVtLkWdLzS5fJu4G8yOSI9CO4/qPfnivQ/BXjiDWBHY6rss9YAA2E4Sf3jPf8A3ev1rsw2Iv7k9/zOevQt70djtaKKK7TlCo5lyM1JSMMgigCuvWnFQ5AP50BcE0+PrQA4cdadTWOOPWhTxzSAdXK/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9MA+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqACvKvgF/zUf/ALHPUv8A2nXqteVfAL/mo/8A2Oepf+06ANbWP+Ssr/2AG/8ASpK0sc1nat/yVlf+wA3/AKVJWoR2zXRT+Eze4zHSlx/n2p4qtq+o2OiabJqGr3SW1qn8THlj/dUdWPsKptJXY4xcmoxV2+hYCn3wDS7OOnFeYn4karq11t0LTYbazOdj3S+ZK3oSAdo+nNadrq3i+dpSslkNo+UG1AyfzrjlmFJPS7O2pl1el/EST7X1O8xigcVxumeNJ4kdPEVikMkQBlktQcJyByCT9etdqNrokkRDxuoZWXkMD0IrelXhWV4M5KlOVN2kNxzyOaMU7FKASfWtSBoHNYfj7WBoPg3UboSKl1MhtrYE8tI4I4HsNzf8BrU1bU7HR4Fl1CcIz/6uJeZJD/sj09+g9a8l8Z6jP4n1iyEsCpaW5IjjDEgZ5Yk+pAArixmJVGDS+JnRhqPtJq+wmgWUln4ViV1YTFUyp9Sc/wBa6e3vLi4jkkjO/ZJt46iqckBMVvB/tq55xnHarVhII7aQwIFYP+ZzXix91WPRk7u5uo8d7pbiT7465HSneG5lWCfRrhhvtG3QA/8APJuVx7DkfhWZBfxF5MttckKVx1p3iKxuhc2mqaXJ5dxEp2ttyH55Vh3H+RXfhMSqT97Z/wBXMHDm906K7SazZXGSjdP8KzdZtBqFs8EqAiRcY7Vbt9cTxD4e8+OPyLm3fyp7fOdh7Eex7GoUZ2VZNx+Xp7V7VO97nLKNtJI8++GGqt4b1mbwbfyGKSGdrvS2bpIh5kiz6jBI9s17nFKJEWRCMOAw+hrwL4v2E0Is/Eemf8f2lzLdLt77Tkj6EA169oOs22o2VtdWTj7JcQpcwn1RxkD8DkVzZhS5Zqqvtb+q/wAzOnquR7r8ixqEez7TLDgbBkjNVLaRLjTxNAwjdB8yE4x7isvXr8JPKFf7/GKq2crReQ6kqjcEegNeLJpnZBXLOo2Jmk8wDBJzvjGN3v7Gub1fQ4roMr7XbIZdw2kEdwR3rurG5hmt/J84xTgkEZG1iOuf5/jU0+mCVCNg34yVOCrf59aXJc0VWzszkPD3jjUNCkFn4iWa8sh927AJliHo4/iHv1+tem6XqdjqtsLjTbuG6hP8UThsex9D7GvPtS0w7SvlElf4c8r9PX6Vw93bz6ZOdR0S8+xTBvmeJtgP+yw6fmK1hiJ0tJar8RSowqarRn0LRXnPhv4jIYo4fEka28pHFxEN0be5AyR+GR9K76yu7e+t1uLKeK4gb7skThlP4iu+nVjUV4s4505Q3RLIvOaSP71SdRUXQ+4rQgkIBpnKY5yPWpKCKAAdK5X4sf8AJLPGX/YFvf8A0Q9dSoI6nNct8WP+SWeMv+wLe/8Aoh6AD4T/APJLPBv/AGBbL/0QldVXK/Cf/klng3/sC2X/AKISuqoAK8q+AX/NR/8Asc9S/wDadeq15V8Av+aj/wDY56l/7ToA19W/5Kyv/YAb/wBKkrVxzWXqv/JWV/7ALf8ApUla+Oa3p/CZvcfbRh5QGOB1Jr5I8T+O7rxX4gXUtQitvs6y+XBZvKQI48/dVs8t3Jxye2OK+uYI/M3x5x5ilc+mRjP61+duvW15Yahc2F2siT6dcvDOgONjq208/UYzXJjYSqcsU7I97IcZDBSqVnHmlZJdGu9vl+R9SeCvEXhtLYi+1BbRozlUmQhsemQMHHTj64rr4PEmm3mrJZac8svyh9yqcEHoQe4PrXyHpepvLqGxZ8wRsN+bjfkH0G0bhyRx6A17t8HvE1lELaGYkz20RR95BDR+YSrIe6jOD6V5qTvyzXQ9/F4TC4inLE0OZvXTT71pqrnrd7ZQ5acxqtxtG7PQjsGrlfCnipvDWuyaJrYkGjzBpLacJu+zvnJQgc7CDken0zjuTNb3AuGhmRxJ6emK8z+I2mM6fbLIAvayxyLs68Dn26Vnzzoy54bo+ZUFU9yaPSLjxp4XtmKyaxCxXkrGjtj8hXP3vj9r6NW0EJb2rcC5uY90r/7kecAe7Z+lef22lW+pyiabCRyAO2OdwHf6ZroUki0rTFmNmXjDeTCsaAcnjk9ST6Vr9fxFV8q0v2Ip4OLmoRTbCaKW6l+1M8s88h5lmO53P1PYenT0re0/RXe4tIggOWBfIzye59DWhoOnJcf61RHBDjnOQT6D1q9PfPFdpbaZsLMwLy9gKztbfcbb2sZt/p0yNcLFOJbxgyxKqfc9SB7Ckgs1hsreBz5TQndM0nG9s8VJcRy214gS8ha7mOFCE4/WsDWm26tM8hLpGQioRnc3frUyklqy4wclp6lvVI7WzZnjn2SEjleQBUk2tLZWCQyzLKsuSpJyRx1+nSuYudPFw0wYg55KE/KPbIrEMLJeCBIyxjAUsuTx7ZrJ1GtUi40r6M6+41Q6XqrXqELuhUXca9JIz1YY6lSd3510rXGVMIf514yO/wBK4QyBZPOfBSJdjAjrnGQP0pX1xLG1ijRnaa3la3x6qD8p/FdtfQZTXlXi6T3jt6f8B/mYYmnZKR0etbXtZ7eZQUkUrjOeornPhnqZj8JahoW/ZeaBcnax6G1kLOh/Btw/Ks7xH4hlZDHaowOMbj/DVf4aXFvc+P5rWKRXe80Wf7XETu5jkQo59OpFevmWH/2STe+5wpWmpL0Oue6e5t7hjulZ8fw9OeK2LHWBiG2uLC6SVUwHC7kf6EdPxq3Y6VHFokcskkatKjZGQA20/e+mP5VzOnXmixziB7lPOjBPmSP8qZ9TnAFfG3aep2xirHYRwW5/fJl3fGVZsOnoQSOSD+nFXIdRWIY+2Kkqtk72Gw+4HY+o6V5VqHxKsLG7ezS709mjbB8h/NOPUbc1Db+MdPuPNmha9mfHzFLeVsn0+6AKtTj0LcG9z2G/vHdNzRIYz1aLJ/TqPwrAvBHdQsI41YvkEOfvexBrzGw+KlpDO0N3LbQjOFWWZk/PK9a6ODxvpN+uCyAHo8cyzKP6ihzi1e4KDjoZ+sQxQzi3RGilAysTDII7lT3x6da57TtbvPD18smi6sthqEzYMGxjBKewPBBP15967K51SwvIQsxSTYcxyfwk+x7GszRNH/tK4ubi6hMbK48tgwIl9wOx7VzST5k4M3i1a0kd14Y+JWtXVkjapoCvJ0LwS+Xn3w2R+tdRZ+OrGfi6sr22f3QOPzU/0rmvD1rHH9naJoJIMsrmQEhe2PY9q1Uj02N52aF1jVsO0cZYKcZ69D+FejSq1LK7ucdSnBvRHXWWtadeJmC7jPs52H8jg1ojBAIOR7Vxcel28oSa0YSxkcEjg1dtQ0NzEqtJGHO1kDYFdkJuWjOaUEtjqK5X4sf8ks8Zf9gW9/8ARD10f+rRRuY5OMk5rnPix/ySvxl/2Bbz/wBEPWhmHwn/AOSWeDf+wLZf+iErqq5X4T/8ks8G/wDYFsv/AEQldVQAV5V8Av8Amo//AGOepf8AtOvVa8q+AX/NR/8Asc9S/wDadAGzqf8AyVpf+wC3/pUlbB61kal/yVlf+wC3/pSlbJHNbw+EjqYvjPW28N+GLq/hAN2SsFuCMjzGOAfw5P4V5b4c0Wa/vby61A/bHmQfazMoc3HGMOSPmGOMHtxXXfGBmmj0KwXo0z3D47bQFX/0I1c8KQpFYFVIXzQRn8M15GMqOVflvoj2cFV+r0OaG8t/Q+fL74K3+q+IbtPD97bWemZYxQ3DSf6MSSQivhiU3Y5POOuSMnznSNSudC1WeOHzmubcvnyWL+W/IJUEA7SM57Yr7KiMUFkX4UTOVTb1Y+teJ/Fz4TPOlx4h8JpcS6rJIJ7i1BGJt/DlF/vbsEjoQTgDGDPPGp7sjsoY32E/aUtLdN9Oyv8Al22MjTvirq0MyQxQq8chGWaxVYhkZ5YYIH416Z4N1y38RaVOJIAlzE4S6QA7VJB2sMk8MAfoQfavl5FvJLafTZdMuhcIwNwW3loyDjJQD5cGvV/hfrRhub2KOZBJdW8YYkYPmRsM4HbgmsZwcGlf9T3WqWY4eXJFKSs7pcvdNNNK9tHfXX019Rlt/wCzLtolGIGY7CBwAecflj8q2dLtl1KSwSeVvJtMyHJ4ye9XdPs7fULGGOVwXkQLuHZvUfiBVfw7EAXglAVvNMeT7N/+upinF+6fLynKk3y7rQ6DUZIbW3UwQutoFxjoXPr/APXrGmvns7O4lKIHYBdqep6KKteJbvz1jihYCNXxnt161jX/AM09hHBkNMoEIPPJ+9Iaqd9+pnGEkk59See4ubSCwuJvKEm3cwB545x9ay9Wu2WKa8ulXlt6Kw4yf1q/q066dch2y83lhIY2Gdo/vEeprk/E+sC3hh/taRnuQxEUaLliP8+vSspvlRtTi5M14J2h8ORvqZijuJZNy7Rg7fcdu1YdzeOkyRwEyySsp4/hFc3ea1d6pIkSqGzwkSksTz046mtbTND8ZakVk0zT3msw3MkKJyRwQGYgHHTjIqYxnU+BXNXy0177sX5jL/Zd1HK65MuwEH3GOKyp7jyr3U7nO6NXRcFeAxjGefXgcVvReD/E4MazaDIk28v51xdRhAT3OCc/lXKXU13bXeoafdJFL9hvpBdvCGzI/AJUnGBjAHHbOa9LLqjwNb21VPls16nNUlGsuSL1E1GSeWza4EL4YkLEGALY689vx61f8HfEDwn4TS5k0fwzrh1C8yt1LLEm+YAcKJC2AufTj2rTEIaKKO2REtthwmPug/1+tU10RIJopCTLGq7drdj/AJNTjM0rYiWukVsv63MnQ2sznfFvi3xl4ltoY2t9P0+zC7IreGLzpFjP952PJ+gArnW8CatrU+laOLh7i+vJCiLcOwjgUfekKr8oUDJ6H9a9oi0KO2mt7iSIAM8ZI4+XIIArc0CCD/hPLyaKPaINMWNCRyC0vzY+oVa5aMZTqLmdiqklTpvlNfwd4c0nwRo0OmeHbdIQqgTXIUCa5fu7t1OT26DoK6vT9WkVwJXZh/tHNY5o969k8q/U7Ge3sdVgCXdtBcxf3Jow4/I1xviH4Q+CNbVy+hwWNyRgXGnf6M6n1+TCn/gQIq/Y37wMAScV0dpfRzAfMAalxUt0aRm1sz58174N+KvDUs114T1OPWdOA3vY3SiOdh/dGBsY47/L9DWD4U+I8EF0LaLT1Jik2XEMoaKWEg4II7EH2r6uHI4r5V/am8LzaR4w0rxP4fLWdzeIyyvD8u6ZCDub/eUjjvtOa4MRhIxXPDT8juoYiU3yT1PbraSLUNMj1GFklBX5kT5SM+uKRrZrIMIrg26zgNjeGUn8eK8e8C/EVvEJhSSW2sNbCbbm2Z/LSXGMOmeMH07HIr0O11e4N4Le8t2V1HAVlVceuTxWSqWduo3BnQ2l+9uJIUWe4eFgGZzgMCM5X1FWLS9Nxq1mXiMasxypOSPlNcQNSNxNf20U1o0uS42zBwvcA4OfpXQ6W+2402RUdEYsfmwcEqTgmurDycpJGNSNtTv52+aIDuT/ACrnfit/ySvxl/2Br3/0Q9a3nBmgY93GcVkfFb/klnjL/sDXn/oh67HozmHfCf8A5JZ4N/7Atl/6ISuqrlfhP/ySzwb/ANgWy/8ARCV1VAgryr4Bf81H/wCxz1L/ANp16rXlXwC/5qP/ANjnqX/tOgDb1H/krS/9gFv/AEpStsLlqxL/AP5K4v8A2AG/9KUrdXh62hsQzzvxnM134ye2XOLW2RQMdyC5/mKow+c2nxw2zsFX5j6gniotSleL4naxDcgqfPjkjLcbo3jXBHtwRXQyaUwlt1RcRo2N49ck4z9K+fqNyqTb7s9ZLlhFeSM5kFlHanzXcRyyAFjnqMCny3bGQxkYGwLlhxke31xVXUGuLa8njdGktPvIy/wtnkH+dOZ4poynm7iuSMDkHr/gKV7Ct1Ok0F7WQmWO1gkLDyyzr2Bz/OvBvjfbQeGPibZ3sFvaRRXtqLiSPmOIvkq43Do2Np49eete26MjabpGDu+Xn5u5NeDftKpcnR9Nv5G3Ib11w46ZTgfkD0rSn78lG525fiZYepKtzbLz1PTvh54r0jxLHHpttaS2F7aRPPtE3mxyxrjJD8HOT0I989q1ItRtJ5rhrcmR7aXLMB98kHFfM3w68Qx6PfQSLcvnEisqII38uRMEKM4JHXrzXvXhJYf7N861uY7iNwZN6HliOxHYj0NJKyfM9Uehj8LRUHiYX5ZWsr3s/tJvX8zprYfby8c6fuAVjH+yByf1qvHMrXc9yUCx2y+WDnooPCirZc6fpTM5wQpYHHcgf41itcA6HGEG5p5Sw98etJPqzyIxlUvKW36le6nYibVr/LSSNiNB3I6Vx02lXPiHVh5jzMzuFEUQ3E5/hHqffoBWj4rvpLqO1iiXYsbCIZHVieTXrnw00S303QYNRZN13dJuVm6pHngD64yT7gdqeHw6xE9dkROv7GmpLd7Fbwr4AtNNiR9RRTJt2/Z4zwB6Mw6+4HHqTXbBtqJHEqpGgCqijAUDoAPT2oJyaSvchCMFaKPKnOU3eTKd4C618+eM9Mms/HOvSWpOy6nEkkeOrFVP9c19FSx7vcV5N8RdMa38VPcE/JdxRXEfu0eEkH5BT+Nc2Mhz07eZthZ8k/U43Qp7gx+RfxEyxsQsqD/Wgf1Fdbp0IuNShVlBiI/Go10iNWtnw21Ji+4H+Fhz/Sr9tFJpt6mV8xGbcWHXjtXj8jjueg5J7HVNYY0b98CTu2hkXIBB4yfpWHoBDeNNXCEGJLGJI8fxDzDk/wAq6y0uGutGaG3U+dKC6qT90gHoPwrkvDS7PEl/5hImltgeR12vyR+YrspJKpH+uhy1XeErnTGkoPWivROASpYpniIKk1HRQBuWGrFflk6Vyfx7toNQ+Gs142SbG6t7gY64MgjYf98yNWgODxXE/GXWWHhmLwvajzb/AFuRFKf884VYMzn6kAD8fSssRb2Ur9jbDtupG3c8q1jwfpuqOYSg85c4fB+b8RyDWSPhzttmU3DSruCYZmJz6etet65on2J0kM8fn4Dp+7OHwoyuQcZ4rJXy3Ek8k0m5Dh2L5JXrXiJOOl7Hr899TlvAujHw94604xxqsbEwyKFwGGM8/TAPNe6RPFFe6alt5ixmSQmN/wCE7TXnWl29u3jyyjuYXa1hRrhp0OdilcLnHBGWH513N1MsOr6Um9ZAbgx78YbhSOR9K7cF7s1fuc2IfN9x3du4xbqc/eLdewFUfiqc/Cvxl1/5At51/wCuD0sEuZ4F7FWx+lM+KRz8KvGJzk/2Necj/rg9epU0m0ef0JvhP/ySzwb/ANgWy/8ARCV1Vcr8J/8Aklng3/sC2X/ohK6qkIK8q+AX/NR/+xz1L/2nXqteVfAL/mo//Y56l/7ToA277/krq/8AYAb/ANKUrdPWsO+H/F3F/wCwC3/pStbh6mtYbEHm/wAZ7K4t30jxJZxeZHa7ra8wOVjYgo30Dbh/wIVc8Ma6NQ09rYncQfMEg7n/APVXdzwQXlrPaXaCS2nQxyIejKRgivF9N0u58FfEE6RdytLp95GXtJT0IAPb1xwfcV5ONpOnU9otpb+p6WHmqlP2b3j+X/AOp1bTJZVUW0jRs0eTn7p/+vzVnS/DRtIJZbl2ZcDbkjLVaeSOSz8qXLjcGUDrmmahrZW0C8YjcDA/u+9ccu7G+bZFXxTrlvawwRrGY41O7rlm+tY9qula9amLUora5t3KlobmJZEyCSDg/wA64/xhqM97qbwQsqnkFjnA4yP51Y0G3nTTizOzTEDJI9unvXPGu3PTodMKfJFNbnH/ALSvgHTfDWi6RrmgQmzje6FuywO3kplCykLztOVPIP4Vy3w2+IX9mzCOW2+0wyEecqMVkTIwSueCOM4P5ivdI9QTW/CWo6TqNtFdwMoWW1mGQcHIP5jIPUHBBr5j+JuiW/hDxaBo5uDaTxrcQm5XLxkkho92fm2kdeuCM+/p07V4eZ1UcRUoxlKq705WUl102f8AkfUnja8gn8NxX2mzrcW1wkZilHQqR6diOQR2Ix2qhE5W902HgxpAGIrx7wZ4nmvPDt5pbsyxMEu44z0Vs7Xx9ePyFemaZd7xp0hYbpImTnjGAP8AGsGnazPSq4BU8Nam+aN5NPuuW6/Aju3in1OGGRNqMzPv9D0H86+hEgFrb29sowsUaxqPYKB/SvmbUyy6h5LMok2jaQc4+bP4V9OQyefa285/5aRI/wCaiu3Ln7rR8xj1blY0DjrS7T2H1p+OKK9G5540L/8AXrC8caAviHw5cWaOkN6v72znbpFMOVz/ALJ6Edwa6DjFRXQzAcVMkpKzGm1qjwvS9SuvsZhnj8meA+TLbSZ3RMOqn+h7gg1vafem6h3kjeMHHt6UeNNNMWu2+rQKCJALe5z0yPuMf/QT+FZ+5rG4guER1jkYIY/Q85rxq0JUpWex6NOaqRTOs0q58q/iuItxIUqyE8Y/yaseI9KNrewappKFxGhcKXzvz95Py/p6VjRyEAyWxOTyOcc4p1lr0kE0a3w8qORMrJ2DD39cjmiErbg1c3bK5hv7Vbm1ffGevqp9CPWpcfWuXt4YbzWvtel3Jtbxxl0TCrKP9oHg/lXXQW2rPHtEVmW/vHPP4ZxXfDERktTjnQaehDg9MUSlYIjJcSJDEOS8rBAPxNO1W1uorXN1qiWo6H7MoDH8TnFcmLLQPthOoK983JMlwxlY8deeg+lTPEqOiQ40L7sfqXjfTomaDQh/bF8c48gEwIcfxydPwGfwrI8PWq2+uvqmtN/aWtXJG/CYSNAOAg7KP6Vo3HiFI7J7fSbWCBXUBUSMAnH06Z607R3VB5k7ZYptYr1Y9z9K46tWVRq70/A6qcIwXuop+MJmmuvsn2dk84iWNt+eRwenQjP5Vz8enrcaOLi0YBi+ySMj5uSRkD6jn2r0S7WLU5bX7ODGdvzqqjIJGM+2R1rB1ybw1Y3iCaaCC2g+R18zaWfGAijq7ew6VLpKTuy1OysZPgd49PXVJdiyzTOtmFkJVQgGRj0ySfb0q9qN0P7U0SPLeYlyGG5stgA9T+OKy18P+KPE2pC5tEi0XTzgCa4HzOo6Yj6/nXdaJ4A0qyeCe7vr69vIjuMhYRqzeu0A+vrXTQpSTWmiMalSN9WadrcgTWz5ztYjH1q18TXD/CjxiV/6A16Of+uD1o22jWOzYBN1zkyc/wAqzfidbRwfC3xkIy2P7FvOpz/ywevQqNSlzI409C38J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVVIBXlXwC/wCaj/8AY56l/wC069Vryr4Bf81H/wCxz1L/ANp0Abl9/wAlcX/sAN/6UrW9jn2rCvP+Sur/ANgFv/Sla360jsSNx9a4X406e8nh6w1m3H77SrpXdgORC/ysfwJU/nXeU2e2gvrS4sryJZrW4RopY26MpGCKitT9rTcO5pSn7Oan2PDYPE0m2LzZj5kG0k5+8p4qn4m8QmySSSSEuju0K+W2MuVPNYHj7QLjwhrrWMjs8CANDK38URb5T/Q+4rK02cXWF1aKSWKWc7AnJV1JHzexzXytSU4twl0PbVOLtJbM2tDuobiZ725V3DTlWkPRTtH+Fdnp7qYWltkdV5YoTnCr/wDXJrlrSKCTSH0+2gYWwU3Akwfvg45/IV1miKghgVRlZYyp59Rk0qSFUZQ1a7XTtRt7q3TiT5ZR6g1r6r4Q0TxRZQrqmnQ3lqvzgZKuuR1VhyP/AK3Tis/XtNaaICMZIAPT/PtVjwvqkto0UU7/ACYKHJropTcJkttLmifOvjXTbf4feN2sNF1KWawkhWSF5gC6oxO6OXgAkMp5HXg8dux8O+O9NmWxSe1kiMD/ADTwziWPkc/IRuH5ms/9oXw89ra2GrME3NcyxOwPJVxuT/0F/wA68p8OXn2a6eMnCSLjgDqOn9a9WcOeHtI7npYfGRw+IWDm70ns/Vf0j6c8Z2gt/EZVijNJMpEkZBBUjPX0r3vwjc/bfCOjz9d1qgP1Awf5V8z+HtQj13Q9LuQT5lmi20u/qXQAZ9xjb+ftXuPwS1cal4LWzfAuLCR49vqhYlT/ADH4VngpqNRxfU8jH0mof4dDu/pRSkYNGK9U8kQDNMuB+5bipe1RzjMTCgDi9WgF3DdW5/5aoV/Ht+tc9HHHfacsciZUqOCPun/Guou1Inb1zWFeWstnPJd2qGa3cl5YFGWB7lfY+lc9enzq5pRnyuxUsy1tdxRSgkk4U+vtU+pwxNbyfJvQAk4yGT1DKf6U2G6s75FVTkE9TwyEVPq0N1dxDyWXpgseMVwShZOx1qV2clNAcAQOVK52kngd+D1rUTWNYt0UQ3CGMrk7vvj6Gq02n3kY/eRYkH8Q4DH+VV7VJJZSs5dCD0YYNc6lZ2NmtC3Pqs10rCVwZhxuxjcPf361QtZ2uoVb5skEbe5/u/yNWpLGM3SshLtgb/QAf5Fbek6etoLi6uCkakFY9w59j9atRcmS2kc9BCRGzIMTSABB6ZzUsBEThbibav8AE2R+g71r20Wra8hsfClrEIom2T6jdHait3UYBJPPQdM84rq9K+GGlRRRNrVxdalcAZcGQxRZ9kXBx9Sfeto4eUzKVZRONTWr6e1+w+FbcTTZw0kwCcHqS38AHXPU9hWroHhTTtHlW8nRL/WcYa9mXJTPVYlOQi/Tk9ya7PUNNtNMtlt9NtYbW3Xny4kCgn146n3rHzXbTpKG+5yVKrlsWd5Zt2auW7Vnrygq3AelbGSNi3bBHNY/xUP/ABa3xj/2Br3/ANEPWnbnp7VlfFI5+FfjD/sDXn/oh6RSLPwn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QldVQMK8q+AX/ADUf/sc9S/8Aadeq15V8Av8Amo//AGOepf8AtOgDdvP+Sup/2AW/9KVroAvJrAuufi+g/wCoCf8A0pWujPU1otiSMDinAYpcUuKYzjPi74YHibwlJJbx79QsA00QA5kTHzx/iOR7qK+ftKWJbS3lxIZo51br94cDOPw5+tfXERKNXzx8VdHh8J+K5ZrZALG5KXSJjiPc+HUe2SePQivEzXD3tWXzPSwNbR0n8i/btbOp+ycJO2WyemRzkfUCrunAFxGoKGPGD6da5W3laRHEeFkBXHOQGXPH4iuu8OLHdxB0LlSgwX69q8+n72x0y0ReihADmYYaM7gR0IPWsPUbAJJdKq4kz5iYHauxeHdCH/vjbjFY9wCZ7d2X7www9wSDW0ooyjKxjpbNrul2aMoZ4W8qZGUMrp1AIPBrO1fwH4Xtp/sU2gaa4nby98cQjeMsPvKy4xg888e1b/h9vsOvywgYV1yB2yKTxvcqmoWlwoyH5IA6ds1rCo+T0OuNeUuWm9UjxD4Xs39iLD53LXUobP8ACcAY/IA16x4Qe70HVV1fTmZ7aL93PCDwyZ5ryGeOLQPGevaXabUhjuEvoIw3RXUFgB7Er+Ar1T4cXwmgvYJSdsybs56ev86VTSpdaPc7MRSTw0aq2tZ+t7P/ADPoa2uIb21hurVxJBModGHcGn1w3wh1BrnRL6yc7vslwQuf7rDP8wfzrugPWvcpT9pBSPlasOSbj2EpHGY2HbFPA56HH1pcD6VZmchfrtnORxVQcGt3WLQ5LDpWGwxQIpahptvfqS4MU/aaPhvx9foayw+p6OCs2JrftMq5Uf7w6iugpynHPbvWc6UZa9S4VHEo29zY3sQaRTGxGCVOVI/D+oqP+zdOBDrdFyvTe3IHp61sWGi6RdSs01oI5W6vDI0ZP1wcfpWsnhDTh8y3F9j087P9M1zvDK5uq7ONnNlalpNqyZ6E8DP1NTeF9GbxcFv5ppI9JSWWIAZR5WRyjKO6qGVgT1OOMDmvQLDRdNs5BJb2kfmr0kf52H4nJrJ+Ghz4buCf+gtqn/pfcVpGjGJEqrZ0dlaW9jax21nDHBbxjakcYwFH0qeiq91cpAjEnn0rUzMrxC64255rmj1q7qVyZ5Sc1SoJJYz8v0qzAaqx9CKsQnk0xGrbnisv4nnPwr8Y/wDYGvP/AEQ9aNueRWX8TDn4WeMR/wBQa8/9EPSKRe+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqBhXlXwC/5qP/ANjnqX/tOvVa8q+AX/NR/wDsc9S/9p0Ab1z/AMlgT/sAt/6UrXSY5rm7j/ksKf8AYBb/ANKVrpmHJq1sSIBn2pR60oHOTS0xiDPWvO/jlpSXvh+xvCQDDKbd8jqkowPycIfzr0Ws/wAS6WNc8NalpmQHuIWWNj/DIOUb8GCmscRT9pTlA1oVPZ1FI+ddOhSTTpDGfLdFUEL9MZ/MV2ng6Yy21sjriYoUOB1I7/rXCafC1vG+xTt2sJFP8HPIPtmvQPDX7uU3HJjYrIpXnOVAI/ArXz1Jao9SromjprTa1kUb7yHnj8azb+34Zh95H3DHuOf1FX4ZRHcskfzxydPb3/nUd2GSaLjOTgn6V0NHOmcz4htvKvbC+hUq7SBWH1qHxR8+pae7A/ZogzkdsrzW7qUP2i0RU7Mu0E+/FZmtWguLK3fOCzyA8dznFRazdjeEtUfLXxIlvdL8fJqCyL5rRQXMLYyCNo4I78hgR9RXrHgPxPpk9u1xaZiimw20n/VPt+ZD9DnB7jBrC+IXgLU/ENlo76LaG51NJWtCgkVfMViWU/MQBhsjr/EK880xdW8B609v4l0m/s4JvklimiMbcHh0yMHH5EHrzmu32ft6MXHdHT7WFLFTp1X+7n17Po/66H178CpHkttbuCD5cs6KD2JwxOPzH516wB/jXAfC3SJND8H2FvcjbdXGbuZf7pfBA/BQv45r0JR8oPtXo048kFHseLirOvOzuk7fdoN20oB/SnYGelGKowIbiHzY2B9K5XULYxSHjg12I45rL1e23Lkd6BHKEYNJViSLBI5qEjB5FAD4JDG+QeRW7Y6mAArn25rn+tODGgDsYtSiLAEgZrlPAOpJB4Xlxjc2q6m3/k/cU2Fz5q896wPBBJ8OSc/8xLUf/S6ekwudrNrDsOD1rPnunlPzHP0qrRSEBoNOCE9eBUsUJY4UEk96AGRqQOepq3bxO54FaNlpRbBcVs29nHEOmTQNIy7a1kxnBrH+J8LR/Cvxjn/oDXn/AKIeu1AArlfix/ySzxl/2Bb3/wBEPQUHwn/5JZ4N/wCwLZf+iErqq5X4T/8AJLPBv/YFsv8A0QldVQAV5V8Av+aj/wDY56l/7Tr1WvKvgF/zUf8A7HPUv/adAG/P/wAliT/sAN/6UrXTnqa5if8A5LEn/YAb/wBKVrpyPm9qtEiUtGPr9aUDPOKYwAJFPiwGH5UgHJ6U4A7u4980hHzv4sszpPxE1q2KnyJJPPXjAKyYcgfiT/3zWv4aTyry7T5hER5sZ7Ee1aXx1tja61oupc+XcRtavxwCp3L+jP8AlWT4dcW8yRkFiwZh/u5FfP1YclaS8/zPXUuempd0dnv86C3ukUqrnp75Pan6ogSJZM/ddX/DoaemHspWUE7Zdygc8f8A6806dDJbtC3VlIX8Rx/SqkZIy79HjtXA6jDjH1qjr0u3SwU4H+sA9881pzvus0cjBOEI75xVPWod+kSMByqkkD6Ui4vVHBauJJNBKwnEkYd+uOcZBGOhziup+Hvju08T+HrLQ/FZgubmePC/bUWSO5AbADhgQXyO45471zlk3nQXKE7v3Ocf8BrlfCPhK910wR2LiOaKZvnJwIwGyWPsKrCTmqiUOp2ezo1YOFd8qWz7f8A+lYpGE3zdf5V0Nu4eFSOuK5qViZMltzdzjGT61oWF3swCeDXuHzqNkAUoHIpI3V0DLjFOpFB3qO4j8yIjnNSYpaAOXu7cq545rPljwenFdlcW0cwwQAfWse8051yQMj1ouI51lwfam1emt2U4K1AYeehouIZb/wCtT6isLwQf+Kck/wCwlqP/AKXT10kEJ81evUVheAoj/wAI25A/5iWpD/yenpAawUn2+tTwwMx+UEn1q5aWLzMOCRXQWlhHCoyBmgaVzFttLd8Fga17PTUi5Yc1ogADAGKKB2AdKKKKBhXK/Fj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD0AHwn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QldVQAV5V8Av+aj/9jnqX/tOvVa8q+AX/ADUf/sc9S/8AadAG/N/yWOP/ALAJ/wDSla6lhya5eT/kskY/6gLf+lK11pUbj1/GqRIzacjIwPWlC9qdj1ORS0xjQMnkEUuBS0e1IDivjLpv9o+AbqSNN81nJHdRjGclWwR/3yWrzjw8yzrbTIoCsMY6fKw6fnXumr2Q1HRr6yJA+0wPFk9tykZ/WvnbwVK0un+TKMSx/fB9myc/jkV5ONjaqpd1+X/Dnfhnem12f5nqGnAIJmPDyKHC+hHDAfWn3oaOJGyeDkN6qeR/UU+xjigm8yZgq+b+5IOflx3qe7UPE6AfKp+XJ6KTx+X9axa0Hf3jJulKTMB/q2KyL+NGpBfsTmQZU5RvoRipJFJsyn/LSAlev8PUVXv8PpjA4Ac4PtmpLW555pEbRag0TZzs2Nn0ruPhZpqWPh67uf8Alpd3koHsitgD88muSiy2uMzYGNoBx1r0HwIMeFYh3FzcZ/7+sa3y5e+/IWNb9n62NrGaVcgjGadipbWPzJQK9a55hraSWKnd0rRxzTYIhHGFAp+KQ0FHalApaBjcUEZ4Ip1FAFK5sEl5UAGqD6YwPAzW5RigVjEttPYTKSpAyM+1YPw2sVk8MS5xldV1Rfy1C4rucVynwy/5Fm5/7C+q/wDpwuKAsdNDAkK4UVLRRQMKKKKACiiigArlfix/ySzxl/2Bb3/0Q9dVXK/Fj/klnjL/ALAt7/6IegA+E/8AySzwb/2BbL/0QldVXK/Cf/klng3/ALAtl/6ISuqoAK8q+AX/ADUf/sc9S/8Aadeq15V8Av8Amo//AGOepf8AtOgDoX/5LJH/ANgBv/Sla65uvSuRfn4yx/8AYAb/ANKVrsCOTTJQ3HNKBx7UtFAwxQBxRS0ACV4Bc2S6d4p8Q2xBTy7yRlXGMJIfMH4Ykr6AUc1458Q4BafEZmYYiv7JCT6spZD+myuLGxvFS7M6sK7No29LkSQi3xlkU4BOQeP51pmdZYoztwVGHXrkHg1g6PGk7BGZkkY4U+pGP8K3pzHEysn+rDbXB6gHrXHujWS1M6KMmSYMcl0K5PTIHH6VXfEtgynpwDV4qYgBkExvtJ9un8jVBVZYZozwQT19v/11NrFo4LUB9m1PKjIZsZ9Oa9D8EKE8Psn926lJ/HB/rXn+vHbdhhnhvT3rvPBTg2F3Gp6Sh/zX/wCtW+B/iSDF600dBV3S/wDXD61Sq3pxxKv1r1DzDo6WkHQUtIoKKKKACiiigAooooAK5T4Zf8izc/8AYY1X/wBOFxXV1ynwy/5Fm5/7DGq/+nC4oA6uiiigAooooAKKKKACuV+LH/JLPGX/AGBb3/0Q9dVXK/Fj/klnjL/sC3v/AKIegA+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqACvKvgF/zUf/ALHPUv8A2nXqteVfAL/mo/8A2Oepf+06AOhbn4yR/wDYAb/0oWuyI5rm/EXhC21rV4NTXUtW069igNt5lhc+XvjLBsMCCDgjj6mqX/CCP/0Nviz/AMDl/wDiKZOp2O2jb61x3/CCP/0N3iz/AMDl/wDiKP8AhBH/AOht8V/+By//ABFIep2W2k21x/8Awgr/APQ2+K//AAOX/wCIo/4QZ/8AobPFX/gcv/xFAanY45ryr47xeSvh+/CHK3ElsWHo6bhn8Y66X/hBn/6GzxV/4HL/APEVynxS8GPaeCb6/XXNev5LEpcpDd3Ikj+VgGJAUdFLHrWGJjzUpI6MK7Vo366ffoM0q4AWIqclpO/fIH/166m8VGjdRkFwGIP5H+ea8x0G8LWEJ3bvmC5z+X9a9IWcXVpBODgp8jD1NeXGVzsqU3EYT+9Yn+NAT9ehrL1GQpITj+HNaTbdyfN2Iqnq0J8iFg2c5U+1UQjgtaAknYYOK7DwK5+03kefleBHHvg4/rXGa8PLkVtzDB29a1fCtsdR1GC3GpalZM0Mn7yxnETnbg4JKnj2+lbYJ/vGXiVemz0raasWQxJ261zB8MP/ANDV4v8A/Bkv/wAbp0Phdy+P+Er8XfjqSn/2nXqHlXPSl+6M0tcXF4IdkBHi3xVz/wBPy/8AxFO/4QZ/+ht8V/8Agcv/AMRSHdnZUVxv/CCv/wBDb4r/APA5f/iKP+EFf/obfFf/AIHL/wDEUBdnZUVxv/CCv/0Nviv/AMDl/wDiKP8AhBX/AOhu8Wf+By//ABFAXZ2VFcZ/wgj/APQ3eLP/AAOX/wCIo/4QR/8AobvFn/gcv/xFAXZ2dcp8Mv8AkWrn/sMar/6cLiq//CCP/wBDd4s/8Dl/+IroPDei2/h/SItPtJbiaNHllaW4k3ySPJI0jszdyWdj+NAGnRRRQMKKKKACiiigArlfix/ySzxl/wBgW9/9EPXVVyvxY/5JZ4y/7At7/wCiHoAPhP8A8ks8G/8AYFsv/RCV1Vcr8J/+SWeDf+wLZf8AohK6qgAryr4Bf81H/wCxz1L/ANp16rXlXwC/5qP/ANjnqX/tOgD1WiiigAooooAKKKKACqesWKanpF9YTf6u6geBvoylT/OrlFDV9Bp2d0fMPhiVk0XyrgFLi2dVdfQqdrZ/EGvQtNuT5MiA4yfNTPsef0rmPFGmDSvF3iS1j4R3+2IAMYEmHP8A48Wrb0+XZa2UwBIChn/3ehr59Jwly9j3JtVI8y6nSSFnlQbRz824VYuohcaY6A7XXLKevNQPt8qI7clSBuB5q/aRTNHIsTc4ziumOrOB6K55j4lt1khlIPo/4H/Jqfwbc+XrmmMQMPL5RP8AvoR/MVpeJYhGspbgAkEex6j8+a5rw7Mbe9iY/et50J47bhTw3u10u50T96kz19utOiOHFLMNsrD0JFNT7wr1jxzp7I5t1qeqmmtmACrdBQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr8WP+SWeMv+wLe/+iHrqq5X4sf8ks8Zf9gW9/8ARD0AHwn/AOSWeDf+wLZf+iErqq5X4T/8ks8G/wDYFsv/AEQldVQAV5V8Av8Amo//AGOepf8AtOvVa8q+AX/NR/8Asc9S/wDadAHqtFFFABRRRQAUUUUAFFFFAHjPxiie18Z2Fwowl5p7wHj7zI+fzxIKg8ISLcacITzlFUj2ya6T44WQfRdK1AKTJaXqoT6JICh/8e2flXG+D5fKvI4/4WI9uma8bErlrvzPYovmw6a6HWW82LQRtnfG2GzzkdjXQadkxmU5+XIBx3x3rGuI9rFkwB0YH0rY0h8W8ib9qycfpVU97HLV2ujmfE8JkgfcOTwR0615/pv7vVJ95YFl5x2IH/1q9P8AE6SNCHZcqwwR715oE8vXXAyFcZX8P/rGqjaNeLNqbvTaPZZGDkODkMA3503vUFhJ52m2cg/ihT+QH9Kmr1jyjf0hsxkVo1k6M3WtakCCiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvxY/5JZ4y/wCwLe/+iHrqq5X4sf8AJLPGX/YFvf8A0Q9AB8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJXVUAFeVfAL/mo/8A2Oepf+069Vryr4Bf81H/AOxz1L/2nQB6rRRRQAUUUUAFFFFABRRRQBzPxKs2vvAmtRRjMiW5mTjPzR/OPxyteOaNcr9rilXgH5hX0LPEs8MkUgykilWHqCMGvmvRlMUYgfIeEmIg/wCySv8ASvLzBWlGR6mXu8JRPToplklkjwPuhx9PStjScmLdbuFZiFx2PXkVzOkSbzDKrDcF2tkcEGtzTn2EbW4xnk96zpO7TM60baEmuQMLDZPFs2qcMK8tvYHTUoXHO1+vqD1r2PURussjlWBBGc15Lq4EFxhuDHJ179aqrpJMrDu6aPQPDbM2hwK64MTPGPoGOD+RFaNYfg+YSWl5GD9yRXA9mH/1q3K9iW+h5s1aTNbRmIfHtW1XPaU+JRz3roakSCiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9AB8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVUAFeVfAL/mo//Y56l/7Tr1WvKvgF/wA1H/7HPUv/AGnQB6rRRRQAUUUUAFFFFABRRRQAd6+e/ENsdP8AG+twbAgN0ZkA/uuA/wDNjX0JXkfxX0/y/FFneIOLm32N/vI3+DD8q4sdDmpp9md2Any1HHuil4flxNH0xypFdPblkDHABDZ56GuU0mD96AR7j611cK4kBjYYYYIPpXFTTRvXte5rpsezUqy/dJ57HFeaeLoSJpWGQwIJH1716PHFHLZkxr+9X+62Mj6VxviyFZBu9PlP+frW9aN43McPK0xPAEr/ANoXcbAeXJbI6+5VsH9CK7I1w/g8CPVLJj3WSI8+oyB+Yrt+9ehSd4K5y4j+IyxZNtmH1rqEOVBrk4DiWuptzmFT7VZiiSiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvxY/wCSWeMv+wLe/wDoh66quV+LH/JLPGX/AGBb3/0Q9AB8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVUAFeVfAL/mo//Y56l/7Tr1WvKvgF/wA1H/7HPUv/AGnQB6rRRRQAUUUUAFFFFABRRRQAVyPxFsPtVpYzjrDKVP0Yf4gV11U9XgFxp08Z9Nw+oOf6VFSPNFounLkkmeeWdkUdGCnkVt+QMqQh/AVdhscJ0wQeKvLblVz/ACrmVI3nVuZlquwEZ6dCDWRrdt9ohYOuT34roRFtdscZ56VXuIN4bvmtXTurGMZ2dzi9LtTbXtu3BEcytwe2a7VlOTWabHDVubM4PqM1pTVo2FVfM7lVVO4GuhsjmAe1Y/l1rWAxEPerM0WqKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK/Fj/klnjL/sC3v/oh66quV+LH/JLPGX/YFvf/AEQ9AB8J/wDklng3/sC2X/ohK6quV+E//JLPBv8A2BbL/wBEJXVUAFeAeB/Ft94E1XxzY6h4G8b3/wBt8TX1/BcadpDSwvE7KFIYsuc7CeMjBHNe/wBFAHlX/C5P+qcfEn/wR/8A2dH/AAuT/qnHxJ/8Ef8A9nXqtFAHlX/C5P8AqnHxJ/8ABH/9nR/wuT/qnHxJ/wDBH/8AZ16rRQB5V/wuT/qnHxJ/8Ef/ANnR/wALk/6px8Sf/BH/APZ16rRQB5V/wuT/AKpx8Sf/AAR//Z0f8Lk/6px8Sf8AwR//AGdeq0UAeVf8Lk/6px8Sf/BH/wDZ0jfGPcCD8OPiTgjH/ID/APs69WooA8jX4uBRgfDj4kf+CP8A+zpw+L4xg/Dj4kf+CP8A+zr1qilYdzx6T4slmyPhz8R/x0P/AOzpjfFXcMf8K5+I/wD4I/8A7OvZKKLCPFz8Ujn/AJJ18R//AAR//Z1MvxXIUA/Dn4j8emhf/Z17FRTA8e/4Wx/1Tr4j/wDgi/8As6ng+MBjGD8OfiQR/wBgP/7OvWqKAPKv+Fyf9U4+JP8A4I//ALOj/hcn/VOPiT/4I/8A7OvVaKAPKv8Ahcn/AFTj4k/+CP8A+zo/4XJ/1Tj4k/8Agj/+zr1WigDyr/hcn/VOPiT/AOCP/wCzo/4XJ/1Tj4k/+CP/AOzr1WigDyr/AIXJ/wBU4+JP/gj/APs6P+Fyf9U4+JP/AII//s69VooA8q/4XJ/1Tj4k/wDgj/8As6P+Fyf9U4+JP/gj/wDs69VooA8q/wCFyf8AVOPiT/4I/wD7Oj/hcn/VOPiT/wCCP/7OvVaKAPKv+Fyf9U4+JP8A4I//ALOj/hcn/VOPiT/4I/8A7OvVaKAPKv8Ahcn/AFTj4k/+CP8A+zrF8b/E+fXvBev6RafDv4iJc6hp9xaRNLohCK8kbKCxDk4yRnANe30UAc18Mraez+G3hO1vIZYLmDSbSOWKVCrxusKAqwPIIIIINdLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The intertrochanteric region contains a large amount of cancellous bone with a good blood supply. Therefore, intertrochanteric fractures typically heal well when properly repaired.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5730=[""].join("\n");
var outline_f5_38_5730=null;
var title_f5_38_5731="Patient information: Tongue cancer (The Basics)";
var content_f5_38_5731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"22\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83257\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/12/39106\">",
"         Tongue cancer",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/19/7477\">",
"          Leukoplakia",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/13/7378\">",
"         Patient information: Dysphagia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/53/6994\">",
"         Patient information: Mouth sores (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/20/8515\">",
"         Patient information: Throat cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tongue cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tongue-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25361114\">",
"      <span class=\"h1\">",
"       What is tongue cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tongue cancer happens when normal cells in the tongue change into abnormal cells and grow out of control (",
"      <a class=\"graphic graphic_picture graphicRef83211 \" href=\"UTD.htm?38/12/39106\">",
"       picture 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Sometimes, tongue cancer happens in people with a condition called &ldquo;leukoplakia,&rdquo; which causes white or gray patches on the tongue (",
"      <a class=\"graphic graphic_picture graphicRef62948 \" href=\"UTD.htm?7/19/7477\">",
"       picture 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361163\">",
"      <span class=\"h1\">",
"       What are the symptoms of tongue cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have no symptoms. They find out they have tongue cancer when their dentist or doctor finds it during a routine exam.",
"     </p>",
"     <p>",
"      When tongue cancer causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A sore or lump on the tongue",
"       </li>",
"       <li>",
"        Bleeding from the tongue",
"       </li>",
"       <li>",
"        Trouble swallowing, speaking, or moving the tongue",
"       </li>",
"       <li>",
"        Mouth or tongue pain",
"       </li>",
"       <li>",
"        A lump in the neck",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not tongue cancer. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361178\">",
"      <span class=\"h1\">",
"       Is there a test for tongue cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. During the exam, he or she might use a special mirror to look in your mouth.",
"     </p>",
"     <p>",
"      Your doctor will also probably look in your mouth and down your throat using a &ldquo;scope,&rdquo; which is a thin tube with a camera and light on the end. During this procedure, he or she might do a test called a biopsy. For a biopsy, the doctor takes a small sample of tissue from the area that looks like cancer. Then another doctor looks at the sample under a microscope.",
"     </p>",
"     <p>",
"      Other tests for tongue cancer can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An imaging test, such as an MRI, CT, or PET scan &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        Fine needle aspiration &ndash; Doctors usually do this test when people have a lump in their neck. The doctor puts a thin needle in the lump and removes a small sample of tissue. Then another doctor looks at the tissue under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361193\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began, and, if so, how far.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your tongue cancer and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361208\">",
"      <span class=\"h1\">",
"       How is tongue cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for tongue cancer involves 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; In most cases, tongue cancer is treated with surgery to remove the cancer. Sometimes, the surgeon needs to remove part of the tongue or mouth in order to remove the cancer. If this happens, he or she will &ldquo;rebuild&rdquo; your mouth during surgery.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After treatment with surgery or radiation, many people have problems eating, swallowing, or talking. To help with this, you will have treatment called rehabilitation, or &ldquo;rehab&rdquo; for short. During rehab, doctors, nurses, and other health professionals will work with you on eating, swallowing, and talking.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361223\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Follow-up tests can include exams, blood tests, and imaging tests. People who are treated for tongue cancer also need to see their dentist for regular follow-ups.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean your tongue cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361238\">",
"      <span class=\"h1\">",
"       What happens if my tongue cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your tongue cancer comes back or spreads, you might have more surgery, radiation, or chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361253\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for tongue cancer involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25361268\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/20/8515?source=see_link\">",
"       Patient information: Throat cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=see_link\">",
"       Patient information: Dysphagia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=see_link\">",
"       Patient information: Mouth sores (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/38/5731?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83257 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5731=[""].join("\n");
var outline_f5_38_5731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361114\">",
"      What is tongue cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361163\">",
"      What are the symptoms of tongue cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361178\">",
"      Is there a test for tongue cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361193\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361208\">",
"      How is tongue cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361223\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361238\">",
"      What happens if my tongue cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361253\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25361268\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/12/39106\">",
"      Tongue cancer",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/19/7477\">",
"       Leukoplakia",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=related_link\">",
"      Patient information: Dysphagia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=related_link\">",
"      Patient information: Mouth sores (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/20/8515?source=related_link\">",
"      Patient information: Throat cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_38_5732="CRPS child foot";
var content_f5_38_5732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complex regional pain syndrome of the foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAWMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD54mgBb5kGPUdKa0bI/wBximMYBq78u4rC2XzyGprwM5AZlHsOtAFFlYqCqHI6imbd6kYK/wBKuPAFYkFh65NI0XAYHK9z6UAU4rcnIkbdjoTTmTA4+7jrVsRfJwRk84psilTgHGR060AVNoIwB07kVGwbgHdz3HarKxMqsGJweuRQIwpBAbnuaAKgG0FSCx25yBzX0ppp2wxHBzsAAx7V87hCrEqATx+NfRWnn92Nw5CDBz14rgxu8T18sWkvkbsACYHlgnu3YGrD72QtwExt471XtJDsKscsxy30qwHDnAPC88elcB7KQ4AmVd5BAHOO1TmUiPapFKoRgFxhQMsPWnRBfM2kgYGDQQytdKBICOScDI7VBNsHUckc1alQGUANyuRyOtVpEBkAcHr60xFaX5juYqBjgdKx70bWJMft1rZuQyncoBGD17Vl3jeYpPGSOazbaLhuc7eFQHwMY5x61x3iKbybG5K45U/gfSun1A4JZSRmuI8YSBLA9CGbBAp0lzTSDEy5KUmcPxzwaF4HIIJqXC4z0HpmmYzkEf8A169i58sBHy0yNVXcM7jnmnrnknI9OKc0WYiM7Q3XFAhGGDjqe1IowvPU1IqFVAA+UDqaaVB6SAr7CgBjbhwASSOtKi7QOeB1z3oOImG8HcfQVKFA5J/DFJgRAEnGMj1r1v4Yx/8AFPQqqE7ZH5PfmvKiMcqCfYV6z8MpWTw+Mx8eYw571z4n4Ud2A/iP0PRLADZnILdxWiq4yQW6Vm6SrkkstbIIwOzY/P2rhZ64RlSGOeeKkK+Yi/IDyc+9VizvlQuCT2q9BjOOc+9UIgAZZAhB57dRV2INIp77eB6UwIGYOcZI6VOEURhTuTngrTB7CSROMPGc7SOnaqU6lAXVc84wTV67+YAnKqcAc4JxVS4O4sTnCEYAxzTI1tqZ15tBBz8xHAHIFY940YDKSxZxjPQ1s3QyGYfKcdueK56Zmz86lmz970pajijNvjs2KycAev615f8AEu5C2cdsGy0kgYj0wP8A69ek306kvgDNeP8AxEkE2uBAxYIufxNdOHSclc58bLlpPzOT4xSEYqXaCOc0zBB5HFeimeGNxRS5FFAHVtbBrkzlm39AM8f/AK6kkiAIYAeZnGfSr+BvVsNGCcFNucGmOo8wHqT3xVEFZ4dwO4A8ZNVohHKhEL7VX72Oc1fKc7kcYBxUc1q6ADbsDHnYOKAKQgt1+dw+V5y57UoWJuVIYH+6asPbndgOCuMFSBzSGFUPzhFC9NooAgCBV4yeemaikG8qDuAz0x0q2ypKBsYZ6jDUjqcjkA/nQBWSPLgg98Yr6E09S0Q2joAG/KvBYYyeBtDE4ya9608EhY1bh8E15+N3R6+WbS+RrW0ZRTjqeetWoCY3kYruUelNgU/Kx5ABGOlOUpklcrk4PcE1xM9dO5dQKoOevTA5qKNCwdeN3bJp8MRXL7SSORzj8KfH5YUtwFcZx71Ittiuscr4DKBgYzTGXjII4HerbN5QPzbvQY6VVfaygsnH3cZpivczb1zyu0s3PSse6bapXncF61tXw+RsDoe1YOokA4C4IHJz+lS0XFtHP3/7xcnp2NcF4yZmSNYyBh8sPUYrtb1wD8pyOeBXC+JNzyhQQcDNaUI2qIwx0v3LOZK7sB149RRIr/KIxhe/erR/1Y3gj696Y0QbHOCOnvXpnzpBEpOXkfLE9McY9qlKbm9z60/a20FcMCfTpQCdxWRDG/bd0P407iGsokQhuc/L04qBWij2ZOIkO0A88+pqYO0zsNwC4wQvpTpYAUClVYHsKEFxg2ls5Jz3ppBwwbbkdP8A9dEUYiO6Ntq9CjDIqxhX+VcH0xwBSAapBTjpjtXqHw0x/YygngO2a82WLYwyoB6Zr0j4djGlNgEfvjwTnI4rnxC907sB/EPStNY4QDPUjjuK1sBgVyNw5FYulthmZssuPpitiNhIMYOcckd64bnrkqRfMuOv86toh2KM7jjrVXlR87ce3er1vH8oZMbfTPSqExJFC8qw4PSkgyqOuMZJxg54pzEKoLEDJweOtH8RAHQdqAGS4kAHXyxjk85qkzsiHc5DZ7mtFMAgnA3Hoe9U7gqxypGzPp1NMlvoZd4QA+5mXdzx/jXN6i2H6EBffvXSXpz2G3pkGub1Tc+8jg+9C7DpnPXkv97gg9q8h8QzC41q6lB4LkA/SvUNdf7PbTP/ABBTj2968idWYs2SQxJIrrw66nn5hPaKImiXPU0x1HQ5/CpyDtA/SmElc5HHsK60zyyLy19aKk3r/kUUXYaHojwRnLIxYHtnpUSx7WYgYA6HFalzZKCMhhg/wniq2wR78hmUeorYzKqBSm9gqHGTVdktZWE0UzAjlwCQGNW7NUmjcqkZj3EKScEH3oEHlsGdGAz1XFAFB2gC5dM8fjVa4hnaSPyWVVxnDjIxVm7tPLv4JoSB5jfMnbFR3st0LgQwEBjzjZnj60AUmttufKAjVD0Axk1OFI2llOD19q0Uj3hcggnr9ajePDsAyAL1ycUAU41Z2Kqnftxmvb9Mk+VCdpwqnge1eOS25AJ3FSCCQO9evaRlkUjndgZ9eK4MbvE9fK9eZHTRO8gDbeB0xVi3X59hYYbkYFUU/dghcfQGtO2UvCDzuHP1rz5OyPWSLDERI+0t68007SeP4jzSgAlVLc9x1xQpEWEPJ3daFtcQ2WKRogYwFGeo61nXDgyBV4b1rVyn2tnWaQrtChc/Ln6VhagWaTO3A54oSKSuyC7kYA/NgLwfesDUyQsjAjJz96ti4ZvLfB+YnIWsHVpCGAUbgM8U3oaJHOXSkD1rh/EA3XUpyAFPPpXbz5+djyzZwOgrjbpfMnkY5574rXD6yucOYNezsY4SRt6yEspHDDjioZN9sihFZkPU5yfyrTiGd3mqyuBwEOVxmlaJlbBGCe4Fejys+fumVNi9cnkdDQ4ZV2KvDfKqH+dTlFRC0jYUZO7HT8KgginYkyN8xHBPUCqULg5WK6worCOMHzCeSpwT6mpZo23FBIXI6gjB/OnrbSCQMkuB3OMkj0FSSxO7bVVgJTgndjYv+NVyE3IU8pCW2EBupxkE0oSIhzGQWHftViKPaAq5wBwe9V3gEykPGU5/MfhUum+g1LuCOzKTgdABXofw9kxYyIe0nb6VwAt2hUBHXZjhW7D612nw3kcQXLOhXEgx/tDFc2Ii4xuzuwMr1bHqVg5VMAnAFatrgMwQYJ65rDsnY7AmB68ZrbtOGYtnPX/69ecz2i3ISI9wA4PcVoQMixElSPlzmqkOMZYcZ+tWCwz83QnsOlNEsUkY5BIPTHanBCshKnax70+KME9yMVL5BJAzk+tUrgV2jf5TgkjuR0qldMUjBLDPYDvV+cMiuu4ncfy+lZ19herHcB09qZD1MW9BjaTIc55AB4rndSYjlsqfX0rY1KdUO3adynANc7qc+4sN2eMULccTj/Gdz5ekyAMQznAPqK85cqmCSFz7113j145JILfDZA3NzXKhFZQCCT1ya9GhT9y542NqXqtdiFlEiknp60xV+bGTUrrtyFGD6CmP8vJ7+grZQZyOQ3YTz8pop2M87v1op8jDmPTrHz5pmIiuIh94iUZVvpVm6STzkjEKMjDczZ+6auzyoJYAzORISEVFJBI9+gFOMql33Rn5V5PWtCDEuLOK4cCVWXvhB1PrmmyQKZWghdhIig4weB6+labuJYmNrIJHAzt2c/TFNijeSHdLGVfuDxQBkfZ2hOyVwz9jSvaxcvOhAHG4c1fKs0jiOVcryQRkimri4R44H3KPvvtG0n0zQBQEKFAIyGVenrVS6tni+z74zKucEZP6+tacsTwNgEEsP9Xtww+lQ210LiVw6tG4BB8xhx+FAEAhmMZDLgt931r0zRSwjjAYldoP41wSIqIOVY9VrvNGwI0DA7cAj1rhxq0i/wCuh6uVP3pL+up0lrhcF1Oeo4zV8XRVQFUrx2rPgV3curEHt71cMYd3UsVfPWvPep7dkXo9x+f7uc5z1NDcsoGSoGRUczgYYHJXr3xU1pGdhdieeh/pUt2HZWuVk2CTYjHI5ziqGpNslX5g2DyTWpdqwHDAcdBwTWRdqZQRKACT1FNdwuZ93NiNiuAx6HGa5/Usqc8HA55rZujtjIfOVOTiucvnJUvxg0xoxblsqxJOf4c+tchLuY9SPx966nVCY4pHPB2nH1rn5YZ3CeSELlQx8zofauvBRTk2eTmk/cS8xiQmRDskA4596a8BYKof5j2x1q3FbSYLS7FfHzCPlfoKo3XmS3cdv/qmJ+Z8g/J7Y6H2r0zwyNYhcHO/zLeIkegL/wD1qlwioXZm3s3SrE6QRSQjIiTJO7OQAPT1NOljEkaytxEHD5A5OP6UAVXQIu8bUHq3OPwqSPEiHbtdT/eHU1YkiUkF1GX6A0R2fknG4YAxuNAGS7AIrXCsEY7VKdOPWp1ik2gmPgnkN1xV02qqqjP7pSSB707Yu5Vj4IHTFAGOLeR7qN3cImT8o5yK63wMwVbkAk/MOvasZIGQk7QpBPbPFbnhRNssrAgs45NYYlXps6cG7VonpOmgblfOeK34cCLcuSe4rm9IVi6orHHQ8V0lgSoO3OVOOa8Y+isX7aNjGecE85qxBAxzvbii2BbGVwC1XwCysFwfrQS2NC4Iycn2FPQEEbjnJ6momLtINgxgfNmiSUphWzuz3HFUkIhlVQSZGY5JwBWRqBaZ3PljkbQTwa0ZZc7iCAO2R0NYt7M2cE7to4x3pi6mBqz+WGODySPmNcndlsE7gT3xXSazIpyMgsOh9K5LWLgQW8rMQGxwfSqSG3ZHn/iSeOe8eTkBcLWQHUrkN8p/WrlyVkctIQxPr3qKRQY8JGDgcDFezCPLFI+ZnLnk5PqQSKxOAMj1qGLLMc7uPWrAQghcn6EU/aM5zzVEkG360VJ5Stzv6+9FAHtqW8RQIBtU1TubgWSN+6kdNvDxrlc5xg96055LeygR7osqjgu3QfU9qVfKkVTHLyTkFWyD+NAGNIDJF+9XykbGcqQce2O9LHaLFF+4BWM/MSSSW9znpWq9qwG5j5gY54Xn+dRSWrbQ0ca7v9s449KAMUxW0jM62+WYFWKtzmm2+mNau7QEnzP4WXGPy6mttbcCETPE3mD5gFA/pVNZ5wQyRxtD3XcQ4/CgDOvo90oYQMWY4IXqOOtQ/YFXauyKNWY7u5P41tzKZoZGCna4AL/xA+1IEDJ++AOOBnqaAMye3j8lgqLuPCnHANdbowKW8YL8qNhPrXFR6dp9peMwnnDvykMkuVB9hXcaMAxGDlSciuHHO0Eepla/eM6W3QhwwYHGOPU96u+ZukA45HT0qlEPkRU4Gfxq1MAmwKN3q1eXF6nuoniBVQpxyfTrVnzVjTYwPXkAVShmAfCg5x2q1ENxYEgg8470PcbRDdFGUYIBb17VkXzlAyxuN/8AOtW4AAZnBOO1Y98dxBOVGeoHNWmKxh6hMdpXBB6kt0rBuMux6FcgEelauoSfvSA24dQaxrqQlWwcCgqxj6048h1UEnGBzVebToGR1wWU46HnpTtTAfyombPmSICPx9a0gMzXEjx+XGhyDnjH/wCqvQwC0kzws2fvRXqY0ka21kWhQvg7Y4R9929P89qrafYyxidryGMKuG8xBksxHzc+nb8K19MslM0t1KCN7Hy1c52J647E1dKAKAhxznjiu88kxbqxguY42ZP9WOMjBNT/AGYARvl1jReUAx+dWHdxvJtHkkJ2qijqPr0qS3R5bMi5ZHK537DkLg+vegCn5Ky7XliVgD8hI6VHNCyuMruT3q/NZ/brfcplAAwoDdvYetEvnRuNkAZEXlARn86AM3BWRVigkZG6Mvr/AEptvbyxmUymUqjHDSFTvz6Y7VrXUUZEcjKyugJVA3r64qIMkkHmsSIl4OR39BQBnXMaGIgncXwNo61f0D5bxo/JZQFyCTjHIqrd+YkXmwWpkHGSXCgCtLR1zfsI1wAnJPU1lX/hs6ML/Gid1owCMHl544xXU233RtUknmuUsSBg444BrrdPCiIHnaQDzXiH0fQ0omCQ7RkkD8c1ZaTBGAQwHf3qGFP4uhBHbrU6oSSJB34AFNWIZGWLYycAelOdlb+PB7ZptwuCAEYADJIqGVmVAIznHc96qwFDUl2yMzE7T+tYGoXIjAEZwhGMVpXMshdw5PHb0rB1SRgcIoIHU0B1MG+dfNOMY/u964vxPcB0eNcqCcZNdNfyFpmAyGHc1xmupHK7B1MqqS3XGD7VtQjzTSOfGVOSkzAMCxDDuuzvmoIN0eUADLnO4NnIqVlLRDzEAiJx+/bP6iljuIR8rIikcblIYke+OR+NeufPkUgKKzZJAGdvofSoo3Mu9MGNz6jg1akQKf8ARjv9s5yKGjAOSQqd88GgDMMEykjJ49DRWmYyTnePwNFAHvE8CTRukiIVbqrAHOKrSxKkqGOOMZ4HAAGKs2dtJEPLmunuAMkM6jePQHHFFxYi5i2uxGG3AqeQe1AGff2Ul3brGmqXNuivvdoQqu47Jk/dH05NTXMXmruhIx1wTxj06VbaBI4yGIPHU8ZqBUL5SRURTztEnzY9eKAKO2RYgsdqI84DPvOMZ5NLHbGMu8MzCI8/KBgfUmtCJJUPlx7CmOjnmmLH5SeW2wL/AHcZBNAGUY1OpwhZbjd5DHYqkxEbvvE9N2f0pHh22yi6Yu2cgodue9XEswlyMzPETyEjPy/y/Sp2tY5kKzqrgDHSgDGtnWVWKwlUbhgSa6DQ1UD5RjYTgY6YrLMH2SVo4IkaEgbV8zBB/GtnQ1RQTkkHPbrXn49+7E9bKV78joLbJUMAT8uTTmcseDwfekVnMeUACtSRqAcHkV5l7HvJE9uCG4BBx1rQjZFhycEg8ECq8a7EOAWBJwT2qSWPbLlGUIRk98GjcCnfSKd+dw25PI61zd07ZYFmyT61uag5eJm++3r04rn9RVx847nqOgqlsF0Yt0G3EYOc8VQuk2xnJ6CtaVSRuYdOayr9/nbA6CiLuORz7hW1O0V9pUzKSGHXFaEUTX0mGx9kt+XBH327L7Ad6pWsUk+v2aW7rHICzB2GcYU5x6muq0zTYrO22RxBFJ4x8x9yT3Jr08CvdbPns0d6iRSaDzVaMqVGBkbscU5ITk/IPYVfMRWdgOVIwKYEVrtRKFztyATz9TXceWUfLLIc7o93BG7JNNhtFhgMca5iY5YAcD/GtUQgu48tACMKxHeoU89leVI0gtlYkSOSSVA5IAHrQBmyNIJzbrbybkGS7YCH0APXNWLS2RImZ23StyWxwx9KluZbSCCCa6Z40J2r5vA55yPSpLhFN7CY4hKqglk2nleu4dh+NAGbqEMEZXznMbOdqknGfamy2isIl+QxjBAQhh07dqa7TahqcUy2iSWdqGKpwzSFuCMngD/CtBbVYIgqwJCVydikbV5oAzJFjRWaZPkU4VBx+lWNJgljMU0+BM6ncBwAOw/KpZUCzKrjEkgJ2r1an2bKbh4QqlEQEEHueo/DFY1/4bN8L/Gj6nS6QPMQA5yea7LToswIOSccZ7VyuiRNsXGcV22norIFYdB1968U+lZctgBG/mcEHipHfCAqQGp0MbOjBgD249KSaIAg46cGgyICd6scg8c1VnCqgTJUHoTVplKPnA2noM9arXLvz8ozn8h61SZRiXe5TITg565FctrZCqD0yRXQarPGchdxI/GuU1dgY1G3k9z1oTuDVjndVuBHCxA5HQ5rlJ4zLKRNENudysW6/hW7qhLsqseN/wBKxrtt8haJfKLcbmGQAPp3ruwcXdyPLzKauoIz7uIEosaEgHBVSMp70yKwiDsUjCb2Bfj71WrCCfzS2zy7fknOOT71JYxNL5zOSAz/ACgGvQPKMya2y0srYGeF2jBHtUXlvs+UGRTyVkGcD61NqVnePfCG2R44RgvIT19anaBZFGN2F5IJHNAFLD9raT8GBFFEtoJJGZt2SfaigD6EZSsh8sMcc4FNYERMyEIexc4xVmIiZW5ZMHbzxUV3bR3EEkMq+ZC6lGz1IoAofZZ550c3NxEqfM8UWwpJ9cjP5UqwxC+eTyUWV1ClgvzEDtmpFtZhYmyhmliKxiNJsfMOPWoNJi1W3WWK+aCdxjy5Nu3jvmgCwER5DtUhh61WAjuGORICpPyuu01emtzIEVA6sGDERnr7c+tJIr5+ZTke+eKAKFyJPs58mMkhScd6LZHa2VpV8njGHOT+NWJrZfkdHMLLnJHORTY3MkbASeYCcewoAppFHEAVYCQjJc8k/jVvRASpKqSvU460+eLy4nLIoVVPQUug5/d8HlcHivNzDaPz/Q9nKFrP5fqdDa7Qu1wSue1OXmVSgUBuM9adEAIZD/Eq9Me9OsowZSwBCls/iK849yxaji5YZyMdKGiAhdCNxc8EelTx4Q5Ock96jdT5hK43ZOfwoWg1tZmJcLH5kqIdvGOax7oN06oBzWvdhg/zMpyeTWZ5PyHksrHNNyHJK+hl3qgAqPuYBPaudv1VWfbnPpXT3ikDbjHqK5XUyNzDI4NEXoQ2Z+jMF8UWG7OMSfXOw126mVkQyY3Y3MwHANcHpEqp4ktpfL8wKzfJnG47SK9CWJRCo2hV5IGc7TXq4L4GfO5p/FXoVkQxD92q45Y8k1GptbKQyyv++unB3Oc/QCtJVEuCJOx3EDHFOgSIhRw6qSAWGTkV2nmlJgZsRjeNjZxjAP1pxjcxlW+YgYx2NW58I20fe9DRFHK9upaIRt3UHOKAOcl0eG+vIXmUmO1G2BG+ZSc85HtVi801Gu7a7M9zC1qSx8mbakuccSD+IcdOOp9a2D+6VQCpZmCrk45NK6gNhgGb07GiwFCCGOInYoG45zioruJUZZH4UAs+O4q0PNNzOmwmCNA7OwyXY5+UfTFMQpdfaFnCi1ACjcpVlGOd3p7UAV3jBZZYRklcBiCODUBthC0e1VDFeSo61YsWa6SR2Rlts+XCrZBKjof/AK9PIIvQGOQqDkCubFytTZ24CN668jptBXKoAvIA5rrrSNETPr81c7oSAexPT6V1FpEQgyQcc4rx46nvSLcYCjBJGeeBUdycnqNuM9KkYqF5GCajfcQABnPr2rTlMyjKpXazFS4rPv3ILfMQf51rXB2ZG0EjisS9Xcd3TjnHrQUjB1LEYJPU9a5TVpGyRjt27V0uqMShRX3d+TmuU1Jgp+b0/OpvrYbOeucNKA5GF7t3PYVVns5J8eS8ca/38Z5+lXYZGQzsImZGdV3DsT71YMPlBhlVLAYQtyTXsYeNqaPnsXPnqtnPPZveW5hukbdG+VYHCvj1FWHhxCyxkb9pA2Dv7VpyxOU2AAsowMngH3qCOORmx5ZRh1XdyPfFbnMZk0XmRRqrEMoAYjn6jNQ3NoCUKSmMg85X7w9KvPFHYRRQRsQhY4BOTnvSvGqxsEBlOfu0AZ0lvG7lm3kn06UVfjtXMalY4yMf3wKKAPaI5i7lJlj8w/3c1IEYMxXbt6YarTxgKV65HUcfnVSWS3DhJJUDEA43UAQ+W3m4EoLAfr7UpDEHkHHepfLR3XykbAPLjHFOa3UqVdWxyDzQBV8sM/7uRkakeZHm8tWzNz8rDGasooMf7lcL0JZCP50SxEw4B+Qc4P8ASgCirAA+ZGVPQg859arxJDE7BdqtI24g9cCtI7XiVduSMADpioprcI+SpIPfrigClM6tZyupBwhzS6JER5bIzKgyTtH3vSn6om3TZSpGMBcY9SKn0uHECllbA6dq8vH6ySPbyle7J+Zs2mTGS3XoaswDaN3oe3fiqtrCocEBhlOOatqC6lGO09cqO9cB7cHfRk0JcuAGD4pt2rNKwRto5yR602GNFPIIPqeKmaEh3LNx2prcdXR6GBOCZG6BgO1UZJMocev6VqXkCiU7WI454qjcQhIX4O5hkHHSholMwbuRssc/NwOneuR1NiWkbjqeAK6/UgFt2I5fHauM1NjhyD26UpEyRD4ex/wlGkBlG1rgLg9DlSK9LTa8pWPa+087ea8pt7hrO/tLpj+7guI5CcZ2gMMn8jXrfk+XO4AVPm428Z969bAv3GjwM0X7yL8iIyxtcNApBlRQzKB0BOKfcQsLeRUbypNpCNgHaexpbVV86ZYYDFGjEByoAcnkkd6dPGJWR5SSqj7nXNdp5YiW4IVpTudV5cjrQCj4Kt16Gm3LSsEtreJzNJxv6JGB13H+QqKcRRfZ7bziXmbaiDlmweSf7qj1oASVfnDcALyMD7x7YqQRI1wJJSGKAYRex96bqMF5c31lBDIYLeP55G7MB2HH+c1BpNrO13cXt1NIEYlRGygb8dxQBclTdGep74AqssK+UwcZX+LPf61aYsZQQMwkEkE8n0/CoLRblkkadcLuIGT2zxxQBWSNbe2+RFjhUfIFXpnvUdnFvuHLtubgBhxRLb3M+pRtOjLbx52MJyOf9pcdPfNT6Qo5fkhmPP415+Ol7qieplkbzcjq9JiygGO+AQa6CBsBQQcnisnTNqrhRgjua0yXXnA3nsOgrz4xZ60tS0cg9cmhwdpUdT19qIxkhQwzioZJfLYhvlB7960IZXu2K7QMZ7msi9UbGLeh4NXrmQMflJNYl7MyouXbOM9aRUUYOoFtzFcDHFchq0pMrZwSorqb6TfGTkcmuQ1gA+ZjAPOc0kle45C6bsNkU2gvuMhXucnj+VSXFpGZIp3idXQ7lHb6mrOnRxx2lsqwkPIEZiwz+vXvV42wwYkZfMb5tpfqM+nXFe5BWikfLzd5NmGxdQ0jjc2MRYH+sb+9UMUC2kZd8tPISWfOfrj2q5PFc3erwQR3BjWHLTSIAcoeiDsPrVswj7ThAGA4HcCqJMRYopH8wtuBG5SOwP8AKmwWUNqD9nDZY8MSTmtCOIm4uJB86swUADsOOv1pphE8qSwyARKD8oPBP1oAotaqWJ559qK0ZLeUtlVYDA4BFFAHqbW4l+d2ymPuk4BqtdadbXQQ3FvFKM5BBrRIzErEFWIyR3+lRmZRjG1TnGDjn2oAh8kJIIoY2UN829B8ox2qrdrcxSP5SyOGI+bqq1qRP+8Pyjng+3tVe+QGPCuUbPGBkGgCOMSCPax3N3zSmBSQcHd6gmpIkO1cMzHHOR0NJGjvvjfepJwGHHHtQAzywDyvzZ70wgl1G0Yzliab9i+yMHLSSk9NxzmrCusqoV+XdyAaAMjWmcJCp2rG0g/HAJxV7TmXyEJHPQVn+IA0jWSMUB8xiNvcADrUll5gUFTuPavHxrftT6XKaalRu31N/cuVPcAZxTkZV27wc7iQazoZJY0YSkjHQVK11uXaxGcda5D1oUddDRhO4cgsTUzMcbQM57H+E+9U7TckZYYPpk9acZdhJA+960EVI3dkRyQgySM3Jxzz7Vm3ir5Az3GAa13ZGX5ABkc1n6gf3YwF3DsKFa4uU4nVmdUZT/ePbpXKzqZXIIH5112t28jBsnvk4Fcfd71uAueVPU+lVKNyZbFXULZnsrhY8FyhPrz6V61o91/aFvFdQQbLZoUZHPVmIGQB6V5aApjYAkkjvXe/Da8Nz4XNmzbpNPmaFuMZRvmX+ZH4V24GTUnFnjZpTvBT7GtIwa5NqMi4eMspKHaq5xkml1K2unjg+wyx7mnXe2MFEAOcH8hWttYRZ4BbgDFVpXlDP9j8lthKsCNvI7Zr1DwxhhBjMMh4YbcHntzVfT9PjshsjPyoNsSuwYqvfHGcVbijaaZZZFMW0fIpHIyOc0+4tYGnWcbQyKfmJx9CaAK4jjUtOeqnqRnHtTbhBHaNkhZGwAB2JNTRm2S8FoJd0rx+aBjt2NKLZI5GkZ2DP6nqaAK7A/3eRxu7VE8J25G0u3GR2q+QHQEgbRzuNVLW/t7ywluLRTNGHKRgD77AfyoAr3aCOwl384XJBGee364qLTYykMR7jrUusIy2sEEj5lmYbgBxheT+FS2CZjwckk15WLfNOx7mXQ5abfc3NKQvteTnd0FbAVQoZsg1Q0+LbBhRjHr3rTjViAxH7sjg1gkdzFinRSWH3vSqzypLJkgn+lLNE25toC57iqqts4Hbj60EjL5lEWEHOec1zGoh9vBrob4gscfWsC+UEfLjPepZcTDu5SkYH58da5HWDthmYnPHOK6fU2CoQmcrkc1yepbWikB9DREmo9NDq7WLNvDmMxOirnd2GBSXdmsty80AEVxsERmVAXKZyVDdfwqdruKGW3ttxeWRB8qjO3jvVq58qGMrKMhsAnnFe5DZHy8t2Y8VvFA0lpaHy2Ub8ufvk9ye5qW+tZJYQqSPAxdG3oegB6VYC2y3qQwpm4YZHH8A9T6U+C2kjE5ncSF5NygfwD0qhFCKxSO3EAJZMnJPAJzzioZLeNT5QjCqo+VV4JHpV25LmdI7eWIbW/eow3NjtinTxBcsuN5OM0Ac5G2pSoHl0xLdj/yya9Qlew6fn+NFashKOyqqYBxRQB6VNG043QShSuRu6gUrWluYw8sYkYKCXIzkjvRPK1rbFUgaRYxkCPv7VWEtw9wsllZPMsoxveUqqDGckH+goAkaOGGf5nKvOw2J17cmrBiGM7s4qUIz/MTtc8Bx1quJA8sizb4vJ24k4Akz/OgBskQeYNgg9BjvTPmaaSJoH2JjDluGNWUVQzvlst6+lJKrK+VVmTvg0AQRgJ8mN2Tx81JcSpHLHuAUOdqj1NWGQDHTPtUc1sJChlG4AcZ7c0Ac74mZY7qyBOPlYkY9SBVuy2lFG0DHPHQ1m+KVVtYtI+QPKHA/3jWhanbbEL2wK8nFK9Rn0WXtxoKxqOqTDO05VeaqyKVI6ZHAG2pInKoAD94c1KuHfLEBvrzXJKNj2KFXQVGYIC4O0dcDpT9+6MJwx25BFLg73U4wwyTn+dTQlE/iATtgVKLcluFsoyuVOApJHrWfc4875jz0IJ6VfknULjd24JrNlMkshIC5zkmq5TJNtmPrIOWGOvQAc1wmqxL5m4Ahj3r0K+/1eXA3A/nXHarGBKNuCx7VSHVj7uhjqhMXBAIz+Na3w6u1svGRs5DiDVoTFz/z2TLJ+Y3D8RVGeAxgBBnHJrJ1YTJbrcWpC3Fu6zRMDyrKcj9a1ovkmmjzsRT9rTcT3hVBjLsduOADTGt1lciTDZ55NZ1t4ntNWsra80d47kXIDyKfu2oxlw57MDnitaHE0ayoSfM+YcY47V7Kaex8w01oxu0Iu3A/wqpqlhHqNutvKFaJm/eKRncPSrNtMZ95DKUB2/L2qcOkRRE5dug9aYiillFFdCaGNVYgRnAxtQDAUUsto0k8S+eMJyyHr+lXEV3wWAU5p5gCs8i4D8fNjnj3oApRL5gDJEUIyAG4P5VFb2flSIkaJHbxriNF9e+auqoRSqg7Sdx7025cW9vNMQcRoW9unFJuyuNK7sjmNSl+0avJsA2w/ugffvitPTiVdQc4+lYthG5ZDyzH52OMck5rqdOQnBxx/KvFnJyd2fUUoKEFFGlbyhgBtwM81fdkCgknjgDPWqtvbOYlJxg/N05p1wAzqpBDZzzSGyQOrcg4A7VSlKgM2cZbpU0sSEMVlII7VSaBiN2cgDpnvSFYivFyAVPPbFYd6yxh92MYq+TIu4OBkD1rC1OZShXBLdfxpFGLeMSXYcL1zXKXxytwT12ZGa6W7lypGcjoOawZkDmVCBllwe+KcdzOXY9Hiji8qB9oZjEu046AgUyaEGJlBAJ45FR6G5m0XTmHA8hQR3yBirTRPIrJHt3HoX6V7cfhR8zJWbRnTQeUsQ2uzsQHEQxkD1PYVMFHJGNmDzVm6WGOEGaTCoMu2cBvqfSq4laSSMRQ4hBwGOPmz6VQii0gt7XhSznpjgufTNUwL4XGblYFttm/fnDxnqVI6H6itsxiVGaRFwG49u2RUZt05IPU885oAyII4byJbiJZDHINynkZFFanlqOBkAcAA4xRQB3aksrbABt5J9DUccYQFhkFv4h3P1qy8blSioqrjgDsaQEqAHICr1NAFQGbowBB4GOpPvUc/wBlaVYpTGZ8b9jHkD1xVrG87lZlUMGwp+9jsfamtEq+ZKyb5GAydvX0H5UAM8whvlOOOakRw7KzY2/dyD0NVPs8gMzO5iXoiE5B4/Tn0p4hERgeeIs0W5gEbKgsMZI9aAJ3jQSIxJ3ew4NNdGjVvm3A5IIH6U2FRKrFJQ4bjoAV+uKUR5RtjHeoIHPFAHHeJHaTxHGGG3Zbx4x7ljVyAlVAHTHSqHiAsfF8keGEv2SElccdW/wrRsVY4QklGHBNeTiP4jZ9FgtaMUPicgEuSGHAXPU0kMkhnXJ5xnk1OYWXK7lwehxyKdFEgkPynAGOO9YtJo9CmrFyF/MDA8+tRzAhiEfcD7dPanK5VgNmFxihhhS/fdzU2VzVXZCXIPzc4FQNOFJKjP8AWi7Yopxhc8A1lPOVRvMb5Rn5qTNIx0F1GZSpLbeuMd65y/AaX7uCT1xV69mLOTzxWdKwZS7bsj3otqVNWhYbOPM2plQVHfvXO6yxKlFACqPmx9a3vndJFQllxuxmsDUVdtqDHzfex1rogedJdyv4T8RXnhWWS7hja4sZgUvLRuRKmeoH94dQa+hbeRb7S7efT7mJ4LmJZYZlGVKsMg4/pXz75CLbgZ4Hau7+CGsCJtQ8N3WVZSbuxLHqv/LSID2OGA9zXdRnbQ8nH4fT2kT0AaeWf57glVOSFXbub3qxCgcFnjMMmSvzYPAPBGPWp0USQsWYkNyD2H+NVLYWtnHM32hp5m/1spIJOO2BwAB2FdJ5JMYpDNliAhGAo6/WohIJGCFTgkjI6ZFLGy/ZzeQiSUyKChOeR24otFnSWNWh8tGGX9M+oHbNADInkZ51aAxRo2xGZgd/HXHp2rJ1xHttAvZJJS0shRWIGFHzAAKPpW5eBtu/BkJ4WNep+vpXOeLXvpbG9VoFisIfKLOSD5zlh932HrWdV2izWgr1I+qM3T2YyKoIPPauvs4lADFsEjFcRoih7oAnBJ6ivQtLgyEzyCMYFeO9WfTl2JgFXLA56elSNlpAQQcc1P8AZkjiZeoJ7VTkhaNv3JAB7HtQyXZkdwoIO8bfpVKSMIcZPXdmrJeRSdwHDc1XuzlQwBIHUVmIwrkLvZwTtPTNc3rWBGc5BY8V011AWUFWOM55Nct4k3pbgyIwAbjtVIox5hmPrjt0rPjjxcEEDcfWrkhAjU84znmqrn94COp4+laU076mc+iOz8FyedoSgbcxSPGV7gdR+hraOwLyMA8Vz/gJpm029jWEsjXRbzCcKBtGefXPaujeNZCuzkD5c169P4EfO1lapL1KLBriIRuiLFnJU85HrVSSFpudwjSQ7VHQ49RWndmOC3aSTOyMcqo5xVK9RbMpMXZ5A21d59eoA7VZkQxl1maDhUx8gLZbaOpPpTVidHY7QDg985q9uUR+Ycgvwcjn6VRu1mSyumilP2mUlbfIGFGOPy60AY8tvbJIwleTfnJwrkZ/DiitaM26Iqq8mAMfMuSfeilYdz0Nwpj3I2S3QjvUE7LHErzlgrEIAOuTUeqXIgNtCjFWmbaqRj52A649B6mrRt0k2owJRBwtMRCgjRQ8fIxkc9fwp4UBQcknOT6VEtjbjUJrlMNc4AP+yo7D0otl2rODcmW4PO1iP3Y7ADt+NADVtSEOSGYMTlu+TmklhCshz0IYnvU8a+VbopyxxknOetDguVEeCvU0AU5kUSxlIm2vzuQc/jTyGjbY48wE5BxtP0qeSMx4MRZn6nPA+lSAeYqMUKHqq9T9aAOF8RPjxuSQciwgwD65ep7V28yMnIUDnPbPem+NLeVvE1tMrHeLdUIHTALEH6/NSRWDSJkEhjxgnivPqpc7PqcthF0ItmrIm0gnJ64x3NSxqNhOCPYiqws2yAJCk2MgDkLTWhugSnnsWJAOB1rCcUelTpp6Jl2QBQWOT7VXeYkPkYCjjtmmpBcqGJcHHOCap3ImUHKZ56E9ankRuqPmR3V0HKg9MVjXMxIcIuST0qS+nZGJ8sgDjrmsp7og5YD149azfYbptbImmG5VK5B9KpSKdjZxx096s+aZVHPI6VDOreWwxnA6elXCOpx1ZNaFGaUqpYcE8fWs8R5k3HII9asTByfMftwAaiK7j6L7VtY5b3K8sYLkEZxzVFdR/sLWdM1m3LltPuEmbHJKZxIv4qSK1du0keo4zWPq9uJIZIwoxIhU4FbQ01Mq0VKNj6fu7ZFnfyiBCOVIPBB6H8qrT2nmqkfzAIwYk9+Kz/Blz/afgnw1cs5/5B8DTMx6lV2dfXK5rUJllkLRN5UKdWIyX+ntXandXPmGuVtCwoEjRVUqifKB7U7YpkYqSCePrUqHzEDLyp5FVruUBlSMnzGbH3eg7mmIJIx5bKD1HUVzvjNX/wCEXugo/dq8QBY853joPSumONgkk+RcZ57Vg+NsSeHpMMdvnRhQf4jmoqO0Ga0P4kfU5zwxCPOBI5B49K7+1DR7SOR7etcl4dtSnfLd/auzijiChXY5HevFPp5Eu6Rm6Dr0qORjvbcv5U/y13ArKwX19arSeaSxHIz1oYuUY7ozkMBnp0qC4GY+MED0pVjJkfd8vU/WmE7UBznPXFQKxmXOA3PAJrlvGjK1gdpxzyM1194p2qAOT0PWuN8ZRSCPdjCdMVa0BHMqDHAGBXJGeKrviRwzcAjkVMgJjCDAGOKbY2r32p2dknW4lWI+y9ST+Aqqd27EVWkrs9D8LWT2vhmwV87pAZnHuxz/ACxWjc+Z5b+UBkD5VX196staAXolViERPLVM4AHQVUvpo47OWRZo4sssZaX5VBJAFe0lZWPmZPmbfcp/ZrqWzdn2G9Zfuk4jQ+nuKV7WYpAkjxtMpHmSEcH1C5rV2cKFJOOD3zWRPax6yfJuIQYY5lljJByrKcgmgQpWZnCNbqIQTtO7mqzxI8pkkHyn5Y27gdT+NLK9xfS3ESERwswBx12g/M349KtyQyOw2sFIGAoHGP8A61MDJmuTHIyqJMDphgKKsLaXO0b0hlbu+wc0UAdsY40mM0MSPOFCFz125zgelLOwijaVg5AHJUZx+FTKvIBwB1JppmHkMyEOAedhzQAgYKOOdw69M0LDHFI7oqq743nHJx0qMxD7QJCxJXt2FOaZTKwRSRtwHwcZ7UANMaiUuq4mkAVn7kDpmoY5oni8y3yyEkAgHBIOOKsLEAcPguR8xBp21do4G1R09KAKrMRIiEkcZb/ePQVKDIJNi7VGAc5BOf6U0RGRWuFBTcCFLfl0qKBbewgd0Ulo8yPk8u2M8n8PwoA5vUZN2v3Gcv5YVATyT61pKh8lQDnuOK5bSJnuZpJ5iPMdy7ODnJJzXX2siyxAnrnGa86T5pNn02HXs6cY+RbiiQOQG+XaOvr6UeTHKQKl2hIjjDFvuk+tL1YAqA2Oah66HXTk9ytJbx5Plg46jnvWTPbujSCWXcQSwPTit9woACj5vasbUWTe3HI5zUvRHZCo+hzN+mxG2465yfpWIY3dgSFznFbOpck7s/WslpWBVR3OAaxZ1OTUSzHA8UfyBWwOSRwBVLUGdGO4DOODWhKSkeHbKY7GsvU5MQg8HAxk9q3irI8ipLnlcxJi7jjucCmxqejn5ulJIwXJV+O9RtIGYcA+9apX3RFrEsgAfAB59e9UtQwIuhwauMwKCQ8BTx7GsjVZwFkkkzhVJJA7d6tabESaeh7z8JoxJ8LfDX2kDMcUh+b/AK7OAfyrqURYo1QA4OcDOc5NYPgyxk0vwToltIdjf2bBsQ9pGG9iR9WrplTagHTArrh8KPmKms2/MqEEXaL+8GEzx93HpSkM+WyEB/OpSheQr1AHfsfeo4JC8DOqNtYkAt1bHf6VRBQuZWintbfeNshd5HkOTtUA4Fc/4pvYr24tLWzcSRq3mSODxk8KPfjJrc1a9ihaKN7QzLJ8nAG7B6nH931rk4pPtmrzXSqqI7naiDAUDgAflXNiJWjZHfl9Lnqc3Y39IXyZQcHPrWwrFjjjr1NZ9irqBnAI65rQtUZvmYnjPSvMse+u5ZYZXHBPtTGGRyCD9acv7tPmI561AJRKxCbvlP3sdaUtSHIVjwSvrUNwsLKD909sdKAsgkKhiF5Jz3qCTk5HSpsSihcF2BAQlf61zerBbmymjwAwB4Jrp3YCUE8VialEpun25AcYzimgkefSkwlQ4/Gtz4d2jTeJLq7b5UtYRhj/AHn4wPwFZ+oWuGkRxkZ4Y+tdd8L7ULoV7dzA75L1owR3VFAH6k104WF5pnFjZctJ+Z1MxYcKjNk9fSoIzJESsYRm6qGHy++atQK5aR5htGcDJ61Iys2ZCflPGMcCvVPDMW908SwQ28JQRxncDuzznv3pDPFbT3pWSSVYIt8qImTGACfqS2eB7Vp3SoIgPLZs54Q4Le2azrlEkKiGBJApVroZ5YhflXPcigCjpYt4rqSILcR3UyfaSsqnaoPG0HoOf4anvFeSSIRTvCI5AzhFB8wD+HJ6CrkQiGPLLZTgqScrnsQaGC7slFBbPIoArNI5Yny8+4orOfTb8ORFrMmzPHm26MwHoSAM0Ur+QHf3KsIuFyo5Kg8t7VXt96ACRY1BP3Y1x2q3LwygEFsAH1JqM2yvKHmyQBgLnpTAJVV4XVCFzxuxzTBHgqOMqMZqSRkUuxYfJyw67aIhtGSclhzn+lAEOwAZRhtGRnGdx+tLJhR84/iwMetJJH56RqDvK/MhQEAHsaWWPMccJdzIrKA3dj3oALltkLMwLCMZwOp9q5/xjMkXh+RmU+YSNhVsbSTjn8yMVv3LCGBmckKMAYGSxJ4A9z0rjviDvt7SyhlQPNeXH2mQ7uFVBgKPYbjz681FR2izWhHnqRXmYuhyBxsI5YgLtGBx7V11jKuxVXIXnOR3rn9KgEMYxDj5iAQeSPWte1J81gcDGBjPQV56PpuhtrKkkJDZEikbaVHAG/DHBxUMOWYRg/KVyGJqZBjG8DCngjv9aLXNKZBdzhXYIxAIyQeRWNdlmJbPUAVp3ZJKsUOVHIz1rOc7o2JUZ6VLXQ76eiMHUhkFT+GKzo0UMNqgnvzWteY3cjPNUVCRzFz0PCjtUcvYqrPliUb+cAZRCcDHPSsW+mLxEEZOR3ra1SZfJBi6A5xXNXsh+YqR1reMe557s9ilM6qwyfl6EVCsv7o4ODzgmmStuZ1buKnt7dBBCWZg65JHatCZOyJ5yUhVdynGDkc1Bo2ky+JPEOn6LCmTdTAy8kbYl+ZyT24GPxqC4uNsbuq/ux0JGOelez/Bnw3/AGJa31/fKDrN5GhMKqd9rASSEIP8TEZPtiqjHmdjzcTiPZwfdnot2rMpeFY1OQBuHCD2qrJIVlG9hGgGVwcs59/QVccLkKerchfSoYrdkOQVZieccYrrPDGhGweSCwqorLJI+8gxREAMDj5u44/Crc8ZK5LsqgYHNQzlLaGFRA8gZlACDgDPU0AVPEd2NP0+5unA82OFliwucM3yjPpya4rTU27ETJIGD9a3PiDJJDpVnCWBe6vA75OcqgJ/IEisnTuFLL3PGa4cVL3rHt5ZC1Ny7s37TcsOZCB3+oq7byBgAM8GqKsqqqtycYxVzYAoPG084FcJ6ttCxI+9ccHmgBoj82R9DmkhVwnzqMHmnzFRGcDik9TLYJHMgBOBgcH396zncqW3fWrXmr5LZyMVn3DfJhevfNIckU7oo+XBxjjr1qrexl7fIH7wcg0x5HEuAMr71PbyAxOr49B60tRW0OP1NCGYMCc8kA5GfXNdH8NWebS7y2JGILve3OchlGMenINZWrW5Gdqj6U74d3BtfFc1qSBDfQFQCesicj9Cfyrrwz5Zo4MbDmpO3Q9BfBkwVyi8gg96qXLq9xHbiIP5r7+SRgDv/wDWrTddynFRspSMYy+OwHNeoeGVb1mihYrHuZ/kUHjk9BiqsVl5CkLIWIHLdMt1J/GrYf7RcGSLEkakxxfNkZ/iP17VLIsaqEMiKwPQ0AZtyZWiZZHbBx8w5NVmSXPRHQD6HNXQ4aVl8qRApwHLAhh7f/XqvdKYyskRAG75l/vD1oAaElYAsFBPXBoqQLkZOBRQBvuka3mJXPmOAFGMAD6/WpJ1ECvICTIeNoPXHtTfI3mMSHdJnJA7n0/CrZVZDtBH7v72BzQBTiiSeESTwNDJIBvViN3HrioxbyeczeZuDEkg9vQCrLqwXanA/UCmOJPNiZJvkT7ygA7xQA1vN80RRRBVH3pCeAPb1NSOhQboYvMkxgAnv60+d9kUkh6Ku6q6lrlY4WyqOgM/PQEfdHue/tQBXtwblUuJEzHy0ZZuCx6tt/DA9BXC+OJ4n8ThIkGLaNUBUnqeWGPxFemKiE+UApwRlAegFeMatcte65dGJZHF058tYuMc9/UEVhXdonbgIt1b9jo7OVfs0aiXMmMlBk7MjkfpVmycI4zw3XLVnaSgSIF8jHJJ6jjGOK1ZFXA81Mgcqc1xpXPdvbQvQl1nwG3tnB9PpVlrg7Q7AqQcfWqEI8y3MkbFSeh64qzIS0Y3Fgqr/D3NDWpvCSsEgMpOeMdKoyRyIjFGDKe2Ksq5ZSN3ToTxSO+f9oAfhS5bmkajiYc0T7mmkUbccAVg6i6CHIyAOh7Guh1R/MjGw7QOSDXGatIZECjAQen1qowSCpV51YpXFzuUopxj0rFupshlIOQO1Pu7gxnjH3sEj0qjcuJG2xKcn071aVjkcx9qPNjweWI59qsMojTgMx+6MDJJ9MVb0vTLme5itbK2lu9QuOI4IlyxX1PYD1Jr1/wV4BttFVdQ1N/tWtsBtwuY7UdwoPVv9r8quMXJ6HFiMXGHqZnw08Am1eDWvEEKGdT5ltYPz5R7SSL/AHvRT06mvSrqNrlw8m2Qsc5bgg+zDmk2MJlIeRlPDZPb+dTusyjfBsYDkq3X8K6oxUVZHi1KkqjvIp7LqMthXlj2/wATBuPQHrS/boU8vzg1tkYBlGBn0z0/OrSoJSk+1kYDGzdkfpTZCHXopOcHcN2PfHpVEBJnPI3KcFc9/ehFMaEP1681AtoI2PkSeSfVB8v/AHyeKkZpowFmh80Y4kgOD+INAHF/EtiZNFXIK/vmGPX5R/WqGkxyuig/d7/Sr3xHkhmbRmhcmRGlBQqQyj5eSD9KXQ1URgnJHpXnYlXmz38vdqC9WadnGHmw33s+lXyg84Ac9iR2qtEmHbyxtyeTU0RKMwGc5zXJJWPQV2XPuY2n8cVTkD7NwPHv/hVhA7AbmGabIrZ/gODUO3UiWhRueEA56VTuyNrcEEDrV28BY7OOO9VDhwBj5hxn1pPUq+hj3JBkDcL60SECMeX95qLuMbmK4JqBX8wBX+Vh2polkF8jGJmwQwGQRXKX94+nXun6qhG6yuEnPGPlBww/Imu3dGOc4weOtcrrVn5kE0ZwMqR0raGmphUSkrM9eBDMSjB42wygentVa8ZnVbdd6yTZBZTyi/xH8qy/Ad8b/wAH6Teu0g22/kXDO3AaI7Tx24Ga2YA0kZlZBiUZQj+Fewz+v417EXzJM+bkuVtGatrFBH5CRytGoxGVBBA9zxyPWp1tkUlsys5H/LTkj8acs0cEJ+1Stu3YJwTtPoSKsFcruRgUIyMHrTEUJF2E84Pr61WCtDn5Y3XJICnkj8auGSNW2SZV8cHFZ+pXEtlaSzC3kugilgE4JI6DH14oAn8zPOAPbHSimw3SPCjP5MbFQWTJ+U9xRQBtSXEm6WA/63IYyDA2xk9vftVqJFZpHkBbewZgOgIGAPyqRokaQybBuIwT61HNiJVSNdztnG4nHHrigBl+Glt5QkzwK6lSyMFZR3INOj8i0it4UdAAo2g/xev1NZes6XaTyw+dNMruciCPkyHsB6Cpnii09ZbuSNJb4ERkNJwmedoz7UAWpJ5Eth+4V55XKxx7uD7n0AFRsNtkyvG5G/AaJyWk55bPGM96fYmY2xnukH2pxyqNlVXP3R/WpY1QTNINwdlAIJOBj2oAoa0/2HSr27YENHbvtIOckjA/U15HDDG92AVyyqDwMYx9K9I+IN0Y/DqWsjRiS6uVVQnVY1+Ykk++3868/hlP2iQrG6uZPnAIAb1wexrjxLu+VHr5ZCyczc01DLGzKIyEXJDDqB6VcCh12sTtJGP9kVVsGTKtHhWx0Pce9X5QElUMQC3II7VinoelLctxuIbRYl343HHH86WNmDkh8g8YHSiNFkh+dhz8y88mknQIIyAV2gYUdfr9KrluOErDZMAyKx+bvn0qtNOPKZXcrjPOc1ZmcFNzDnb3PWsS9kwrcn1pqNh899DN1O5kEL7icHpn0rlNUuR5Ixjd0OK2r/50dixKjqvoK5TUGyzkcIc/hV2uVdbmfM29sMQGPaut+G3g+bxDqDkuYLK2+aafGSD2Rc9zXKaXBLeanDBbpvllcLGh6sTwB+NfTvh3QoPDfhqz0pQJPKG6ZxkeZKeWYn68fhVQhzOx5eMxDgrLdkmh6Np2jWzWul232cPzI5+aSU/7Tdx7dq00jwhyTz69qbFJCRiOTLdfpUYeQSASlWUkjKnn8q6UraI8dtt3ZOFKLlec0m7BwG2n0zg0iSqdo5AJwCRQy7mfzAu0+nOf8KYiJw0KlolGCckYzk/QUiyGaIuIXRj0DrtJ/wAKdcW6zRLEzzbAchY2wQfXNPgRoFxLKzgscM2CaAFERdNzDYerKaawTb2UYptzcJBE0lxMsUe7aGXLZ9M1JEsMuAjJIG49qAOD+Ik3matptuTl4oCx5/vNx/KptIVfKGCMZ29ehrF8Sz/a/FmouDlIpRAo9Agx/PNdFpEOyzVpAVbOduK82s7zbPosLH2dCK7mnAuCVIPBqURjcSM5zmmxEBDjJz2JxmrFq4AIxg1hJanUnZXGooJ+Y9fao50+bAcfzq43K4wM+9VpSAj7gNw9Kghu5mOyk4f14NZrghypLccjFaMsRYjJ2jPGKpTLIJcISQQallJmcQzN+9HJ6VWeMm5B7+taJ+bJYbSOmaq3EWDkE7qAZIEbYGIBHv2rK1W36s3G7oK27A7iy4yRwc9Kh1CBpEYEgha0p7mUmZfgS1iur2+sZ2crauL6KIuRE2cqcr3+bBNdlFAlmWkubqaPs6pEFhPbjGcfmK8+0q4GmeMtJu+fKaU202TwVkG39DivVSshkPJjK9w3B9sV6OHd0zxcbDlqX7laKE4JM3mIw6MBnH1pzkD7wAQD8BTLuYRsN8bAN1kUcA+9EUyTAhMFMdf6V0nGQy/vog0TI6/wkHP5VmTySR3KSyBnCxtsjRsM5zyQvfFaFxB5aySW/wAxX5jGi5Y47cVDDcJcqJXTbcAEbJkCuv4ZOBQAiXCyKHww3c4ZcEUVAxmDH5GooA6sAj5ACTjrjpSRlG2n5XKN196eA2F28jdjr1qCaNxc+ZgcL0B6H6d6AFmUM4uACZVBCEjB54yKq2UYa6VYYk/s+Hdud2JaWYNycHqo55z1+lOeGa4nmXc8TzqBu7pF647E9q0I18pEijh2wIoQAHgAUARMreYBlRFjBx1Jp/lgjKgHHY0rKSwxnGar3UFzdkRWt39kbjLBQd4JGeT0oA4P4mT79dsLRNu23g3SAYyDI2f/AEFRXIWLFn81XlEhkKsNu3GD1B5z0qzrNwt7qt9IDJIElMIaTBZlXgMSOORVSxeUkpJN5ipjaDz+RFcFR80mz6HBQUKaOltWJCFi3mqNoxgfiastvlmSHYpbHzN2FU7dzsOQSWODg9fStBY2gVyBuIXJB9KlLodLsRtMsQYnJCcKByMd6vNLjZKpdoNoCMwyfoazFQOgIA+YHn3BHUVKzyDPlSgHbwMe/NaoTSYl3OWjLhCVDcEetZFxkhvOZQ3TcehrSnUssnQKhGSOM/5NYuo4jQ9Sucj+tMEjF1OYCOQ5VPlPIGc1y923yMFyd/fFb984EZKhSPXpisK6cs2xnUsWBJBz+lPRIUtTvPgPpIvfElzqU6bk0uPK7gMec2Qv4gAn8q90bP8AH1J9etcD8GLD7B4EjkGHm1W6lusj+FB8iZHodpP412SyzPOYmEW5c8jINbUo2ifP4qpz1X5aCb5bTICI8THvwfpT45ovMJ8sxt33KR/9arMDSZBcBD2zTzMdi7ow6nksp4ArQ5yuG892RAVKYJJGAcjPB70rh4eQkkinj5eSPerChNny/e9P/rUgIk4LkqD2oAr3V1b2sW64lSFH+UM4I+Y+9HmOPmjgS7t2HytDIC368H8DT5IV8xdz7lzkKy8Gp2k8uNjsGxRkJGuT9ABQBVxDJGFYGPPOyQDI9j6U+MGNo2Ty2RDnO3gd+1ZUWmQ2uqvdR3U0duw/eQy5bn0yePxq7fXK2Ok3twEdBHBI4yMjoccilfqwtfQ8v09Dc6jLPOPmlmeU/wDAmJ/Ku5txiDC8gjArjvDluTCg28YGceldvbRglI4/lAHBz1rzVq22fTNKMUuxJbJ+7yxIOPTNSwwjduGeeoqZAIkyWzxUkZGBtyT71HK7j5+wxxs24AOagbIOCBtbrmrUxQKCoDPn8qq3ZbAOzBpOKJTKkoVCfyrImUmc7SNvUVrzyoGAlX5T3xVC6IJQoMA1lc0RmSRFmO7kVEArR4K4xkA960HBIAHrVaeIo6kMMDnB70hvYiSM2wAQMUznmpch8sOD71LC4eIhuvUVFaEFwuT/AIVcdDO2hx3iyzDWc6xk+ZnfGRwQw5HP1FenW0p1TT7LUbWVgLmBJdhHGSOf1zXJ+IrZtnHHB4IqbwDeRf8ACK3dtcTmNtMnZEY84jk+ZOB77h+FdtB2kedj4uUVM6N4nhaN7q6jhklYRrGdo3N2VT3J649qmbzNpACb88ZqpPZ6frFjaC5Rb4WlxHcRtLlTHMhyHX0I59uxp08kNhLGJw7G4fajAFjn09hXaeUSARl3KjDLjcfX8aq3htoQ9zKoHAUyJGCeferUsipvf5mA6qi5P5VlXbXIhdlha9tpBkxrHhgPQjrQADUYf4vOBz/zyairEMsckSOIrlAR93aRiilqB0kciSFmUfulPBU8H6VDZ3shW6aW327ZjHAq/wDLX0A9yf0q5CAFCOFCKMAdAoFUcm8T7akmxVOLZccAd3+rdvb60wF0+01BTNJfzKJJvndYzna3YA+ijAq4Mom123Y4zjrQZFXgDazdj3NOO0qMg5Bz170AQvuZQ64wMsR3Iqnq+oLY6Ff3oADRW7mPdxl8YUfma1IyIwzMcIOp7CuO+KdwU0iysYywe8mMrKO6xgkYH+8R+VTJ2TZdOPPJRPM0Pl2bAFm8gDjjc47n3INW7dVXy2wwmBGSU4YeufcVRtlbyXZd6krk56MOh/GtC33JahT8xUcANwy9h+FcCdmfSWtoi7bEyvlS42noB2rZWXfHlSTgY9zWXDvaJdny7eduf51dLeYpOfriqejLJixGXCc9xux+NQbw1ztLHbjBAFBf918zYRe/p7020BR5GA37zkse1WtQtYLze8O3cAM7t2ATkdBXPX47kDAXPHrXRXixw2x8scbtxHr6muflJmOAeNvAI5FUTF2MDUFKQeaGAbAzuHeuX1NCofywN2NuSeef/rmuqvwS2WZs5IOec1neEtO/tTx5o1jJ9yW+jLA9ML85P5LSexNR2i2fTlhYf2XpenabDsVLK1itjtHJ2qM/rT/LkIjbcI5AwxhQePepZ5o5J5ZvPAIyzBcHqetNLRRwh2bzI+xTmuvY+ZbvqyHV7uS009pI4PtLA4KDqR3q1DGEijVAECgDaO1MhnWQZiDbPcd6m2kDjcR9KAEEaFv4ctx9aXpuVG79PSol/cQyGeVpAgJDKnzY9MetQW7XbW0U5iDLKocxswSRcjoexNAFpU3gq5385yeMU44U8MgJ9TzVeFZ43CujPk8YwMD+tWZVX/loFznC8A80AQTwrPtG47k9emKx/HMrW/hK8PIMxjhHbO5hn9Aa3j5qEFZARs27CACW9c/SuO+Jcu3StMhZGU3F2WK5/up/9eoqO0WzbDw56sY+ZjeHo2KHGVHGMd66u1O1QWHzetYmiBYLcfKuOx9avR3Pn3OyJflHUmvNi9D6KS5maKtvJGcmp/nGCSMew6VEgO4BUwQOo7mp5DuiIOAQcGrIRIyA4JGPeqFySbg7s4B496sPITGF2tmq8pclTj5h0FRJ2BDZYxJC3HHHFUryP93ujGT0x2FXw/GHwOelRSH5WwOO1YFXM1YzsBYc+3Sq90CUwRketX2+aNQ1Vpl/dkEcZ60k7DuQW6pgHaQQeM1DGhNyWY7eeoqY5jZV4xjOKIwjMWYHePSqTuG4upRCa1cZ5x1rmvBDCDxrcWUyL5OoWZDrINwLRncuPfBauogmEqGNh34FcbrDPpPiXStRVmjFvdKGZAP9W/yNwfZv0reE9mc9aHNTlE9NhhhtojHBGqQ8kKvHP0ofcY1OQh6kHn8KazzIzI6eaikjzIsA4/3T1/OqJu7SbzZI2VbqNcETAqwH06gV6aaPny4yLjGMD2OKpTqQFRUJQnlsg4qyj7wGUhkI4IzUdxGNq/N16bRyKYEBjBOfMYe26iqzXEaHa7x5H98HP40UAdJLm6lkslLCGPBuGAxkkZEf+Pt9anVVhi7BVOOeBQ0f2eJIY2fuxYj5nbuT9afGm5SsuGRuSrDOKAHbFkCMTwOQcVRillkikkHmhRKyYcYORxx7e9XVjZB8jLsHCqq4wKUOqvtdT06npzQBHA6vvUyBiOSuMf8A6681+Id6LvxbJCACtjAkCqTwzH5mPt16+1elQpKb5VnA8osQrgfdGO9eL3l4dQ1jVLticSXEsiMBjK7zg5HbaBWNZ2ideChzVL9ijL5TIpikdGHB3Dgn1z+laNtCXSQbgsSsDjuT9fSogzeXuSX52GT6j0PvU1lv3gXG6cnJJTk4/wAa41oe2XtPZUOflXaDgnnNWpkBErqp6A5BwKowscRkAEgnrwfpWkRiA5RTnsCetVFF+ZXUlEJ257DIzxSrtQRLuIDHBJ+tG9lLsrkMwxtxkVXmLZR4hu2cYbP481oir6Fi/UzIUQqQB94cZ9aw7wsijKqhIwTjr9RWjdOzkAAJCcnHt3qjqSDYu0qR/dHaqbM9tDB1WQImyPnjG6r/AMHrR7v4l20yKWFtbTSvwDtGAoPP+9WbqqiOCTDFwOW28Yx6103wDi/4qrXLpxt8nT0Tpzl5Bj/0GiOrRzYhr2Uj26QpCrSRx8nqEXn8aoizy0bWZdIlZn8vO3cW65yKuzxz/I0Hlkd1cH+dSvC7jlyAV5HofY11HglVzPaxgWtn5yZ5VJAGA9geDVrzNyKMFC3OG4NCxsAozlhVWeS6iuUSKzjmhblpfNCbD9O9AFoRIT8ygkd+9OCrjC9uQDSqpBAJBzUjLsBYKMewoArlpNuZIVdgf4Dz+tNhlWUNmKWIqcESpsI+nr+FCzLI20uoUnlSOT+tWQAww65+vOKAIjbqVK5OOobPINcN48dp9b0myOCYLdpmC9t7YH6LXewKj3BKD5nIVia8zluV1Dxbrl2/A+0mGPBwNkfyD+RrDEO0Duy+N6yb6GjYxSMqh8AL0rRijWEgsMsOc4qG325LcdeB1qd5WEn+zjnFefFntavcmW4Azg8jj3qZX3IVJ561UCxyN0Kseh709nEXzbhnoa0vcTLKff8AmU5xxRs2SN1Ix1qMXahfmOSTgc1YhIMZ3bRjoBUy0Rm2VXUNJkdajkBbHbNPYqJ8EZU9cdqHwQyqeQOKwNEZtw/G3IGCetGx3AOc5qvqUTw5cHdjJx1qfTZvPiUbsg+nY1N+g3DqZF5IVkU88HFXLcs67kVQR04qfVLTcGIwMdyOlV9JmDO0UxAdRxjvQtwtZBxHIQMA98msDxRZrd2Usf3WYHH5V11xbiRMjHPJOORXPa/bs8Jxk479DnFaw0eoW6m54Uv21Xwzp18+0zeSIph0xJH8rZ+uAfxqe7S6uLtVkWEWRUcnBfPcDuB75rkvhndCLVtU0h84nUXcK+jA7X/MYNdhbNJPc3sjLtQz+TEhGCqKACfxOa9Oi7wR89iafs6sokTwSoQtpKJFUf6u4HB9gw5H4g1Wku3ivALuFrJEA2ySMHjkzwRvXp+IFaRjKHBGfQigkohLgkYz9fatjApyafaXDmV7WCZm6uUDZ/HmiozpNrOfM+yxjdz0x+lFK3kB1SNK6MOMim+aETMyunY4Xdz+FPCGPryT0x3qITMAHaCcpzzGu7b9R1pgTplF3DDp+RqN5I4oy7tsGRkvwBnpUgKsu9B1HXPX8KZcxpIipJGsiOPnDfd49aAKXiLUf7N8PX95GwMqRmJADg+Y/wAqgfnmvGYLcRSIiJmTbjDclumePr+dd948vRd3sWlxMESzHmSMejSlcBT9F/U1wyFGVVDHKggBiQevb2rmq3lsepgocqu+o2fakabiFQ8KCvK807T0/eMEcpKp+g5pZC32WFexOWJ5x60kGUlwdnJxu6nA9a50rPU9FaovQSh2KBCNvOfU1KGcEoeV3Z4NV7J1QlQuFBI561cJUMpYdcCrSNG7Ow2Mvgbky2eMHtVmOACEsQQ7n1yCvbHvTlhUpkrg4Kk/0oUsiBgArJnA6jFWiXK5VulIZZGX5BnCqc/nWNPLtJLhiq5JB9fSti4XeCCAQDnrjGawdUUgKZQAQDgewp3FbuYeoPvSbA5bsD1FejfAO1ZoPFN1nbIz2luj7eBtDsc+v3hXnNyqNMr8BccivWPgLEqeE9akbJ8zVSo57LEnT86cF7yOTG6UWeiorhQyzqc9yODUInKqxaTzNuAQg5571OxEULHaWRVyAo5ot5FngV1JGSM9jXSeISDrwT9aY8KOSXQtwV7cj0p7qjHK9B6HGKguh5hji82RHYEjb93A9fT8KAGqkMjvtdwzYGxuAmPSrSpIkW0nk8DNQrBPI2y4ZJY/vLyQQaeZAWMYIDI2GDZ6UAKpiLeWyxsRxuXGCf8AGibEcJwjMh4ITrUEttG7I9sgSRXDEqcBh6U77WweePyWDRKH4OdwPp7igCS382C7jZITJGcE/wCz+PWvIPD4Etu9xJu3yyPJwcdWJNeuXF2trp9zfhgYYoHm3jrgKTyK8r8Owb7GINjGCf6/1rkxXRHqZYtZP0N22GyPfESMckE5qe3vhtHmZAJxuNQQkRkoS2McBVzUxieRVDhXU/d4wR7GuH0PZ0tqaIIflMn0rD8RanHp0JMuSrHC47mtO2byiIzkH0Brzz4t6ktpDYp5hy0hIHrgVUXbcyjFynY3PDeoPqmtlCxMNvGGOD/Ge1dc8jg4GCR26V5/8Kji1uZwf3k0m4nHXiu580s7bgCf1rKUy5QSlYlV2ZuQAKVJwswjkOc9OaQYSPPY965XxLrA0+901mcqDOEb3pXsTGLlKyOtvIMgevODXNpO+nXjN0iJy3HGK60yh7dJNp+YZBNc7qnzEiWMBWAHB5ptDv0Nlwt7arLAQyMM5FYl9p7pKskZ2sPwqp4I1AxavfaPM7N5TeZD/tRtyPy6V1GpWu9TtGMDr700upLbi+Ux9C1UXLz2twcXUTbWXH45qxqkI28Lwa53UlNhqlrqMeRkiK4X1XsfwNdSxaWBSvIPOTWq1G9GebXMo0bxpomoxFgn2tYZQDjKSfI38x+VetPEscr+xxXlfj21EcaXAYARusnI4BDA5/SvVJ0Mly8uFZW5Ur/dPIrtwz3R5OZxSnGS6kE+cjA4qLdjBOSBT0TAeV3LZ5AHQLVaCUzSHcGUjnaw/L8a6TzDOu7fWJLmR4NTjiiJyqNACQPrmitGTyt53bQ3eip5UM3ZfMAygLDHKd/qPesG/hu45Uae9uVUtnzbe3JcexwSP0rpAIgigybcnABI60118thjgnvTauIRQGHoSBz0J9zRcXUdjZz3dwN0dvG0jA9wBwPx6UhZhICxBz/CBkmsHx7MYfDhiDtuvrmK3APYZLN9MBf1ok7IunHnko9zibwqNHnu7tyZpS07u394nJ/w/Cs2KMNbvcEYDruwOODU2tTteS2mjJGyhxunIbrDg5/M4FXdSjjgtsA4UIBnOMgVxSbPckrIynRW2+XnAHK9vrVRBKDIT1AwPQitCFRsYpwcc5PWoLuNtn7tG3dd2MYqL6mkGS2cgfdG3DL1Bq8sZlt42bBkUnP0xWZBIhIO3DEYz6mtK3PzHeflIOOxBrU0b6li2IQ4dQMDrnOakWNgMbcd175qKONM/KR13YqxDKvluudmTnpTRDepnXp8v5sbcHazdh9fauf1EqxOZAT0GGreu3Lq7y7V8voGHB+lcvefM7DALDJGPSqtbUabbM64iO5Pl3Hpya9h+Basvgm8Vl4k1OZ89P4UH9K8dkDMwLbic17N8JvLHw409HD5e4uZSwBIP70jnH+7ThrM5Mwf7r5nekCT7rAqfemSyR2lu805IiQZYhc7R6mm2aRC2QwspQ8qQMVawrIVkUEEYYEZBroPFI1dMB1YGNudwpZFDKDtyR0prIxQ+VgYHQ8Ckgm2QIzuJGPXbzj/AAoAZawyrI5a5aWA9EcAsp9mHUe1PihSKLcXJjz0c9OehNPtYxFFtjACdgGzQGjuY38pklCnDbWBx9RQA6RAxCGM7PVexql5tres0SSNIYyVZlyCpHvVwSyGzR9rvJsB2oQMn8eKFlaZBvSRHHBVx0/GgDJ8Vlk8Ga1hizfY3GSeTnHpXIaHDiyjUDhRgDua6jx3cfZfCl0hzuupEtU/4E2T+gNYmlxlYk5xz61x4jWSR7GWx9yTfcn2YTKIOOoNSIX2kNFtHqKtxiHjI57kDvUqCJivzfQYrj5XfQ9BysY87bTkNggGvDfjhekavpUYfKrvbnt2/pX0BeWqNu+XPv0NfOX7QNpLbalp8zFgjbkXP51VON5WY/acsXLselfCtvN0ISRnPbIruRCyuOprhPgjGF8C2T7WVWJYFu/NelErntz0rCKtoXN3dysUOzDDjrXjfxjvGt9d8OWyk/v7lWHtyB0r2mdisTZHavCPilG03xa8L2752Knm89PvH/AVcVvfsxU5OMk1vp+LS/U94tnD2kauc4UCqOq7BFh1BUdsdasWBBhUE5IpmoFGBVhmiKVtTNK7ucPPPHp3i7Srhdy+ZutnYjqCNwH513013vBYfMmPSvM/iGxtoLa56CG6jbn64rt4bqP7HEzgLuTcOetC0dmayV0mZetsLmKRFTacEDP6Vf0W8Nx4et5pCQ4XY6+hFVJ5YLgjjcAeCDVfw7Cl6dR0873+yyec0aNsZ1YdjWsHd6CdorUxvGM3nWM6DLZBGB9K7PT7m5k8B6XPaqXuZrGJVY/wkgLux3xivP8AXRDBcXaJ5yxhS0Y5fp1BPbA713/gmCSPwToCyFlcW2/GOxYkD8iK6aHxteR52aNOEGjVs4ha2UNuSz+WBl2Ocnuc02aIM7Z25chgAfTvU8khwxOUQDk461R2hJBPIGFxL+7QE8quc8iuw8UbLe2scjJIGLqcHC5GaKdGLaBBGY1JHJIHUnk/zopagb77WBWSOM9Avt+dMRXyY1UKiDg9MmkibbDvmQpggsPQ1YyrDKkmmBVRLv7dl4oRbhMo6ZLBvf2rj/iTc7dW8O2zMRthnuGBIwWLKgP1GD+dd5GzbHC/6wdAw4ry/wCMomsZtH1ZlJheCWxmY8+XKWV4+nQH5sH2xUVPhOjCW9tG5z1jK097c3vIErlBn+FVyB+vNWdcvR5ul2flsZLmbywRzgbSST7Uum20iWcYOWccEt3Pc1X0k/bfEN1KUAt7RfKiyPvSnliM9scfjXI5aXPckk9C6ykplR8oAyPeo71XERbaVI4FWpcxzsgOAR0FW5rUC0eQglm4+mfrWcdWS9Njl7Vcz5UnZu4BOcGt6GN3dWLBxj+KuTtpZLTW3tJedrcc/lXXWqEnfvwgx05rVGm9izDCW5AQAn5h/d+hqaWym2KVwWIz6/mBT4grsA44q+qLFjA2BDvyOoNXEzqtnP6zbSiJnKdDkIwxzXHakylmc4Vs7T1H6V2urzbBIczSMxBXLHiuJ1jBMwUbTnPI6dKp6ip3vcznlUqoU8BTk+v4V7r8H4Nnwz8Ps8j7mWaTZn5cNO56V4HcSLBZ3L5DS7cIo9a+m/DVj/YvhjRNKYbWs7KKFiOhfblufqTRSXvM5cxl7kY+ZLZNcvdzRyRKkSn5cqTn/gWcVdmZlidv4gDgH1qm5mhkfz5oXgyGTdlGX6noauCKORkf924I+Vxx+VdB5BT0q/F9as7qkMiHLoxxheuefartq1td2kNzavHNbyIHSSNtysD0II6ioYrWMTlvOuGk+7gSHp9O9WD+6t/nmZFXvtGf0oAQLsJ5UjHcc1TS2QvJJC9zDMuflD4U/h0xUlvIXjZ2eRPnJAcDOPapklSZMoWVT3PJz6UASq6yKDnPHccinKAcFTkVJHlU2joentTGIVgDwD+VAHA/EKf7Tq2j2DkqIkkuXHYknav9aYjLCgKnoO9RfEiR7bxrZSMp8uXTgI27ErIwYfqKxIL6WViynJ7DPFcVZXk2fQ4GP7mJv28lxcv5cIxkZ3EkCplgv4pgxkiKj0k6Vg2N+k9puvboCUEoVU4wR2q6k9uRhS+Mdc8VyyVNfEzdud7I3FmcgpOg3LjkHIxXnvxu0aPVfBN2yqPNt/3qHHQitm7mdZVuradvOh+/Hn/WJ3X6+lWdcjXUvDtwYnV4LmE4YHIzjj9aIyV7xZtGlzLXqVvhVaix8A6FHKgDi2DHPcsc/wBa7RpUb5BhSa43Sbq5Tw/pFrYIhuWiVSW6LheTW7BolyVD3V/cGQ8kKAB+HFZJO9luKUUn7zNO4H7kdCDxxXivxVsjb+LfDWqEHHzwMR653DP617UgMdkySNvZD948E15f8YI9/hyO4QZlt7hJcDqBnH9a0aaRNL+Iux3GhXa3WmLMQMnAGOpqLV9NvfKLCRgzc/c7Vz3g7WvKtISJQhUAhgNw6flXQ3ni3UIwDFLZTrggiaHB/MGkrTjcJKcZe6jjfFtm+o+FrractCRvUDBBUg966zwzaHWPD8UjQSvGgCgoSAeO5rk/EXirzbK682C2tdwyQmeT681n+CvEU+lWpSC7uYVPJVJCFP4ZxVXimrlPmlBrZnV3FiLDU03QOIX3ctnggVzdvq8Vn4jvcnaWRcFeqke9a9pdaz4m1Bo9OkuZUPDyyMTFGPVie/tWpqng/wAKaJGNRv7W5vGBCOZrhtkrnvt4AHtWkYyqJuOy6nJVxcKL5ZavyOa06K48Yah5CQhLNWH2u+GcbAclAO7HpXqUVzBK7QW4CNCAvlAY2KBgVDo5jm0iB1slsIOsduAAAvY4FWJV8p95ILYwFzwK7aNPkje97ni4iu60r2siveSNCFZEMjZAKY5x7VBbvNJc3G6HCqQEmLhg5I5wOq4PHNTKbkRytL5TSbj5YToB2JPrUFvBJCQrH5AMsSeWY9a2OcrNbzqxCnIorTAJHSigDY3KzYOw/XmohbgyF43OCem7ioYbKFLi5eOJEMyjMijHP09fenWPmR28aXG7zYxtLdd+O9AFxiwOWXPI/CsPx5YHVPAfiKyTaXexkljyP448SL+q1rS7iu4SLE24AEnginKHkIikCvbyoySNnJAYEHA79aTV0NOzueI2WrIdMNyozGUD9Mjkdag0BwttCQzMXJkYnjJbmuW1/wC0aPLfeG3Hl3trOLFwPunphh7MpDD612tlHHHFtIKFAFGfpgVxSTbPpVJW5ou9x8V0JdfliKkLHbqTjj7zYHP4ZrrbRY57UI4yBx1z9K880W43avq8jEuPPSJSe21R/ia7WzuhDC+5ugyDjrmoW9iWko3OL8a6S8fjLw7JZY3z3KwyJn70ZzuY/TGa7aGwSFAqtwfSudhvPtnjPzWcPHYWzMOMkSOdo/DGa6X7am0EMoY9BWqSYkuXQs2Ue2RFC53DIzzmrFwUPG0D2J4+tZgvoy2z7o5+XPB96huLsDc7uT0wPSq5bA1d3KPiOZVGwkMQuRz0/WvPtakc3O3JEZXB5zmuq1e6S4aZi4Z04znp7VyN6A0h6nJG0AZz7YpyasFras3vhnoSeIfGVpDOM2dkBe3K4zlVPyJ+LY49Aa+jVYsxZguTzXG/D7w3N4a8PKFMP9p3hFxdhl6f3I8jptHX3Jrq7YzSxP8Aa1EMgbG1DkY7EGtKUeVep4uKre1qX6IfNIoCEeUUPD7u4pyHaEZVCRDqMVTljuFjKSLHcIOcg7HPt6Uul/KjIPP2MTgycEH0IrU5jQIDHeAQemakwcDJJA7etR+Z5aJ+7LKTgkdves1dcsT4gn0lNTtk1AQrKLOZ9sm3puXPBHHagC29mpDAykI3Ve/51YhjVIwkYAUdBUccp2Fir8feOeDUm4lMw8E5xu5GaAJTAsuN5OVPHOBmo7wyxQERxiRj1y2Me9Qm4aCIpdXSNMq5LmMoM1ZeRhbbw0ZdlyrMCEz2oA4P4o6fdX3hT+1vLH27RGa4McJLB7cj94BkdsBv+A1wOh6jEdroymNsMrL3B6Gvd7KeQxh5LcxODtZD8y+/PcGvA/iT4TvPBN7JqmmRM3hadtysmSbBif8AVv8A7GT8re+D2zy4iD+JHqZdiFF+yk/Q3tLXRbPUby+1RikLYZFiQyFmPXitKPxVYuhWx8PBgpwsl3cbCR67VB/nXlsXiFZBwwbOCCrdRV6LWgyFQccc+tcUYxerPXlSi3eWvzOy1HXhLKTNolqBjAeGZsj8CKj0+8gt9PnCmZId5kWKTHyZ6gY7Z/nXLLqoKjJ/+vVvSbW78S6tFpWngmR8GeQDIgj7s39B3qXD37x3NFOFKN9kXPCmvnTZIo7izWSaIsyK5KlomJIZD0IPrXbp8RrZUxFosjuT96e4Cgf98gmtfxRonhuXS7LTdT08yW9sojt5ITtmiGMZDDnn05FcxL8KgGzp/iOaOJuQl1aByB25Uj+VavC1YO8bM8369ha7vVTT+f6E114rF0GlnESMeiRjhR6ZPWm+DrdfEd9eXF9b+doyQvblXHyzM4wQPoCeexpbD4c6dBdouqanc6iQc+WiCGPj1xkn867q2VbaMW1tBHHbRLtRIhtRPwrajQm3zVDnxWNpuPJR+88il+G3iPRJfI0WS31PTckRPJOI5VXsGDcEj1BOcVPaeAvEd0y/bptPsUJwS0plcDvgLx+tergRsu7d8jHgE5pY5YSWaGRJADsO05APcVbwdNu+pisyrpWuvuOU0bwlpuj2lxbT20OqSTnbNLeQhldewCnoKP8AhBfDmS9totrEVbJ2M2PpgnFdTMu9MbeWGMjqKrvD/o/lxsyDbtz3+v1rf2NO1uVHK69Ru/M/vM/UVKWEVhYKsIlO0GFQixKOT+JximNDby3EXnxxXHk4IMo3FG7EZq88awxF3ZUiQYVRnAH9STVMqZJ027tsoG87cYxyFNaGRbdcsHPLDoM8VkvBcPqZeZI3tdu/zN3JYfwbf1zWt5hLMOAAOTUMjmNflKsx5A70ARL5jhtygITngYpcqgJfhAOvpR5nmEKflwMnP+NQ3T7oX2ndgjKjnIzQAhcsSVf5e3NFUYdHF3GJ7uV0nkyzKGIA54H5YooA6TzF6MVC9M5oUCB/mbcG+6p/Wm27mUzI67djYIJ6+hqSZQ6iNlJ6HIoAbdxNcwlUPl9CrgbufpTLAOsbxzTQS3EZ58kEDHUEg9D7VYbZboGZsKBjJPSnRywurPbmNixG4A4JPYmgDxP4yaFcW3jI62kbNY3oiuZHK5CSwoEYE/7qqwz23elN03U4ZYD0wEwAR7da9wazTUbeewuvmtryKS2kXsQ6lTmvlbS7u7srJLbUIJoLq2Jgm3JjZIh2sCfYjFc1WLTvc9XBVuaPs30Oi0JJLlb+YRCNpbqQxgjbuxgZ9+lakV0yqY2UiQZBV65TwRqJ+yX1vuG9LpmbEm4DeAQc5478V0V9fpPCI7wsGXO2TaCPbJ9zWPLrc9BO+jMbw5d3MOv64s0bxToYcbu6lWOP610H28rGocLgcjacZrgPCDTS3+u3UEg8triNAWOQSFbp+Y/OunjeRHLXESSbyeVPFUtGO6bN6C/BWSQOVz0XGQBUd88ssJlMjKrY4FU7UnC+XaEqDyoPI9x6028lYRN548sEZCA5IPofStLNjlpsZ88gQuFcuzDnA4Ndr8IvDcd/ct4ivgJbaxuPKt7fb9+YAEuT6LuHHrXnEtyTHPPtPClh6cV9IeC9LGheDNKspMxyxWwnuQPmxI/zv9eTj8KcI3lqefjKzjCyerNeK4WR5WY4J5yRg1WjinXUvOF1mKQEmFxkgexqWxvbTUEH2G6iuAgwSvUZ9R2p6sJGXJBjB+8oI/8A110bnkEjZbIbIHX1p0RG09HU96kYIwwCNw549KaI9jFh1PtQAy4ymDGzbccgdT9KrXGlWV1fRXd1ZxSXEaFFkZRu2nqD+XarBV8yeaRJzkADG0VJCm1Qu9ivYt1oAgt4Fs8tG08kJOPLzkL/AFq5Dt3ERsOgO30pF27jGMlhywHpQjoZGIzu6EmgDP1ma+F5p8FhFG4uGc3Hmr8qxKOecHnkYHU9ulWdLQjT1iZg0IztJXkL2z9KW7cbkKwSTNgjKdh3BzU0SFVV4wVTpsxxQA9RJGx6le7LUguFH7qVVCuCqq43K4PUHt+FLGflI67qBGwOFdsenXFAHn2vfCLwfqsxktLWfRrhmJZtNk2oec/6tgVH4AVzk/wP2OP7P8VSjnpcWAY4+quM1640ZjkzGWyDyOxpj3imTYbaeVycfux0rGVCnLVo6IYqtBWUjyyw+D9naSPda94juLmxhUtJFbWnkbgOoLFiR+FdvoVlbaBZ2um6bYQ2N1fyfaJ4IiW8mIdAzHknGBk981pzCK+vnt0LNBYyK1wuMBpsAohPcAHcR9KsAkSSSOQJZfkyB8zL1xn604Uowd4kVa9Sr8buIyhnYyqpT7wDDOGz71HcGbE32VYvOKZjErEKW98c4+lTTXLxXMMBTKtwWLc/gKTykE3mbB5pH32HI+lamRH5aRqqRgEr/F6etNwwBXd8p9Km2BnOH+b2qG73uEVWVQTyAOSPSgBrxrKuw5A6knioTbxxyAxKqoowEHH40+OQMdgxwMEgcD8alDEZJAGelAEJcBFPI9qqeezXYt41Z3KlmYjCIPc9z7VclJXBVcn+lVBGz3RlEmIwn3R0J9aAHzltjFQGZQcAetZ9zJ5UaxlXeZwPmDDCtnue/pWgWCR7mZRjjnpVGcxSzQK8aszOdmzpwMk/SgCUnfHlcZPX6+lRHaiyO2BgHc3finSgR/NuKhz8xz29veqjyoYsSzLFHGN0hHyrknhefbrQAs07i6SKOPehUZ7bc+tLJuMiRoqhAcyMew9KeZIo5ERmVXf7p/vCq0ELqkwkbbvlLkenNADmVixI3gduaKkJySfX0ooA1/MSeISRgkY9P0PvRbyK6bkOcnGO4oVQpYJ8qtyygYGT1ot7byWkzuG87jk8fgO1AD2Eb5jlXIPUU2OwtE+ZImVj/EGINPE0E3EEsczJ12N09jU6M2UGABjLZNAFFpJracZjka2YjMoIJQ+4HOPevNvH/h27t9b1a8QONI1FvtEkoQssLsBvD45AyCwbpya9XQbpD8vyjIyeQaisIXs55fLlYKcKm0nOAOhqJw5lY0p1HTlzI+OdJjktNa15bGT7VZRMhFzBGWiLh9qjd0Gd2BnqavalrFxEtykjyxeQqoYnXBJPzDIz3x1r6012wXxHoOqaLqUhS1vrd4DIB/qiR8rgeqtgj6V8i+OtK13SNX+weIdMeyuYofsomQER3kZJJeNwMMOhHp0POawlFwdz06GL53ZqxZ8BM8Ph0yyKAL24kuBnjgfKB/47XQm8iVcCJFPrjpVHQtFuNTsVRnaysItsUKrjMiheGPHHNW77w9qem/OrR3to4ypAPmL9fWsnLqkdUKkFJRkxZbp8go49gO1R3DtM48wjOMHBNZcUwbIGcnjDLjmlhmIlKtnaB1HaqjUbVmdUkraGpo9m2oavp+mRA+Ze3MUJ29QCwycfTNfUcwzO/lvsG7A9h2rwz4F6W2oeKrnWSM22kxbVPPzTSAqB9QpJ/EV7gilmw6MuOPmxiuilqrngY2alOy6DvLwCDg54OBjNJs8mNY40BQDaFzzipWIBAZsZ71A0sURDTSKX5APTArU4ydF4LKQGJ5wKeXXAJxycDPf6VXaNsb4Z3R8AhvvA/hSNk3kL+UzDftXPRQepPvQBKYVfBOc/3hwT9aeNycFRJzjhelOJw6AgjIz7daeJAp+7359aAG5CjLAhhxkc1HDEpd3WQjIxtephNHMDsYE99v8AKo8BQS0TKv8AsjNAD1jAGCQT14pyFSn7wlR/CWPWkEsTqAkoPoDxUZkCSBWAO7gcZFAFl4wAVYkJ2K1WliSRQJGY44DkYcfQilRQ8hPIZu56CkLOWwJVEWAPu4Oc8nPpQBK6A4YyPgcZB5P1qtc3klnbSSKyz3G9YIUXjzJG4Uf1PsDSWN7baoLiKxmRpIpPLfaeUaoLFjfXhvpTm2ti8FqQOGYcSSD1yflHsD60n5ATWtuLG0SF5WlKZaWZzzJIeWY/U/0pwkUFem+RTt45AFNt3e5ubgSBPIB2+WVz+JPc+1WJDFnfkGQJgZ7L6CmBEsYM7SMGdicAd6c6OCoUjvuz+lQLIsbQqoMks+X3f14qcvtZ2yGXA79PwoAiAbcMtj1AqG4WYh2QfMn3QQCGqeUF1KncASMlTzSsmxW2KF5zQBSjJAwAqRw48wnkEnsKSeSVYWeOMGXHypnj86nuLdHQLKW2lt5C8bsdqa0ofjI3FugoArRLIS/nNkDAwv05/Wku5YbWEvJIEwMqoHX6VMyt0HHPNZGrWl3eRG1imWEO2WlYbgF9h60AUL3VEntvNSBvLaUxxliV56Zx3+laAhWG4MgKkECOCMD7oA5P1PNTjToIrW0tkjRlgwUZxk5HOc0yQyuN1uFHzEFn6/hQBWvpIktcTCTyy6ktgkHnp7VXu7VL22NqIfLW4dXlydxAHUZ9+K1JnEcZMmMEYNVrdlli86M5WTndnINAGfMtqdZS3WN/lVH4TKgqCBz9D+laDAY4IJoZVRnkVPnfAOKSbCxhyQFUEk0AM59B+dFVDfRk5VZMduKKANVLCa1Vl0+5eNCpASU7gh7bSeR+oqaweCxtorK48yCROM3L7xKx7h+h+nB9qsoFlxknb05pkx8+4W3cK8LqS2RnkcAH60ATxuqyMrL5fPIIx+NPUiQSq2VZSRx6etUpNJ+bbZ3DxIv3oZiXjYY7E8r9R+VLbXCeaPtStbs52xhzmM/R+n54NAE32q3eZbRbkLOwIwvUVaYiGMEk9cMwHU+tNEAjleURKrsMFgMEj696ejHnK4+tACQnkhjnFUvEGjaXr2lvp+u2MV7Y7t4STIMbf3kYcqeTyKvgBn+Ujd3FJK5yY1jMjbckZwPTGaGr7geJvpltpXiDW9J0txDbwXfl2/2qXcPL8tBtLHtuDEE+tU7+W9gm8mW1nTPHyjIP+6RkH610HxI0Ge28RXN9bBhHc7XRsZH3QGB/KuAuZ7+MSgdV/ujpXnSrcjcdrHs0IqpBMNRtfs+4NGyxkbzvA4J7g/hzWHZW91fXsNnp9u017O+yBAcbm7c+nfNbWleHvE/i2eG002zuJ4bcFDdygxW6c8gucbsZ6DNe2+APAlp4RhadnF5q8ilZLrbhY1PVYx2HHJ6mtKd6my+ZpUxMMPCyd5Gl4W8NReGfC9po1o6yPGRJcyDgzTHG5gf0HsK1miMRLQKFc/eA/iPqafbs0LiOXkMflkUZz/vehp9zL5ToArSb2C/KPu5PU+wrsSSVkeG25O7Gw72C+fzt5GBjB705YIWJkEYBJyxK5BPamzeYh+UAkngYqeJmZMNgHvTELtRti7ucjH4VIqbiwbkdPrSNFHJGRIFIIIJBwabaQJZwx28BbykAChmzgfWgBSrKyiMrsHUHk47Yp29Q+VOPapWjzjbjJ7ZqGYIvMuUQHqTj86ABXjLbjtwe45FTBxvAjGT9ay54JG2G3mEidQFAHHpnpVuwmSUuNrxyocMjjB+v0oAtbd38KjjJ471C482MhZNozk7ADg1JkqxzyvUYqNreGdgcYkHI2HaR+VADXdixRGxIoBzjjH1qTakgHmBc8k57VKIcEHJJXuT1rOk1S1tnmN4Z7UQ5Z2MLFdo7ggYNADtTV2WG0snEVzellMioAY4h/rH+uDge5qeNbcW/lpGVggKoi4xgAYA96ztCjmupLnUrpDFPdEBYgMeVEM7FP+1jlvc+1aJiYSbk5CDgE8HPWkgCeGNgM/LEuSSvB571BcNHcFrYN0Ub/XB9/erDhnZVZCEHJPY+1EmAM9D0pgRLGsK4jAUE54/pUU8kccZlkYrtPGP4j6Gn3JdVQK3lhjhn6kD2HrUTWaMmyVm4Py+o5/rQARTvMsbKNiMCx9cdAKlj2njoMcA0rldwUNw3QDsKRtm5e/GaAIpW2hmycgcHPSqcVt5T7/MYgcIMDA49e9WXQtIHY5XqFxxmmgEtzgY7dqAIm3Act0IPNIhZlLnGccDPGPWlYNI2W4ReAPU+tIx2rgDHHNAEBcgbm6noPSqkllE7xT3EfmThsg5+7z+VWGZjcbU4Up96onUvIFVgu0grzksMUARX0Au1eJnYRsu0lTgn2qSIAxqg2IqfLtAx07UyaIyxSRQTeUXY4kQ/y96i0+SQ6ekl38soHz5H60AWlUDJqBQs7AEDGe/YDqalDg42njGc+lUrC4uLie5t5rRoYosKkjsG83PXp0oAbA91cRiVI4AjEldxIOM8fpRVsSRwgRjChRgBVyBRQBqW8XkW37xnkZmZ2Zj0JOcfQDAqaEqVIT7meTim22PJyBlicY9u1SFs4xwg64oAie7dNQitxbyiBifNnI+UccAY6mlijW+twtxEjROc+XIuRt7ZB708yGWMCPKojDBY8H6U+KYMzqq4IHBzxQBUa0mgybGfylz8trIN0JH81/D8qrTalJDdRR6lavbRPlRIMNGT2O8cD6EA1oNIRceWUJAA5/z2qUpuG1lDoeqtyD9RSsAnlAhgCf8AgJyRSxsUVY5JPMc52sRgnH+FVI7YxSN/Z05i5yYn+eIH6dV/A/hSG78ry47yL7O7EjJJaNvXa/b6NimBavrdby2AxDJ6JMoZGPv3H4VQ/wCEZ0VZFk/sy1EoOcgEjP0zVo2rxwFbSRY3yG3P8wx3H/16kjkmUfv4PmPVkYEColThN3kkxptbE2+RlCh1AXoMcADtinOzFBtYLJ7jtUMj8mOX9wG+7IDw30PapJDtT92yO/TDtg47nPrViFZo2YiMgtjccDjGf8aUqSfemhUjwEBGR3FIcnpuxxyBmgB5DqpO3IA7cmkRxt5RsEdMYNQ/2haxS7LsyWbD/n4G0H8elSvKyS4jjWWNhuV1bp/n1oAfFzIDKoVSMYqeR4flR3XcwIUDrTYsMobAJpjwLIT/AAP6g0AOwJVO7lSMZBpFkSOJjKRsDbVABbFOSCSJ4nEmRgiQbQAff2psTgPvt5EkibIYoQee1ACJDFFMAgSPdz8o2g/gKleAM6SB23oMDBxxTwuVOwAN70zczIrKxDY544NAGdqF9PZzYEXnJtyqjgsQeRk8Vq7P4kHOOmeAaQFnHAK+uacFKrwTgdhQA1CzZDAD3zzWfd7r7VUsEYG1tiJ7zoQZOsUR/LefTC+tP1y7n0+yNzaKktwziO3t3IAnlfhEz2GeSewBParem6ebGyjgkl82fJluLj/nrM3Lt9OwHYACkA/5tzOxBLc47k1FCZ5JC0oRFA4ROcH61NtO7cxVR6A/rVed8loA53MNwCnGB+FMBwkLBw0RjjBzu3dvU+gpqMXjQkBmIJ6Yx6fpViBA0SiT5s8sCKx7Mzq0vmsRLO8hjyfujOEAH0GaALXlrLK7vtJQlVYHp0yDTbx2FmxgDNJnG5eq+9Jp9utpYwwgklR8zHqxPUn8asLjG3Hy44PvQBBKYw6o06/aBhTzjccU8LneegpJWElwVeIttAO4jIB9qgkeVbhVBxAASxIHJPQUAK0mI2Y9RwKiXLKu/G8noBwKlKFhtGAD15qq9wI5tmOAQu7p8x7D1oAhuZGSSJYVDSsRx6DPJP4U6/LP5jx/Kq53E9PwqG3jlinkUoWhUf6xnGWP+FR3zskGNkku35SiA5bNAE6OvlFy25Mce9RursUVeIyMNjrz71n6VqUWo218LV7maa3l8pzNaSQIG9E3qNyjHUd/rV13mEZ8tA3blvzoAR40BiEWFER4H+NRXaPJtjA3Kxyxzj6U8yRQxb53ihjX7zM2APqTTpGjdFfJCg5GeM0AM2eXGqp82Ovqaing+0WsiRSGCRiPmA6YNEFw7hvMtzCqNtBdh8wzwwxTxMxhZlRg+4qBJxk5/l3oAq3VoxuHMcxRTjADHjiipGt0z84Z27kk80UAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: David D Sherry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5732=[""].join("\n");
var outline_f5_38_5732=null;
var title_f5_38_5733="Sodium polystyrene sulfonate: Pediatric drug information";
var content_f5_38_5733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium polystyrene sulfonate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=see_link\">",
"    see \"Sodium polystyrene sulfonate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/62/22500?source=see_link\">",
"    see \"Sodium polystyrene sulfonate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kalexate;",
"     </li>",
"     <li>",
"      Kayexalate&reg;;",
"     </li>",
"     <li>",
"      Kionex&reg;;",
"     </li>",
"     <li>",
"      SPS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kayexalate&reg;;",
"     </li>",
"     <li>",
"      PMS-Sodium Polystyrene Sulfonate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hyperkalemia",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hyperkalemia (not preferred): Rectal: 1 g/kg/dose every 2-6 hours (Malone, 1991; Yaseen 2008); may employ lower doses by using the practical exchange ratio of 1 mEq K",
"     <sup>",
"      +",
"     </sup>",
"     /g of resin as the basis for calculation.",
"     <b>",
"      Note:",
"     </b>",
"     Due to complications of hypernatremia and NEC, use in neonates should be reserved for refractory cases.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=see_link\">",
"      see \"Sodium polystyrene sulfonate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hyperkalemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1 g/kg/dose every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 1 g/kg/dose every 2-6 hours; in small children and infants, employ lower doses by using the practical exchange ratio of 1 mEq K",
"     <sup>",
"      +",
"     </sup>",
"     /g of resin as the basis for calculation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 15 g 1-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 30-50 g every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral/rectal:  (454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kalexate:  (454 g) [contains sodium 100 mg (4.1 mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kayexalate&reg;:  (454 g) [contains sodium 100 mg (4.1 mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kionex&reg;:  (454 g) [contains sodium 100 mg (4.1 mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral/rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kionex&reg;: 15 g/60 mL (60 mL, 480 mL) [contains ethanol 0.2%, propylene glycol, sodium 1500 mg (65 mEq)/60 mL, sorbitol; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SPS&reg;: 15 g/60 mL (60 mL, 120 mL, 473 mL) [contains ethanol 0.3%, propylene glycol, sodium 1500 mg (65 mEq)/60 mL, sorbitol; cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Powder for suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral or NG: Shake commercially available suspension well before use.",
"     <b>",
"      Do not mix in orange juice.",
"     </b>",
"     Chilling the oral mixture will increase palatability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Powder for suspension: For each 1 g of the powdered resin, add 3-4 mL of water or syrup (amount of fluid usually ranges from 20-100 mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Enema: Route is less effective than oral administration. Administer cleansing enema first. Each dose of the powder for suspension should be suspended in 100 mL of aqueous vehicle and administered as a warm emulsion (body temperature). The commercially available suspension should also be warmed to body temperature. During administration, the solution should be agitated gently. Retain enema in colon for at least 30-60 minutes and for several hours, if possible. Once retention time is complete, irrigate colon with a nonsodium-containing solution to remove resin",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); suspensions made from powder should be freshly prepared and used within 24 hours of preparation",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperkalemia (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F222054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Kayexalate&reg; may be confused with Kaopectate&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sodium polystyrene sulfonate may be confused with calcium polystyrene sulfonate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Always prescribe either one-time doses or as a specific number of doses (eg, 15 g q6h x 2 doses). Scheduled doses with no dosage limit could be given for days leading to dangerous hypokalemia.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kionex [U.S.] may be confused with Kinex brand name for biperiden [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F222052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypernatremia, hypocalcemia, hypokalemia, hypomagnesemia, sodium retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, fecal impaction, intestinal necrosis (rare), intestinal obstruction (due to concretions in association with aluminum hydroxide), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute bronchitis (rare; associated with inhalation of particles), concretions, gastrointestinal bleeding, gastrointestinal ulceration, intestinal perforation, ischemic colitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium polystyrene sulfonate or any component; hypokalemia; obstructive bowel disease; neonates with reduced gut motility (postoperatively or drug-induced); oral administration in neonates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional contraindications: Sodium polystyrene sulfonate suspension (",
"     <b>",
"      with",
"     </b>",
"     sorbitol): Rectal administration in neonates (particularly in premature infants); any postoperative patient until normal bowel function resumes",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe HF, hypertension, or edema; sodium load may exacerbate condition. In addition to serum potassium lowering effects, cation-exchange resins may also affect other cation concentrations possibly resulting in decreased serum magnesium and calcium. Commercially available liquid product contains propylene glycol; in neonates, large amounts of propylene glycol (eg, &gt;3000 mg/day I.V.) have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use (dosage form) containing propylene glycol with caution in neonates. Use caution in premature or low birth-weight infants due to risk of digestive hemorrhage and colonic necrosis. Use with caution in children when administering rectally; excessive dosage or inadequate dilution may result in fecal impaction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment with this drug alone may be insufficient to rapidly correct severe hyperkalemia; other more rapidly effective appropriate measures should be used; enema will reduce the serum potassium faster than oral administration, but the oral route will result in a greater reduction over several hours; severe hypokalemia may occur; daily evaluation of serum potassium is recommended at minimum; ECG monitoring may be appropriate in select patients; systemic alkalosis has been reported when administered in conjunction with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide. Intestinal obstructions due to concretions of aluminum hydroxide have been reported when administered with sodium polystyrene sulfonate; colonic necrosis and other serious gastrointestinal events (eg, bleeding, ischemic colitis, perforation) have been reported, especially when administered with sorbitol; increased risk may be associated with a history of intestinal disease or surgery, hypovolemia, prematurity, and renal insufficiency or failure; use with sorbitol is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F222004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Sodium Polystyrene Sulfonate may enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction.  Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin. Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Sodium Polystyrene Sulfonate may enhance the adverse/toxic effect of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Laxatives: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis. Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bisacodyl; Dehydrocholic Acid; Lactulose; Polycarbophil; Psyllium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Sodium Polystyrene Sulfonate may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meloxicam: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sorbitol: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Sodium Polystyrene Sulfonate may decrease the serum concentration of Thyroid Products.  Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Never mix in orange juice or in any fruit juice known to contain potassium.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11510210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if benefits outweigh the risks.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum sodium, potassium, calcium, magnesium, ECG (if applicable)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Removes potassium by exchanging sodium ions for potassium ions in the intestine (especially the large intestine) before the resin is passed from the body",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within 2-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination: Remains in the GI tract to be completely excreted in the feces (primarily as potassium polystyrene sulfonate)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g of resin binds &sim;1 mEq of potassium; 4.1 mEq sodium per g of powder; 1 level teaspoon contains 3.5 g polystyrene sulfonate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \" 'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5733/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone TA, \"Glucose and Insulin Versus Cation-Exchange Resin for the Treatment of Hyperkalemia in Very Low Birth Weight Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 118(1):121-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5733/abstract-text/1986079/pubmed\" id=\"1986079\" target=\"_blank\">",
"        1986079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vemgal P and Ohlsson A, \"Interventions for Non-Oliguric Hyperkalaemia in Preterm Neonates,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2007, (1):CD005257.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5733/abstract-text/17253550/pubmed\" id=\"17253550\" target=\"_blank\">",
"        17253550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaseen H, Khalaf M, Dana A, et al, \"Salbutamol Versus Cation-Exchange Resin (Kayexalate) for the Treatment of Nonoliguric Hyperkalemia in Preterm Infants,\"",
"      <i>",
"       Am J Perinatol",
"      </i>",
"      , 2008, 25(3):193-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5733/abstract-text/18425722/pubmed\" id=\"18425722\" target=\"_blank\">",
"        18425722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12799 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5733=[""].join("\n");
var outline_f5_38_5733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222031\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062273\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445048\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062267\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222010\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062276\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062270\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062275\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222054\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222052\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062280\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062266\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062265\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300068\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222004\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062282\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222006\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11510210\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062272\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062264\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062278\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062279\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062281\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12799|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=related_link\">",
"      Sodium polystyrene sulfonate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/62/22500?source=related_link\">",
"      Sodium polystyrene sulfonate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_38_5734="Ganglioneuroblastoma";
var content_f5_38_5734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Ganglioneuroblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The neuroblasts, which generally have a more mature appearance, are clustered together in foci or nests surrounded by the Schwannian cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of MJ Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5734=[""].join("\n");
var outline_f5_38_5734=null;
var title_f5_38_5735="Apoptosis and autoimmune disease";
var content_f5_38_5735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Apoptosis and autoimmune disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5735/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5735/contributors\">",
"     Keith Elkon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5735/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5735/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/38/5735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis refers to cell death that occurs in a programmed manner, is characterized by cellular condensation, and is noninflammatory. By all of these criteria, it differs from necrosis, which is often referred to as &ldquo;accidental&rdquo; or pathologic death and which is accompanied by cell swelling and inflammation. A third form of death, autophagy, arises due to nutrient starvation and also has a characteristic morphology associated with the formation of autophagosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/1\">",
"     1",
"    </a>",
"    ], but it will not be considered further here.",
"   </p>",
"   <p>",
"    Apoptosis plays a pivotal role in the following processes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morphogenesis and tissue remodeling during embryonic development",
"     </li>",
"     <li>",
"      Cell death associated with homeostasis (eg, immune system, lungs, gastrointestinal tract)",
"     </li>",
"     <li>",
"      Elimination of immune effector cells that proliferate in response to activation (eg, by microbial infection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The morphological features of apoptosis have been appreciated for decades: cytoplasmic and nuclear condensation, incorporation of intracellular constituents into membrane enclosed &ldquo;apoptotic bodies&rdquo; that may bud from the surface, and surface expression of opsonic receptors that allow cells to rapidly phagocytose and to digest the corpse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/4\">",
"     4",
"    </a>",
"    ]. A key feature of this physiologic death process is the preservation of plasma membrane integrity. Rapid ingestion of the apoptotic corpse by phagocytes with continued digestion of the cellular constituents prevents the cell from undergoing post-apoptotic necrosis with rupture of the membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the relationship between apoptosis and autoimmune disease is presented here. Before discussing this interaction, it is helpful to briefly review the biology underlying apoptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR MECHANISMS OF APOPTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical pathways responsible for apoptotic cell death have been elucidated in some detail. A genetic framework for the core death program has been provided by studies of the roundworm, Caenorhabditis elegans [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Caenorhabditis elegans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic observations of C. elegans, a translucent nematode, have identified a subset of cells destined to die by apoptosis. Chemical mutagenesis has allowed the identification of genes that regulate this process.",
"   </p>",
"   <p>",
"    Ced-3 is a downstream effector of the apoptotic program (",
"    <a class=\"graphic graphic_figure graphicRef73569 \" href=\"UTD.htm?36/6/36972\">",
"     figure 1",
"    </a>",
"    ). It is activated by ced-4, which is inhibited by ced-9. In turn, ced-9 is inhibited by egl-1. It follows from this scheme that the expression or activation of egl-1 results in apoptotic cell death. A number of different ced genes also encode proteins responsible for phagocytosis of apoptotic cells (",
"    <a class=\"graphic graphic_figure graphicRef58618 \" href=\"UTD.htm?1/30/1506\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Higher eukaryotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the genetic blueprint utilized by C. elegans is followed in higher eukaryotes, the situation is complicated by the expression of multiple genes that correspond to each step delineated in the nematode (",
"    <a class=\"graphic graphic_figure graphicRef58618 \" href=\"UTD.htm?1/30/1506\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Just as ced-3 is a downstream effector of apoptosis in C. elegans, ced-3 orthologs comprise a family of proteases called caspases in higher eukaryotes. Caspases digest structural and enzymatic constituents of the cell to bring about apoptotic death [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/8\">",
"       8",
"      </a>",
"      ]. Not all caspases are involved in the execution of apoptosis. Human caspases 1, 4, 5, and, possibly, 12 and mouse caspases 1, 4, 11, and 12 are likely involved in promoting inflammation.",
"     </li>",
"     <li>",
"      The ced-4 orthologs (apoptosis activating factors [APAFs]) bind to the caspases and facilitate their conversion from inactive zymogens to active proteases.",
"     </li>",
"     <li>",
"      The ced-9 and egl-1 orthologs comprise a large family of proteins related to B-cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      2 (Bcl-2) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/9\">",
"       9",
"      </a>",
"      ], an oncogene that is transcriptionally activated by the t(14;18) chromosome translocation found in B-cell follicular lymphomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"       \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"      </a>",
"      .) Overexpression of Bcl-2 inhibits apoptosis in these cells, an essential component of lymphomatous growth. Just as ced-9 prevents cell death and as egl-1 promotes cell death (by preventing the function of ced-9), individual members of the Bcl-2 family can interact with one another either to promote or to inhibit apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Triggering apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In higher eukaryotes, the core death program can be triggered from without (external or extrinsic) or from within (internal or intrinsic) the cell:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      External triggering involves the ligation of dedicated death receptors by soluble or cell-associated ligands [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Internal triggering occurs when cells respond to environmental stress (eg, heat, x-rays, ultraviolet irradiation), to damage to deoxyribonucleic acid (DNA) (genotoxic injury), or to misfolded proteins (endoplasmic stress). These events alter the function of mitochondria, an organelle that is essential not only for cell survival but also for the regulation of entry into cell death [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of extrinsic and intrinsic triggers of apoptosis are depicted schematically in the figure (",
"    <a class=\"graphic graphic_figure graphicRef61795 \" href=\"UTD.htm?40/9/41119\">",
"     figure 3",
"    </a>",
"    ). In this example, ligation of the dedicated death receptors CD95 (Fas) or tumor necrosis factor-receptor I (TNF-RI) results in the recruitment of adaptor molecules (eg, Fas-associated protein with death domain [FADD] and tumor necrosis factor receptor type I-associated death domain protein [TRADD]) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Proteolytic cascade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adaptor molecules subsequently bind both to the cytoplasmic domain of the dedicated death receptor and to the inactive form of caspase-8, an &ldquo;upstream&rdquo; caspase that initiates a proteolytic cascade leading to cell death. Because the zymogenic form of caspase-8 possesses low levels of protease activity, its aggregation allows one molecule to proteolytically activate an adjacent molecule, thereby initiating the proteolytic cascade. This culminates in the activation of effector caspases (eg, caspase-3) which directly cleave structural proteins (eg, nuclear lamins and cytoskeletal gelsolins) and enzymes, such as the inhibitor of caspase-activated DNase (ICAD). Cleavage of ICAD leads to the release of active CAD, which enters the nucleus and cleaves nucleosomes at the linker region, yielding the characteristic &ldquo;DNA ladder&rdquo;. The end result is apoptotic death of the cell.",
"   </p>",
"   <p>",
"    In response to environmental stress or cell damage (",
"    <a class=\"graphic graphic_figure graphicRef60345 \" href=\"UTD.htm?2/2/2080\">",
"     figure 4",
"    </a>",
"    ), the BH3 members of the Bcl-2 family such as Bak and Bax alter the permeability of the outer mitochondrial membrane, resulting in the release of cytochrome C and other effector proteins. Cytochrome C is a cofactor that allows APAF-1 to promote the activation of caspase-9, an \"upstream\" caspase that is essential for initiation of the intrinsic death program; the subsequent activation of effector proteases, including caspase-3, results in apoptotic cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These basic pathways that lead to apoptosis are regulated by several proteins that bind to death receptors, adaptors, or caspases to modulate their function. Examples include Bcl-2 family members that titrate each other [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and may bind to APAFs, inhibitors of apoptosis (IAPs), some of which attenuate caspase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/17\">",
"     17",
"    </a>",
"    ] as well as the PI-3 Akt pathway that activates NFk-B and also blocks death effectors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/18\">",
"     18",
"    </a>",
"    ]. Not surprisingly, entry into apoptosis is a highly regulated process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Noninflammatory phagocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the hallmarks of apoptosis is that cells undergoing programmed death are normally phagocytosed by macrophages and dendritic cells without activating an inflammatory or immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/5\">",
"     5",
"    </a>",
"    ]. This is, in part, triggered by the expression of phosphatidylserine on the cell surface which, in turn, is recognized directly either by cell surface receptors or by opsonins (bridging molecules), which link the dying cells with phagocytes. The efficiency of the phagocytic process depends upon the presence of the opsonins that include normal serum components such as the complement proteins C1q, C3, C4, and members of the pentraxin family, including pentraxin-3 (PTX3) and C-reactive protein (CRP) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Binding of protein S, an antithrombotic plasma protein, to phosphatidylserine on the surface of apoptotic cells also promotes their phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL CORRELATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations indicate that dysregulated apoptosis may contribute to the onset or perpetuation of autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Autoimmune lymphoproliferative syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most striking example of abnormal apoptosis leading to disease is a rare autosomal dominant condition known as autoimmune lymphoproliferative syndrome (ALPS). Its onset in early childhood is heralded by lymphadenopathy, hepatosplenomegaly, and autoimmune phenomena including hemolytic anemia, thrombocytopenia, and autoimmune neutropenia, often in combination (ie, Evans syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in Fas or FasL found in these patients interfere with the elimination of activated lymphocytes following exposure to self or foreign antigens. The persistence of these cells results in expanded populations of lymphocytes and predisposes to autoimmune phenomena and to the development of lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients require medical intervention for autoimmune manifestations, particularly clinically significant cytopenias, and usually respond to brief courses of glucocorticoids or other immunosuppressive drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/246?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although mutant mice bearing inactivating mutations in Fas or FasL develop a clinical syndrome that resembles systemic lupus erythematosus (SLE), mutations in this death receptor pathway are only very rarely described in human SLE. Nevertheless, defective apoptosis may be involved in the production of autoantibodies reactive with self proteins, a common abnormality in those with SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large number of spontaneous or engineered mutations in mice reveal that defective uptake of apoptotic cells predisposes to lupus-like diseases. Examples include mice deficient in opsonins such as C1q and MFG-E8, as well as mutations of receptors responsible for ingestion of apoptotic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/23\">",
"     23",
"    </a>",
"    ]. There is evidence that this process may be perturbed in some patients with SLE. Impaired phagocytosis of apoptotic cells by macrophages in the germinal centers of lymph nodes of patients has been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dendritic cells, which are antigen-presenting cells that migrate in search of antigen, also efficiently recognize and phagocytose apoptotic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Via a poorly understood mechanism, this process allows the dendritic cells to transfer peptides derived from the digested corpse to major histocompatibility complex (MHC) molecules expressed on its cell surface. The ability of the dendritic cell to present peptides derived from other cells is known as &ldquo;cross priming.&rdquo; By this process, antigens expressed by poorly immunogenic cells, such as tumor cells, can be presented to the immune system by a highly efficient, professional antigen-presenting cell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible adverse consequence of the ability of dendritic cells to present antigens from apoptotic cells is that self antigens may provoke an immune response (",
"    <a class=\"graphic graphic_figure graphicRef51145 \" href=\"UTD.htm?28/22/29026\">",
"     figure 5",
"    </a>",
"    ). The immune system employs elaborate mechanisms of central and peripheral tolerance to prevent this possibility, a process that may be dysfunctional in SLE. This is supported by the observation that proteins modified by cleavage (by caspases or granzymes) or by posttranslational changes (eg, stress kinase phosphorylation, crosslinking by transglutaminase, ubiquitination and deimination of arginine residues) during cell death may be targeted by SLE autoantibodies, suggesting that dead or dying cells may serve as a reservoir of autoantigens in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities in biochemical pathways of apoptosis or in clearance of apoptotic cells in patients with SLE could be caused by genetic or environmental factors. Mutations in the genes encoding C1q and CRP, which facilitate the clearance of apoptotic cells, have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], and genetic variations in",
"    <span class=\"nowrap\">",
"     ITGAM/CR3,",
"    </span>",
"    which promotes the clearance of apoptotic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/19\">",
"     19",
"    </a>",
"    ], have been implicated in gene-wide association studies (GWAS) of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/31\">",
"     31",
"    </a>",
"    ]. Because viruses typically encode antiapoptotic proteins, viral infection could delay the apoptotic program, resulting in the accumulation of modified self peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/32\">",
"     32",
"    </a>",
"    ]. An example may be the viral FADD-like interleukin (IL)-1&beta;-converting enzyme (FLICE)-inhibitory protein (FLIP), which serves as a substrate for caspase-8, thereby diverting the protease cascade and prolonging cell survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the presence of autoantibodies is not thought to directly contribute to the pathophysiology of rheumatoid arthritis (RA), the presence of antibodies reactive with self immunoglobulin (ie, rheumatoid factor) and citrullinated proteins, such as vimentin, collagen, and enolase, are sensitive markers of this disease. Citrulline results from an oxidative post-translational modification of arginine produced by peptidyl arginine deiminase (PAD), an enzyme that can be activated during apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/33\">",
"     33",
"    </a>",
"    ]. Other targets of anti-citrullinated peptide antibodies (ACPA) have also been identified, and the role of these antibodies in RA is a matter of significant interest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2234?source=see_link&amp;anchor=H5#H5\">",
"     \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\", section on 'Autoantibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal apoptosis in synoviocytes or macrophages has also been proposed to contribute to the synovial proliferation that is characteristic of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Systemic sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial cell apoptosis, mediated by anti-endothelial cell antibodies and lymphocytes, has been suggested as a pathogenic mechanism in scleroderma. Examples include increased apoptosis in a chicken model of disease and the ability of sera from patients with scleroderma (plus activated lymphocytes) to induce programmed cell death in cultured human dermal endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Whether expression of type 1 interferon in this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5735/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] plays a role remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95778664\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apoptosis refers to cell death that occurs in a programmed manner, is characterized by cellular condensation, and is noninflammatory. Thus, it differs from necrosis, which is often referred to as &ldquo;accidental&rdquo; or pathologic death and which is accompanied by cell swelling and inflammation, and from a third form of death, autophagy, which arises due to nutrient starvation and which also has a characteristic morphology associated with the formation of autophagosomes. Apoptosis plays a pivotal role in morphogenesis and tissue remodeling during embryonic development, in cell death associated with homeostasis (eg, immune system, lungs, gastrointestinal tract), and in elimination of immune effector cells that proliferate in response to activation (eg, by microbial infection). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In higher eukaryotes, the genetic blueprint for the core death program is complicated by the expression of multiple genes that correspond to each step regulated by just a few genes as delineated in the nematode C. elegans (",
"      <a class=\"graphic graphic_figure graphicRef58618 \" href=\"UTD.htm?1/30/1506\">",
"       figure 2",
"      </a>",
"      ). In higher eukaryotes, the core death program can be triggered from without (external or extrinsic) by the ligation of dedicated death receptors by soluble or cell-associated ligands or from within (internal or intrinsic) the cell, when cells respond to environmental stress (eg, heat, x-rays, ultraviolet irradiation), to damage to DNA (genotoxic injury) or to misfolded proteins (",
"      <a class=\"graphic graphic_figure graphicRef61795 \" href=\"UTD.htm?40/9/41119\">",
"       figure 3",
"      </a>",
"      ). In some cases, ligation of the dedicated death receptors (eg, CD95 [Fas]), results in the recruitment of adaptor molecules. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Molecular mechanisms of apoptosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Caenorhabditis elegans'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Higher eukaryotes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adaptor molecules involved in externally triggered apoptosis subsequently bind both to the cytoplasmic domain of the dedicated death receptor and to the inactive form of caspase-8, an &ldquo;upstream&rdquo; caspase that initiates a proteolytic cascade leading to cell death through a proteolytic cascade. In response to environmental stress or cell damage (",
"      <a class=\"graphic graphic_figure graphicRef60345 \" href=\"UTD.htm?2/2/2080\">",
"       figure 4",
"      </a>",
"      ), members of the Bcl-2 family alter the permeability of the outer mitochondrial membrane, resulting in the release of cytochrome C and other effector proteins through several steps in the activation of caspase-9, an &ldquo;upstream&rdquo; caspase that is essential for initiation of the intrinsic death program with the subsequent activation of effector proteases, including caspase-3. The basic pathways that lead to apoptosis are regulated by several proteins that bind to death receptors, adaptors, or caspases to modulate their function. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Proteolytic cascade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the hallmarks of apoptosis is that cells undergoing programmed death are normally phagocytosed by macrophages and dendritic cells without activating an inflammatory or immune response. The efficiency of the phagocytic process depends upon the presence of the opsonins that include normal serum components, such as the complement proteins C1q, C3, and C4, and members of the pentraxin family, including pentraxin-3 (PTX3) and C-reactive protein (CRP). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Noninflammatory phagocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of observations indicate that dysregulated apoptosis may contribute to the onset or perpetuation of autoimmune disease, including autoimmune lymphoproliferative syndrome, a rare genetic condition in which mutations in Fas or FasL interfere with the elimination of activated lymphocytes following exposure to self or foreign antigens; systemic lupus erythematosus, in which defective apoptosis may be involved in the production of autoantibodies reactive with self proteins; and, possibly, rheumatoid arthritis and systemic sclerosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical correlations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/1\">",
"      Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/2\">",
"      Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999; 96:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/3\">",
"      Nagata S. Apoptosis by death factor. Cell 1997; 88:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/4\">",
"      Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/5\">",
"      Erwig LP, Henson PM. Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 2007; 171:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/6\">",
"      Horvitz HR. Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res 1999; 59:1701s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/7\">",
"      Reddien PW, Horvitz HR. The engulfment process of programmed cell death in caenorhabditis elegans. Annu Rev Cell Dev Biol 2004; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/8\">",
"      Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22:8543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/9\">",
"      Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 1999; 10:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/10\">",
"      Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/11\">",
"      Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003; 112:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/12\">",
"      Aravind L, Dixit VM, Koonin EV. The domains of death: evolution of the apoptosis machinery. Trends Biochem Sci 1999; 24:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/13\">",
"      Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/14\">",
"      Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/15\">",
"      Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/16\">",
"      Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/17\">",
"      Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/18\">",
"      Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/19\">",
"      Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998; 188:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/20\">",
"      Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/21\">",
"      Anderson HA, Maylock CA, Williams JA, et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/22\">",
"      Grodzicky T, Elkon KB. Apoptosis in rheumatic diseases. Am J Med 2000; 108:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/23\">",
"      Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell 2010; 140:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/24\">",
"      Baumann I, Kolowos W, Voll RE, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/25\">",
"      Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/26\">",
"      Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/27\">",
"      Utz PJ, Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 1998; 41:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/28\">",
"      Hall JC, Casciola-Rosen L, Rosen A. Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am 2004; 30:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/29\">",
"      Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/30\">",
"      Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/31\">",
"      International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarc&oacute;n-Riquelme ME, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/32\">",
"      Granville DJ, Carthy CM, Yang D, et al. Interaction of viral proteins with host cell death machinery. Cell Death Differ 1998; 5:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/33\">",
"      van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Ann N Y Acad Sci 2008; 1143:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/34\">",
"      Kobayashi T, Okamoto K, Kobata T, et al. Apomodulation as a novel therapeutic concept for the regulation of apoptosis in rheumatoid synoviocytes. Curr Opin Rheumatol 1999; 11:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/35\">",
"      Scatizzi JC, Hutcheson J, Pope RM, et al. Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis Rheum 2010; 62:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/36\">",
"      Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/37\">",
"      Sgonc R, Gruschwitz MS, Boeck G, et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000; 43:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/38\">",
"      Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5735/abstract/39\">",
"      Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58:1465.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5594 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5735=[""].join("\n");
var outline_f5_38_5735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95778664\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR MECHANISMS OF APOPTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Caenorhabditis elegans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Higher eukaryotes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Triggering apoptosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Proteolytic cascade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Noninflammatory phagocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL CORRELATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Autoimmune lymphoproliferative syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95778664\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5594|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/6/36972\" title=\"figure 1\">",
"      Apoptotic program c elegans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/30/1506\" title=\"figure 2\">",
"      Ced genes phagocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/9/41119\" title=\"figure 3\">",
"      Apoptotic programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/2/2080\" title=\"figure 4\">",
"      Cell damage release cytochrome C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29026\" title=\"figure 5\">",
"      Apoptotic cells immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/58/30629?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/246?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2234?source=related_link\">",
"      Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_38_5736="Sumatriptan: Drug information";
var content_f5_38_5736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sumatriptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/37/15958?source=see_link\">",
"    see \"Sumatriptan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"    see \"Sumatriptan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alsuma&trade;;",
"     </li>",
"     <li>",
"      Imitrex&reg;;",
"     </li>",
"     <li>",
"      Sumavel&reg; DosePro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sumatriptan&reg;;",
"     </li>",
"     <li>",
"      Ava-Sumatriptan;",
"     </li>",
"     <li>",
"      CO Sumatriptan;",
"     </li>",
"     <li>",
"      Dom-Sumatriptan;",
"     </li>",
"     <li>",
"      Imitrex&reg;;",
"     </li>",
"     <li>",
"      Imitrex&reg; DF;",
"     </li>",
"     <li>",
"      Imitrex&reg; Injection;",
"     </li>",
"     <li>",
"      Imitrex&reg; Nasal Spray;",
"     </li>",
"     <li>",
"      Mylan-Sumatriptan;",
"     </li>",
"     <li>",
"      PHL-Sumatriptan;",
"     </li>",
"     <li>",
"      PMS-Sumatriptan;",
"     </li>",
"     <li>",
"      Riva-Sumatriptan;",
"     </li>",
"     <li>",
"      Sandoz-Sumatriptan;",
"     </li>",
"     <li>",
"      Sumatriptan Injection;",
"     </li>",
"     <li>",
"      Sumatriptan Sun Injection;",
"     </li>",
"     <li>",
"      Sumatryx;",
"     </li>",
"     <li>",
"      Taro-Sumatriptan;",
"     </li>",
"     <li>",
"      Teva-Sumatriptan;",
"     </li>",
"     <li>",
"      Teva-Sumatriptan DF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F224322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       1B, 1D",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F224280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     A single dose of 25 mg, 50 mg, or 100 mg (taken with fluids). If a satisfactory response has not been obtained at 2 hours, a second dose may be administered. Results from clinical trials show that initial doses of 50 mg and 100 mg are more effective than doses of 25 mg, and that 100 mg doses do not provide a greater effect than 50 mg and may have increased incidence of side effects. Although doses of up to 300 mg/day have been studied, the total daily dose should not exceed 200 mg. The safety of treating an average of &gt;4 headaches in a 30-day period have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal:",
"     </i>",
"     A single dose of 5 mg, 10 mg, or 20 mg administered in one nostril. A 10 mg dose may be achieved by administering a single 5 mg dose in each nostril. If headache returns, the dose may be repeated once after 2 hours, not to exceed a total daily dose of 40 mg. In clinical trials, a greater number of patients responded to initial doses of 20 mg versus 5 or 10 mg. The safety of treating an average of &gt;4 headaches in a 30-day period has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      SubQ:",
"     </i>",
"     Initial: Up to 6 mg; may repeat if needed &ge;1 hour after initial dose (maximum: Two 6 mg injections per 24-hour period). However, controlled clinical trials have failed to document a benefit with administration of a second 6 mg dose in nonresponders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cluster headache:",
"     </b>",
"     SubQ: Initial: Up to 6 mg; may repeat if needed &ge;1 hour after initial dose (maximum: Two 6 mg injections per 24-hour period)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is not recommended (due to increased potential for adverse effects).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F224281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F224282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Bioavailability of oral sumatriptan is increased with liver disease. If treatment is needed, do not exceed single doses of 50 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasal spray: Has not been studied in patients with hepatic impairment, however, because the spray does not undergo first-pass metabolism, levels would not be expected to be altered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Subcutaneous: Has been studied and pharmacokinetics were not altered in patients with hepatic impairment compared to healthy patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Oral, nasal, and subcutaneous (limited to Imitrex&reg; injection, per prescribing information) formulations are contraindicated with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as succinate [strength expressed as base]: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alsuma&trade;: 6 mg/0.5 mL (0.5 mL) [autoinjector]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 6 mg/0.5 mL (0.5 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sumavel&reg; DosePro&reg;: 6 mg/0.5 mL (0.5 mL) [needleless autoinjector]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as succinate [strength expressed as base, preservative free]: 6 mg/0.5 mL (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]: 5 mg/0.1 mL (6s); 20 mg/0.1 mL (6s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 5 mg/0.1 mL (6s); 20 mg/0.1 mL (6s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as succinate [strength expressed as base]: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16031498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zecuity&trade; (transdermal system): FDA approved January 2013; availability anticipated in fourth quarter of 2013.  Refer to prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F224256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Should be administered as soon as symptoms appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Each nasal spray unit is preloaded with 1 dose;",
"     <b>",
"      do not",
"     </b>",
"     test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert nozzle into nostril about",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch; close mouth; take a breath through nose while releasing spray into nostril by pressing firmly on blue plunger; remove nozzle from nostril; keep head level for 10-20 seconds and gently breathe in through nose and out through mouth;",
"     <b>",
"      do not breathe deeply",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: Not for I.M. or I.V. use. Needle penetrates",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     inch of skin;  use in areas of the body with adequate skin and subcutaneous thickness. Alsuma&trade; is a prefilled single-use autoinjector device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Needleless administration (Sumavel&reg; DosePro&reg;): Administer to the abdomen (&gt;2 inches from the navel) or thigh; not for I.M. or I.V. administration. Do not administer to other areas of the body (eg, arm). Device is for single use only, discard after use; do not use if the tip of the device is tilted or broken.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F224255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal, Oral, SubQ: Acute treatment of migraine with or without aura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: Acute treatment of cluster headache episodes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F224330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       SUMAtriptan may be confused with saxagliptin, sitaGLIPtin, somatropin, ZOLMitriptan",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F224320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (12%), warm/hot sensation (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (&le;86%; includes bleeding, bruising, edema, and erythema)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort/tightness/pressure (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Burning sensation (7%), feeling of heaviness (7%), flushing (7%), pressure sensation (7%), feeling of tightness (5%), drowsiness (3%), feeling strange (2%), headache (2%), tight feeling in head (2%), anxiety (1%), cold sensation (1%), malaise/fatigue (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (4%), abdominal discomfort (1%), dysphagia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck pain/stiffness (5%), numbness (5%), weakness (5%), jaw discomfort (2%), myalgia (2%), muscle cramps (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision alterations (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Throat discomfort (3%), nasal disorder/discomfort (2%), bronchospasm (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Nasal spray:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Bad taste (13% to 24%), nausea (11% to 13%), vomiting (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal disorder/discomfort (2% to 4%), throat discomfort (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Tablet:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain/tightness/heaviness/pressure (1% to 2%), palpitation (1%), syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Burning (1%), dizziness (&gt;1%), drowsiness (&gt;1%), malaise/fatigue (2% to 3%), headache (&gt;1%), nonspecified pain (1% to 2%, placebo 1%), vertigo (&lt;1% to 2%), migraine (&gt;1%), sleepiness (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1%), nausea (&gt;1%), vomiting (&gt;1%), hyposalivation (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck, throat, and jaw pain/tightness/pressure (2% to 3%), paresthesia (3% to 5%), myalgia (1%), numbness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear hemorrhage (1%), hearing loss (1%), sensitivity to noise (1%), tinnitus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Allergic rhinitis (1%), dyspnea (1%), nasal inflammation (1%), nose/throat hemorrhage (1%), sinusitis (1%), upper respiratory inflammation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (1%), nonspecified pressure/tightness/heaviness (1% to 3%, placebo 2%); warm/cold sensation (2% to 3%, placebo 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Route unspecified:",
"     </b>",
"     &lt;1%: Postmarketing and uncontrolled studies (limited to important or life-threatening): Abdominal aortic aneurysm, abnormal/elevated liver function tests, accommodation disorders, acute renal failure, anaphylactoid reaction, anaphylaxis, anemia, angioneurotic edema, arrhythmia, atrial fibrillation, bronchospasm, cardiomyopathy, cerebral ischemia, cerebrovascular accident, colonic ischemia, coronary artery vasospasm, cyanosis, deafness, ECG changes, hallucinations, heart block, hematuria, hemolytic anemia, hypersensitivity reactions, hyper-/hypotension, hypertensive crises, intestinal obstruction, intracranial pressure increased, ischemic colitis, MI, nose/throat hemorrhage, optic neuropathy (ischemic), pancytopenia, paresthesia, phlebitis, photosensitivity, Prinzmetal's angina, pulmonary embolism, Raynaud syndrome, retinal artery occlusion, retinal vein thrombosis, seizures, serotonin syndrome, shock, subarachnoid hemorrhage, syncope, temporal arteritis, thrombocytopenia, thrombophlebitis, thrombosis, transaminases increased, transient myocardial ischemia, TSH increased, vasculitis, ventricular fibrillation, ventricular tachycardia, vision loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F224259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sumatriptan or any component of the formulation; patients with ischemic heart disease or signs or symptoms of ischemic heart disease (including Prinzmetal's angina, angina pectoris, myocardial infarction, silent myocardial ischemia); cerebrovascular syndromes (including strokes, transient ischemic attacks); peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist; concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors (oral and nasal sumatriptan only; see Warnings/Precautions); management of hemiplegic or basilar migraine; severe hepatic impairment (oral and nasal sumatriptan, and injectable Imitrex&reg; only); not for I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F224242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, such as dizziness, weakness, or drowsiness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension. Use is contraindicated in patients with uncontrolled hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonists. Transient and permanent blindness and significant partial vision loss have been very rarely reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use oral formulations of sumatriptan with caution (and with dosage limitations) in patients with hepatic impairment where treatment is necessary and advisable. Presystemic clearance of orally administered sumatriptan is reduced in hepatic impairment, leading to increased plasma concentrations; dosage reduction of the oral product is recommended. Non-oral routes of administration (nasal, subcutaneous formulations) do not undergo similar hepatic first-pass metabolism and are not expected to result in significantly altered pharmacokinetics in patients with hepatic impairment. Use of the oral, nasal, or Imitrex&reg; injectable is contraindicated in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with history of seizure disorder or in patients with a lowered seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Concurrent use with an MAO inhibitor may result in increased sumatriptan concentrations and increased risk for dose-related adverse effects (eg, serotonin syndrome); use with oral or nasal sumatriptan is contraindicated.  Although generally not recommended, if concomitant use with injectable sumatriptan is deemed necessary, careful monitoring and appropriate dosage adjustments are required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce sumatriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended. If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Not recommended for use in elderly patients; older adults are at a higher risk for coronary artery disease and may be more likely to have reduced hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: I.V. administration is contraindicated due to the potential to cause coronary vasospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Only indicated for the acute treatment of migraine or cluster headache (depending on product); not indicated for migraine prophylaxis, or for the treatment of hemiplegic or basilar migraine. Acute migraine agents (eg, triptans, opioids, ergotamine, or a combination of the agents) used  for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse. If a patient does not respond to the first dose, the diagnosis of migraine or cluster headache should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine or cluster headache.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using sumatriptan in pregnant women. Use only if potential benefit to the mother outweighs the potential risk to the fetus. A pregnancy registry has been established to monitor outcomes of women exposed to sumatriptan during pregnancy (800-336-2176). Preliminary data from the registry do not suggest a greater risk of birth defects than the general population and so far a specific pattern of malformations has not been identified. However, sample sizes are small and studies are ongoing. In some (but not all) animal studies, administration was associated with embryolethality, fetal malformations and pup mortality.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F224286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F224263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of sumatriptan an infant would be exposed to following breast-feeding is considered to be small (although the mean milk-to-plasma ratio is ~4.9, weight adjusted doses estimates suggest breast-fed infants receive 3.5% of a maternal dose). Expressing and discarding the milk for 8-12 hours after a single dose is suggested to reduce the amount present even further. The half-life of sumatriptan in breast milk is 2.22 hours.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F224261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (Sumavel DosePro Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/0.5 mL (0.5 mL): $113.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alsuma Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/0.5 mL (0.5 mL): $109.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Imitrex Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/ACT (1): $50.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/ACT (1): $50.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Imitrex STATdose Refill Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/0.5 mL (0.5 mL): $119.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/0.5 mL (0.5 mL): $119.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Imitrex STATdose System Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/0.5 mL (0.5 mL): $125.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/0.5 mL (0.5 mL): $125.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Imitrex Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/0.5 mL (0.5 mL): $117.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (SUMAtriptan Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/ACT (1): $43.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/ACT (1): $43.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (SUMAtriptan Succinate Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/0.5 mL (0.5 mL): $60.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/0.5 mL (0.5 mL): $92.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Imitrex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (9): $299.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (9): $362.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (9): $362.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (SUMAtriptan Succinate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (9): $243.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (9): $226.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (9): $226.26",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F224264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cetatrex (ID);",
"     </li>",
"     <li>",
"      Fermig (MX);",
"     </li>",
"     <li>",
"      Imigran (AT, AU, BB, BG, BM, BR, BS, BZ, CH, CN, CY, CZ, DE, DK, EC, EE, ES, FI, GB, GR, GY, HK, HN, HR, HU, IE, IT, JM, KP, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PT, PY, RU, SE, SR, TH, TR, TT, UY, VE);",
"     </li>",
"     <li>",
"      Imigran Radis (GB, IE);",
"     </li>",
"     <li>",
"      Imigrane (FR);",
"     </li>",
"     <li>",
"      Imiject (FR);",
"     </li>",
"     <li>",
"      Imitrex (AR, BE, IL, LU);",
"     </li>",
"     <li>",
"      Migragesin (CO);",
"     </li>",
"     <li>",
"      Migrastat (IE);",
"     </li>",
"     <li>",
"      Na Chuan (CL);",
"     </li>",
"     <li>",
"      Nograine (MX);",
"     </li>",
"     <li>",
"      Sitran (CO);",
"     </li>",
"     <li>",
"      Sumagran (AU);",
"     </li>",
"     <li>",
"      Sumatab (AU);",
"     </li>",
"     <li>",
"      Sumatran (SG);",
"     </li>",
"     <li>",
"      Sumatridex (IL);",
"     </li>",
"     <li>",
"      Sumavel DosePro (DE, DK);",
"     </li>",
"     <li>",
"      Sumigran (PH);",
"     </li>",
"     <li>",
"      Sumitran (MY, SG);",
"     </li>",
"     <li>",
"      Sumitrex (IN);",
"     </li>",
"     <li>",
"      Suvalan (AU);",
"     </li>",
"     <li>",
"      Tebegran (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F224241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries; causes vasoconstriction and reduces neurogenic inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F224258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: ~30 minutes; Nasal: ~15-30 minutes; SubQ: ~10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14% to 21%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via MAO-A isoenzyme; extensive first-pass metabolism following oral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Nasal: 17% (compared to SubQ); Oral: 15%; SubQ: 97% &plusmn; 16%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 2-2.5 hours; SubQ: 12 minutes (range: 4-20 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasal spray: Urine (42% of total dose as indole acetic acid metabolite; 3% of total dose as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Urine (~60% of total dose, mostly as indole acetic acid metabolite; 3% of total dose as unchanged drug); feces (~40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Urine (38% of total dose as indole acetic acid metabolite; 22% of total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Akpunonu BE, Mutgi AB, and Federman DJ, &ldquo;Subcutaneous Sumatriptan for Treatment of Acute Migraine in Patients Admitted to the Emergency Department: A Multicenter Study,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 25(4):464-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7710149/pubmed\" id=\"7710149\" target=\"_blank\">",
"        7710149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blier P and Bergeron R, &ldquo;The Safety of Concomitant Use of Sumatriptan and Antidepressant Treatments,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1995, 15(2):106-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7782482/pubmed\" id=\"7782482\" target=\"_blank\">",
"        7782482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyd IW and Rohan AP, &ldquo;Sumatriptan - Induced Chest Pain,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 344(8939):1704-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7996981/pubmed\" id=\"7996981\" target=\"_blank\">",
"        7996981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Curtin T, Brooks AP, and Roberts JA, &ldquo;Cardiorespiratory Distress After Sumatriptan Given by Injection,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1992, 305(6855):713-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/1327368/pubmed\" id=\"1327368\" target=\"_blank\">",
"        1327368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diamond S, &ldquo;The Use of Sumatriptan in Patients on Monoamine Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1995, 45(6):1039-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7783861/pubmed\" id=\"7783861\" target=\"_blank\">",
"        7783861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards KR, Bennington VT, and Ellis J, &ldquo;Intracerebral Hemorrhage Associated With Sumatriptan,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 1995, 35:309.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ilett KF, Kristensen JH, Wojnar-Horton RE, et al, &ldquo;Drug Distribution in Human Milk,&rdquo;",
"      <i>",
"       Aust Prescriber",
"      </i>",
"      , 1997, 20(2): 35-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly KM, &ldquo;Cardiac Arrest Following Use of Sumatriptan,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1995, 45(6):1211-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7783891/pubmed\" id=\"7783891\" target=\"_blank\">",
"        7783891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      La Porta LD, &ldquo;Recurrent Depression After Sumatriptan Administration for Treatment of Migraine,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1995, 15(1):81-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7714232/pubmed\" id=\"7714232\" target=\"_blank\">",
"        7714232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loder E, &ldquo;Safety of Sumatriptan in Pregnancy. A Review of the Data So Far,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2003, 17(1):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/12467489/pubmed\" id=\"12467489\" target=\"_blank\">",
"        12467489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luman W and Gray RS, &ldquo;Adverse Reactions Associated With Sumatriptan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1993, 341(8852):1091-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/8096980/pubmed\" id=\"8096980\" target=\"_blank\">",
"        8096980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacDonald JT, &ldquo;Treatment of Juvenile Migraine With Subcutaneous Sumatriptan,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 1994, 34(10):581-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7843952/pubmed\" id=\"7843952\" target=\"_blank\">",
"        7843952",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottervanger JP, et al, &ldquo;Characteristics of Sumatriptan-Induced Chest Pain,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 1995, 17:3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottervanger JP, et al, &ldquo;Determinants of Sumatriptan-Induced Chest Pain,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 1995, 17:7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottervanger JP, van Witsen TB, Valkenburg HA, et al, &ldquo;Adverse Reactions Attributed to Sumatriptan: A Postmarketing Study in General Practice,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1994, 47(4):305-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7875179/pubmed\" id=\"7875179\" target=\"_blank\">",
"        7875179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmer J, Feldman R, Mancini GB, et al, &ldquo;Glyceryl Trinitrate Reversal of Post-Sumatriptan Coronary Artery Narrowing,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8961):1366.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7752771/pubmed\" id=\"7752771\" target=\"_blank\">",
"        7752771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reiff-Eldridge R, Heffner CR, Ephross SA, et al, &ldquo;Monitoring Pregnancy Outcomes After Prenatal Drug Exposure Through Prospective Pregnancy Registries: A Pharmaceutical Company Commitment,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2000, 182(1 Pt 1):159-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/10649172/pubmed\" id=\"10649172\" target=\"_blank\">",
"        10649172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott AK, &ldquo;Sumatriptan Clinical Pharmacokinetics,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(5):337-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7851052/pubmed\" id=\"7851052\" target=\"_blank\">",
"        7851052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Srinivas NR, Igwenezue KB, Hainsworth JD, et al, &ldquo;Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1995, 35(4):432-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7650235/pubmed\" id=\"7650235\" target=\"_blank\">",
"        7650235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Srinivas NR, Shyu WC, Upmalis D, et al, &ldquo;Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1995, 35(4):432-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7650235/pubmed\" id=\"7650235\" target=\"_blank\">",
"        7650235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stricker BH, &ldquo;Coronary Vasospasm and Sumatriptan,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1992, 305(6845):118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/1322217/pubmed\" id=\"1322217\" target=\"_blank\">",
"        1322217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walton-Shirley M, Flowers K, and Whiteside JH, &ldquo;Unstable Angina Pectoris Associated With Imitrex Therapy,&rdquo;",
"      <i>",
"       Cathet Cardiovasc Diagn",
"      </i>",
"      , 1995, 34(2):188.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/7788702/pubmed\" id=\"7788702\" target=\"_blank\">",
"        7788702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weidmann B, Jansen W, Bojko P, et al, &ldquo;Sumatriptan-Induced Myocardial Infarction,&rdquo;",
"      <i>",
"       Intensivmedizin und Nofallmediczin",
"      </i>",
"      , 1994, 31:353.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wojnar-Horton RE, Hackett LP, Yapp P, et al, \"Distribution and Excretion of Sumatriptan in Human Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1996, 41(3):217-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/38/5736/abstract-text/8866921/pubmed\" id=\"8866921\" target=\"_blank\">",
"        8866921",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9968 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5736=[""].join("\n");
var outline_f5_38_5736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224277\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224322\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224280\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062222\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224281\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224282\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224252\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224238\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16031498\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224256\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224255\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224330\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224320\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224259\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224242\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300101\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224247\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224249\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224262\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224286\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224263\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224261\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224264\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224241\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224258\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9968|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/37/15958?source=related_link\">",
"      Sumatriptan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=related_link\">",
"      Sumatriptan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_38_5737="Pathogenesis of primary biliary cirrhosis";
var content_f5_38_5737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of primary biliary cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5737/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5737/contributors\">",
"     M Eric Gershwin, MD, MACP, MACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5737/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5737/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5737/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/38/5737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary biliary cirrhosis (PBC) is characterized by a T-lymphocyte-mediated attack on small intralobular bile ducts (",
"    <a class=\"graphic graphic_picture graphicRef54128 graphicRef66904 \" href=\"UTD.htm?32/43/33466\">",
"     picture 1A-B",
"    </a>",
"    ). A continuous assault on the bile duct epithelial cells leads to their gradual destruction and eventual disappearance (",
"    <a class=\"graphic graphic_picture graphicRef79032 \" href=\"UTD.htm?42/7/43127\">",
"     picture 2",
"    </a>",
"    ). The sustained loss of intralobular bile ducts causes the signs and symptoms of cholestasis, and eventually results in cirrhosis and liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on the pathogenesis of PBC while its diagnosis and management are presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLUES ABOUT ETIOLOGY BASED ON THE EPIDEMIOLOGY OF PBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise cause of PBC is unknown but appears to be related to genetic and environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. A number of environmental causes have been implicated including several bacteria and viruses and toxins, which are described below [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Some of the most compelling evidence for an environmental factor has been derived from epidemiologic studies, which have demonstrated geographic clustering, clustering of cases across time, and seasonal variation in the diagnosis of PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples, the incidence of PBC has been estimated to be 200 to 251 per million in South Wales and Northeast England, less than 25 per million in Canada and Australia, and almost zero in Sub-Saharan Africa and India [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. A limitation of these studies is that the varying incidence rates may in part be due to genetic differences in the populations and to differences in study methodology. However, that an environmental factor may be involved was strongly implicated in a study from a well-defined geographical population cohort in Northern England [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/15\">",
"     15",
"    </a>",
"    ] and around toxic waste sites in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/8\">",
"     8",
"    </a>",
"    ]. Analysis of cases demonstrated unequivocal clustering in well-demarcated geographic regions.",
"   </p>",
"   <p>",
"    The unanswered question in PBC is what causes or triggers the T-cell attack on small bile duct epithelial cells? Current data suggest that PBC is an autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Like other better characterized autoimmune diseases, there appear to be at least two distinct requirements for PBC to develop: genetic susceptibility; and a triggering event that initiates the autoimmune attack on bile duct cells.",
"   </p>",
"   <p>",
"    The prevalence of PBC in families with one affected member is estimated to be 1000 times greater than that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the disorder is not inherited in any simple recessive or dominant pattern. Familial occurrences of the disease have included sisters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/20\">",
"     20",
"    </a>",
"    ], brothers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/21\">",
"     21",
"    </a>",
"    ], brothers and sisters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/22\">",
"     22",
"    </a>",
"    ], and parent and child [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, unaffected family members are more likely than controls to have impaired T-cell regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/24\">",
"     24",
"    </a>",
"    ] and increased numbers of circulating autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/21\">",
"     21",
"    </a>",
"    ]. However, there is not a significant increase in antimitochondrial antibody, the serologic marker of PBC, in healthy family members if purified recombinant mitochondrial autoantigens are used in the assay [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Antimitochondrial antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130787338\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism underlying the genetic susceptibility in some patients with PBC is not known. There is a weak association between PBC and haplotype HLA-DR8 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/26,27\">",
"     26,27",
"    </a>",
"    ] and the HLA-DPB1 gene in some populations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Accumulated data suggest that there may be an inherited abnormality of immune regulation, perhaps an inability to suppress an inflammatory attack on small bile ducts once it is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/24,26,28\">",
"     24,26,28",
"    </a>",
"    ]. One study found an association of PBC with a variant in the CTLA4 gene, which encodes a co-inhibitory immunoreceptor involved in self tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/30\">",
"     30",
"    </a>",
"    ]. Another report found a significant association with genetic variants at the HLA class II, IL12A, and IL12RB2 loci (which have a role in interleukin-12 immunoregulatory signaling) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/31\">",
"     31",
"    </a>",
"    ]. The importance of IL12 has been underscored in animal models and in a case report of a child with congenital IL12 deficiency who developed primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/32\">",
"     32",
"    </a>",
"    ]. Other susceptibility loci that have been identified include SPIB (which encodes for a transcription factor involved in B-cell receptor signaling and T-cell lineage decisions), IRF5 (which encodes for interferon regulatory factor 5), TNPOS (which encodes for transportin 3), and MMEL1 (which encodes for a metalol-endopeptidase) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Interestingly, IRF5 and TNPO3 have also been implicated in the pathogenesis of systemic lupus erythematosus, systemic sclerosis and Sjogrens syndrome, suggesting that there is a genetic overlap in PBC and these disorders.",
"   </p>",
"   <p>",
"    Why the disease primarily affects women is unclear. A plausible theory relates to immunological tolerance, a component of which depends upon genes located on the X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/35\">",
"     35",
"    </a>",
"    ]. One study suggested that women with PBC were more likely to have monosomy of the X chromosome (a marker reflecting haploinsufficiency for specific X-linked genes) compared with healthy controls or those with hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MOLECULAR MIMICRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular mimicry refers to a phenomenon where antigens evoking an immune response have enough similarity to endogenous proteins to incite an autoimmune reaction. Such a mechanism has been widely proposed to initiate autoimmunity in patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/37\">",
"     37",
"    </a>",
"    ]. Several candidate inciting agents (including bacteria, viruses and various chemicals) have been proposed, but none has been proven definitively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infectious etiology for triggering PBC has been suspected, although a specific etiologic agent has not been unequivocally identified. Several agents have been implicated; some have been disproven while others remain topics of investigation.",
"   </p>",
"   <p>",
"    It is possible that infection and the presence of antimitochondrial antibodies (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Antimitochondrial antibodies'",
"    </a>",
"    below) may be pathogenetically linked. A study comparing peripheral blood mononuclear cells from patients with PBC with controls found that patients with PBC had a much higher number of inducible IgM-producing B-cells and that each B-cell produced a greater quantity of IgM protein compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/38\">",
"     38",
"    </a>",
"    ]. Induction of the B-cells was achieved by stimulation with unmethylated CpG DNA motifs (non-proteinaceous repeated sequences found frequently in bacteria). The authors hypothesized that patients with PBC are hyperresponsive with respect to IgM production and that the heightened IgM production may reflect how various microorganisms interact with the immune system in patients with PBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Retroviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data from one laboratory suggest that infection with a retrovirus may be associated with PBC in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Electron microscopy, cloning and immunohistochemistry have shown a viral particle that has been tentatively identified as a human beta retrovirus. Viral proteins colocalized with cells demonstrating aberrant autoantigen expression. Furthermore, lymph node homogenates from patients with PBC induced autoantigen expression in normal biliary epithelial cells, which also developed phenotypic manifestations of PBC.",
"   </p>",
"   <p>",
"    However, other groups have not confirmed these associations. Biochemical improvement from combination antiretroviral treatment was observed in an open-label pilot study (also from the same group) a finding that has not yet been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=see_link\">",
"     \"Overview of the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Propionibacterium acnes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible etiologic role for Propionibacterium acnes (P. acnes) was suggested in a study in which sequences of the organism were detected by PCR amplifying granulomas from patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/43\">",
"     43",
"    </a>",
"    ]. The significance of this observation remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chlamydophila (formerly Chlamydia pneumoniae)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study reported that antigens to Chlamydia pneumoniae were detectable more often in the livers of patients with PBC compared to controls with other causes of liver disease, suggesting a possible etiologic role [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/44\">",
"     44",
"    </a>",
"    ]. However, these findings were disputed in subsequent report using more detailed immunohistochemical analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/45\">",
"     45",
"    </a>",
"    ]. Furthermore, no benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    was observed in a pilot, open-label study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Escherichia coli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies reacting against the mitochondrial human pyruvate dehydrogenase complex crossreact with the E. coli pyruvate dehydrogenase complex implicating E. coli infection (particularly urinary tract infection) in the pathogenesis of PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. A problem with this theory is that antibodies against the E. coli are often in lower titers than against the human complex, and the E. coli antibodies are more frequent in patients with advanced disease (rather than being present in patients with early-stage disease, which would be more supportive of a role as an inciting agent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     N. aromaticivorans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novosphingobium aromaticivorans (N. aromaticivorans) is a ubiquitous gram negative organism that metabolizes organic compounds and estrogens. Two of its proteins share homology with the E2 component of pyruvate dehydrogenase (anti-PDC-E2), the major epitope recognized by antimitochondrial antibodies. A role for the bacteria in the pathogenesis of PBC was suggested in a pilot study in which 100 percent of 77 PBC patients (who were anti-PDC-E2 positive) had high antibody titers against the organism compared to none of 195 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/52\">",
"     52",
"    </a>",
"    ]. Reactivity to the organism was also found in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/53\">",
"     53",
"    </a>",
"    ]. These observations provide increasing evidence that exposure to N. aromaticivorans is associated with the development of PBC, the clinical implications of which are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lactobacillus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report described a patient who developed PBC after receiving intramuscular vaccination with a vaccine containing several",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    species to treat recurrent vaginosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/55\">",
"     55",
"    </a>",
"    ]. The patient had AMA-M2 antimitochondrial antibodies that reacted against the major PBC-specific mitochondrial auto-epitope (ie, pyruvate dehydrogenase complex E2) but reacted even more strongly against Lactobacillus delbrueckii. The authors speculated that the lactobacillus vaccination caused the development of PBC through molecular mimicry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHEMICAL EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain compounds (particularly halogenated hydrocarbons) are capable of inducing antibodies that have an affinity for the human pyruvate dehydrogenase complex (sometimes even having greater affinity for native mitochondrial antigens than for the halogenated hydrocarbon) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In a rabbit model, one compound (bromohexanoate ester) induced high titers of antimitochondrial antibodies that were similar to those seen in humans with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the animals did not develop liver lesions similar to PBC. Such lesions developed 18 months after immunization in a guinea pig model [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/59\">",
"     59",
"    </a>",
"    ]. Residence near a toxic waste site was associated with PBC in one epidemiologic study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTIMITOCHONDRIAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimitochondrial antibodies are the serologic hallmark of PBC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .) There are four principal autoantigens that are targets for antimitochondrial antibodies (AMA), which have collectively been referred to as the \"M2\" subtype of mitochondrial autoantigens: the E2 subunits of the pyruvate dehydrogenase complex, the branched chain 2-oxo-acid dehydrogenase complex, the ketoglutaric acid dehydrogenase complex, and the dihydrolipoamide dehydrogenase-binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/5\">",
"     5",
"    </a>",
"    ]. Each of these autoantigens participates in oxidative phosphorylation (a process occurring in the inner mitochondrial membrane by which ATP is formed) and have a great deal of homology.",
"   </p>",
"   <p>",
"    A major advance in our understanding of PBC occurred with the identification and cloning of these antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/60\">",
"     60",
"    </a>",
"    ]. Most AMA react against the dihydrolipoamide acetyltransferase component (E2 subunit) of pyruvate dehydrogenase (PDC-E2) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. PBC is the only disease in which there are B- and T-cells that are autoreactive against PDC-E2 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63356 \" href=\"UTD.htm?42/39/43632\">",
"     image 1",
"    </a>",
"    ). Thus far, all of the mitochondrial autoantigens screened have been targets of only the M2 antimitochondrial antibodies. Other antimitochondrial antibodies previously described, anti-M4, anti-M8, and anti-M9, are most likely artifacts of the methods used to detect them [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Human antimitochondrial antibodies inhibit the enzymatic activity of their target enzyme complexes in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimitochondrial antibodies are found in 95 percent of patients with primary biliary cirrhosis when using the most sensitive detection techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/67\">",
"     67",
"    </a>",
"    ], and have a specificity of 98 percent for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/61\">",
"     61",
"    </a>",
"    ]. However, their role in pathogenesis is unclear as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AMA titers vary greatly (more than 20-fold) among patients but tend to be stable over time in an individual patient; antibody titers do not correlate with disease severity or rate of progression [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/1,68\">",
"       1,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no apparent difference in the clinical spectrum or course of patients with PBC who are AMA-positive or AMA-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antimitochondrial antibodies raised in animals immunized with recombinant human pyruvate dehydrogenase do",
"      <strong>",
"       not",
"      </strong>",
"      cause bile duct damage or any recognizable disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with either AMA-negative or AMA-positive PBC have a similar response to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      or liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     T-CELL MITOCHONDRIAL RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the role of antimitochondrial antibodies in the pathogenesis of PBC is uncertain, accumulating data suggest a direct role for T lymphocytes. CD4+ and CD8+ cells are present in high concentration in the portal triads of patients with PBC, often surrounding and infiltrating necrotic bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/72-76\">",
"     72-76",
"    </a>",
"    ]. Autoreactive T lymphocytes from PBC patients are specific for PDC-E2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. There is a 100- to 150-fold increase in precursor frequencies of PDC-E2-specific T cells isolated from the liver and hilar lymph nodes compared to peripheral blood mononuclear cells in patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/73\">",
"     73",
"    </a>",
"    ]. PDC-E2, normally found in the inner mitochondrial membrane of all cells, is aberrantly expressed in the luminal surface of bile duct epithelial cells only in patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunodominant epitope recognized by MHC class II restricted CD4+ T cells in patients with PBC has been identified as amino acids 163 to 176 of PDC-E2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. The immunodominant epitope recognized by MHC Class I restricted CD8+ T cells has also been identified and is similar (amino acids 159 to 167 of PDC-E2) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/75\">",
"     75",
"    </a>",
"    ]. This peptide induces proliferation of specific MHC-class I restricted CD8+ cytotoxic T-lymphocytes from most HLA-A*0201 patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/81\">",
"     81",
"    </a>",
"    ] and the frequency of cytotoxic T-lymphocytes recognizing this epitope is increased 10-fold in liver compared to blood in patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/75\">",
"     75",
"    </a>",
"    ]. An alanine substitution at position 5 of this epitope significantly reduced peptide-specific cytotoxicity and interferon gamma production by cytotoxic CD8+ T lymphocytes derived from peripheral blood monocytes of patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that bile duct epithelial cells expressing this epitope are targeted by CD8+ T lymphocytes in patients with PBC. Why bile duct epithelial cells express this epitope is still unknown. One possibility is that IgA is complexed to PDC-E2 in the serum of patients with PBC and this antigen-antibody complex is then transcytosed from the basal to apical side of the bile duct epithelial cell en route to its secretion in bile [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/74\">",
"     74",
"    </a>",
"    ]. Serum IgA has been found at mitochondrial surfaces and immune complexes containing PDC-E2, and IgA have been found in bile duct lumens in patients with PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/74,83\">",
"     74,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the T-lymphocyte mediated destruction of small bile ducts, secondary damage to hepatocytes may occur from the accumulation in the liver of increased concentrations of potentially toxic substances, such as bile acids, which are normally secreted into bile (",
"    <a class=\"graphic graphic_algorithm graphicRef73762 \" href=\"UTD.htm?7/26/7599\">",
"     algorithm 1",
"    </a>",
"    ). The naturally occurring bile acids&mdash;cholic acid, chenodeoxycholic acid, and deoxycholic acid&mdash;are all detergents and can dissolve cell membranes if present in a sufficiently high concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]; such toxic concentrations are often reached in cholestasis (",
"    <a class=\"graphic graphic_figure graphicRef60177 \" href=\"UTD.htm?3/47/3825\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     WHY TISSUE INJURY IN PBC IS CONFINED TO THE LIVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paradox of PBC is that the target mitochondrial antigens are present in every cell in the body while the immune attack appears to be highly specific for biliary epithelium.",
"   </p>",
"   <p>",
"    One theory is that there may be qualitative differences in the processing of apoptotic bile-duct cells that account for the specificity but the precise mechanisms involved are incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/88-90\">",
"     88-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another hypothesis proposes that any factor (whether it be an infection or a chemical) that damages bile duct epithelial cells may unmask an antigen in these cells that shares some epitopic similarities with pyruvate dehydrogenase complex E2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A molecule that shares some antigenic determinants with the E2 subunit of pyruvate dehydrogenase but is distinct from it has been identified on the luminal surface of biliary epithelial cells of patients with PBC early in the course of disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63356 \" href=\"UTD.htm?42/39/43632\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. The presence of this antigen, found only in bile duct epithelial cells of patients with PBC, could explain why cell injury in PBC is limited to biliary epithelial cells.",
"   </p>",
"   <p>",
"    Expression of this autoantigen on the luminal surface of biliary epithelial cells may also provoke an antibody mediated attack by IgA antibodies, the antibody present in bile [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/93\">",
"     93",
"    </a>",
"    ]. In addition, this E2-like antigen, together with the appropriate class II major histocompatibility complex antigens, and another molecule required for antigen presentation,",
"    <span class=\"nowrap\">",
"     BB1/B7,",
"    </span>",
"    could be the target of activated CD8+ lymphocytes. All of these molecules are found in and around damaged bile ducts in PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/94\">",
"     94",
"    </a>",
"    ]. The E2 component appears in damaged bile ducts before the HLA class II antigens and",
"    <span class=\"nowrap\">",
"     BB1/B7",
"    </span>",
"    supporting a sequence whereby the bile duct epithelial cell injury precedes the T-cell mediated immune response. The histology of PBC is also consistent with T-lymphocyte mediated cytotoxicity as is the fact that the E2 antigens stimulate interleukin-2 production by cloned T-cells isolated from liver tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ROLE OF RETAINED BILE ACIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"foamy\" degeneration of hepatocytes in primary biliary cirrhosis has been attributed to the noxious effects of bile acids (",
"    <a class=\"graphic graphic_picture graphicRef65727 \" href=\"UTD.htm?5/1/5143\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/84\">",
"     84",
"    </a>",
"    ]. Cholestasis per se causes increased expression of HLA class I antigens on hepatocytes, thereby rendering them better targets for activated T-lymphocytes.",
"   </p>",
"   <p>",
"    Reversal of these pathogenetic events may explain the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    , a dihydroxy bile acid, which has been approved by the FDA for the treatment of PBC. Studies in both humans and experimental animals suggest that treatment with ursodeoxycholic acid reduces expression of HLA class I antigens by hepatocytes and also lessens the toxicity of retained naturally occurring bile acids such as cholic acid and chenodeoxycholic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=see_link\">",
"     \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FETAL MICROCHIMERISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The persistence of allogeneic fetal cells in the maternal system has been termed fetal microchimerism. These cells have been postulated to have a role in the development of maternal diseases such as scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/95\">",
"     95",
"    </a>",
"    ], providing the rationale for studies of microchimerism in patients with PBC. Several studies on microchimerism in PBC have produced discordant results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. Thus, at the present time, the role of microchimerism is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5737/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of biliary cirrhosis itself is straightforward after the immunologic injury, and is similar to that which occurs in a variety of chronic cholestatic diseases such as bile duct strictures and biliary atresia in children. Chronic impairment of bile flow leads to portal and parenchymal inflammation, liver cell necrosis, scarring, and eventually to cirrhosis and liver failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of PBC is incompletely understood but appears to involve environmental and genetic factors.",
"     </li>",
"     <li>",
"      It is likely that an environmental trigger (possibly and infection, chemical or toxin) causes bile duct epithelial injury, which in susceptible individuals leads to a T-cell mediated autoimmune response directed against bile duct epithelial cells.",
"     </li>",
"     <li>",
"      Once immune mediated bile duct injury has been established, the disease progresses due to chronic cholestasis and resulting inflammation and scarring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26933737\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/1\">",
"      Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/2\">",
"      Ludwig J. New concepts in biliary cirrhosis. Semin Liver Dis 1987; 7:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/3\">",
"      Moebius U, Manns M, Hess G, et al. T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones. Eur J Immunol 1990; 20:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/4\">",
"      Jones DE. Pathogenesis of primary biliary cirrhosis. J Hepatol 2003; 39:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/5\">",
"      Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/6\">",
"      Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/7\">",
"      Haydon GH, Neuberger J. PBC: an infectious disease? Gut 2000; 47:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/8\">",
"      Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006; 43:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/9\">",
"      McNally RJ, Ducker S, James OF. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology 2009; 50:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/10\">",
"      McNally RJ, James PW, Ducker S, James OF. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology 2011; 54:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/11\">",
"      Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 1998; 42:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/12\">",
"      Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990; 12:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/13\">",
"      Watson RG, Angus PW, Dewar M, et al. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. Gut 1995; 36:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/14\">",
"      Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/15\">",
"      Prince MI, Chetwynd A, Diggle P, et al. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology 2001; 34:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/16\">",
"      James SP, Hoofnagle JH, Strober W, Jones EA. NIH conference: Primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med 1983; 99:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/17\">",
"      Gershwin ME. The molecular basis of primary biliary cirrhosis: interfacing clinical medicine and wet bench research. Isr J Med Sci 1995; 31:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/18\">",
"      Mackay IR, Gershwin ME. Primary biliary cirrhosis: considerations on pathogenesis based on identification of the M2 autoantigens. Springer Semin Immunopathol 1990; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/19\">",
"      Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994; 20:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/20\">",
"      James SP, Jones EA, Schafer DF, et al. Selective immunoglobulin A deficiency associated with primary biliary cirrhosis in a family with liver disease. Gastroenterology 1986; 90:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/21\">",
"      Galbraith RM, Smith M, Mackenzie RM, et al. High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med 1974; 290:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/22\">",
"      Schaffner F. Primary biliary cirrhosis. Clin Gastroenterol 1975; 4:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/23\">",
"      Tong MJ, Nies KM, Reynolds TB, Quismorio FP. Immunological studies in familial primary biliary cirrhosis. Gastroenterology 1976; 71:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/24\">",
"      Miller KB, Sepersky RA, Brown KM, et al. Genetic abnormalities of immunoregulation in primary biliary cirrhosis. Am J Med 1983; 75:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/25\">",
"      Caldwell SH, Leung PS, Spivey JR, et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 1992; 16:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/26\">",
"      Underhill J, Donaldson P, Bray G, et al. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 1992; 16:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/27\">",
"      Gregory WL, Mehal W, Dunn AN, et al. Primary biliary cirrhosis: contribution of HLA class II allele DR8. Q J Med 1993; 86:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/28\">",
"      Mella JG, Roschmann E, Maier KP, Volk BA. Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population. Hepatology 1995; 21:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/29\">",
"      Underhill JA, Donaldson PT, Doherty DG, et al. HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis. Hepatology 1995; 21:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/30\">",
"      Juran BD, Atkinson EJ, Schlicht EM, et al. Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene. Gastroenterology 2008; 135:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/31\">",
"      Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/32\">",
"      Pulickal AS, Hambleton S, Callaghan MJ, et al. Biliary cirrhosis in a child with inherited interleukin-12 deficiency. J Trop Pediatr 2008; 54:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/33\">",
"      Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010; 42:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/34\">",
"      Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010; 42:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/35\">",
"      Kaplan MM, Bianchi DW. Primary biliary cirrhosis: for want of an X chromosome? Lancet 2004; 363:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/36\">",
"      Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004; 363:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/37\">",
"      Selmi C, Ross SR, Ansari AA, et al. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004; 127:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/38\">",
"      Kikuchi K, Lian ZX, Yang GX, et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology 2005; 128:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/39\">",
"      Mason AL, Xu L, Guo L, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998; 351:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/40\">",
"      Xu L, Shen Z, Guo L, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A 2003; 100:8454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/41\">",
"      Xu L, Sakalian M, Shen Z, et al. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/42\">",
"      Mason AL, Farr GH, Xu L, et al. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/43\">",
"      Harada K, Tsuneyama K, Sudo Y, et al. Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is Propionibacterium acnes involved in granuloma formation? Hepatology 2001; 33:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/44\">",
"      Abdulkarim AS, Petrovic LM, Kim WR, et al. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004; 40:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/45\">",
"      Leung PS, Park KO, Gershwin ME. Is there a relation between chlamydia infection and primary biliary cirrhosis? (abstract). Hepatology 2002; 36:388A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/46\">",
"      Maddala YK, Jorgensen RA, Angulo P, Lindor KD. Open-label pilot study of tetracycline in the treatment of primary biliary cirrhosis. Am J Gastroenterol 2004; 99:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/47\">",
"      Ohno N, Ota Y, Hatakeyama S, et al. A patient with E. coli-induced pyelonephritis and sepsis who transiently exhibited symptoms associated with primary biliary cirrhosis. Intern Med 2003; 42:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/48\">",
"      Bogdanos DP, Baum H, Grasso A, et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004; 40:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/49\">",
"      Shimoda S, Nakamura M, Shigematsu H, et al. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology 2000; 31:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/50\">",
"      O'Donohue J, Workman MR, Rolando N, et al. Urinary tract infections in primary biliary cirrhosis and other chronic liver diseases. Eur J Clin Microbiol Infect Dis 1997; 16:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/51\">",
"      Butler P, Hamilton-Miller J, Baum H, Burroughs AK. Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis? Biochem Mol Biol Int 1995; 35:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/52\">",
"      Selmi C, Balkwill DL, Invernizzi P, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003; 38:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/53\">",
"      Olafsson S, Gudjonsson H, Selmi C, et al. Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. Am J Gastroenterol 2004; 99:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/54\">",
"      Kaplan MM. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol 2004; 99:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/55\">",
"      Bogdanos D, Pusl T, Rust C, et al. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol 2008; 49:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/56\">",
"      Long SA, Quan C, Van de Water J, et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol 2001; 167:2956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/57\">",
"      Bruggraber SF, Leung PS, Amano K, et al. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 2003; 125:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/58\">",
"      Leung PS, Quan C, Park O, et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 2003; 170:5326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/59\">",
"      Leung PS, Park O, Tsuneyama K, et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 2007; 179:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/60\">",
"      Coppel RL, McNeilage LJ, Surh CD, et al. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A 1988; 85:7317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/61\">",
"      Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989; 320:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/62\">",
"      Van de Water J, Fregeau D, Davis P, et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988; 141:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/63\">",
"      Nishio A, Coppel R, Ishibashi H, Gershwin ME. The pyruvate dehydrogenase complex as a target autoantigen in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/64\">",
"      Shigematsu H, Shimoda S, Nakamura M, et al. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology 2000; 32:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/65\">",
"      Davis PA, Leung P, Manns M, et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 1992; 16:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/66\">",
"      Palmer JM, Yeaman SJ, Bassendine MF, James OF. M4 and M9 autoantigens in primary biliary cirrhosis--a negative study. J Hepatol 1993; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/67\">",
"      Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001; 34:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/68\">",
"      Van Norstrand MD, Malinchoc M, Lindor KD, et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/69\">",
"      Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/70\">",
"      Krams SM, Surh CD, Coppel RL, et al. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1989; 9:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/71\">",
"      Kim WR, Poterucha JJ, Jorgensen RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/72\">",
"      Colucci G, Schaffner F, Paronetto F. In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosis. Clin Immunol Immunopathol 1986; 41:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/73\">",
"      Shimoda S, Van de Water J, Ansari A, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998; 102:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/74\">",
"      Migliaccio C, Van de Water J, Ansari AA, et al. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: the molecule versus the mimic. Hepatology 2001; 33:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/75\">",
"      Kita H, Matsumura S, He XS, et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002; 109:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/76\">",
"      Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002; 123:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/77\">",
"      Van de Water J, Gershwin ME, Leung P, et al. The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med 1988; 167:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/78\">",
"      Fregeau DR, Prindiville T, Coppel RL, et al. Inhibition of alpha-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis. Hepatology 1990; 11:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/79\">",
"      Van de Water J, Ansari A, Prindiville T, et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995; 181:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/80\">",
"      Shimoda S, Nakamura M, Ishibashi H, et al. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995; 181:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/81\">",
"      Kita H, Lian ZX, Van de Water J, et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002; 195:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/82\">",
"      Kita H, Matsumura S, He XS, et al. Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis. Hepatology 2002; 36:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/83\">",
"      Malmborg AC, Shultz DB, Luton F, et al. Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis. J Autoimmun 1998; 11:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/84\">",
"      Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985; 88:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/85\">",
"      Kneppelhout JC, Mulder CJ, van Berge Henegouwen GP, et al. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth J Med 1992; 41:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/86\">",
"      Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991; 14:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/87\">",
"      Schlaeger R, Haux P, Kattermann R. Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver. Enzyme 1982; 28:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/88\">",
"      Odin JA, Huebert RC, Casciola-Rosen L, et al. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001; 108:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/89\">",
"      Amano K, Leung PS, Xu Q, et al. Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol 2004; 172:6444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/90\">",
"      Matsumura S, Kita H, He XS, et al. Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis. Hepatology 2002; 36:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/91\">",
"      Van de Water J, Ansari AA, Surh CD, et al. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 1991; 146:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/92\">",
"      Jones DE, Palmer JM, James OF, et al. T-cell responses to the components of pyruvate dehydrogenase complex in primary biliary cirrhosis. Hepatology 1995; 21:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/93\">",
"      Van de Water J, Turchany J, Leung PS, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993; 91:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/94\">",
"      Tsuneyama K, Van de Water J, Leung PS, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995; 21:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/95\">",
"      Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma [see comments]. Lancet 1998; 351:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/96\">",
"      Corpechot C, Barbu V, Chazouill&egrave;res O, Poupon R. Fetal microchimerism in primary biliary cirrhosis. J Hepatol 2000; 33:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/97\">",
"      Fanning PA, Jonsson JR, Clouston AD, et al. Detection of male DNA in the liver of female patients with primary biliary cirrhosis. J Hepatol 2000; 33:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/98\">",
"      Rubbia-Brandt L, Philippeaux MM, Chavez S, et al. FISH for Y chromosome in women with primary biliary cirrhosis: lack of evidence for leukocyte microchimerism. Hepatology 1999; 30:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/99\">",
"      Tanaka A, Lindor K, Gish R, et al. Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. Hepatology 1999; 30:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5737/abstract/100\">",
"      Jones DE. Fetal microchimerism: an aetiological factor in primary biliary cirrhosis? J Hepatol 2000; 33:834.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3616 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5737=[""].join("\n");
var outline_f5_38_5737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLUES ABOUT ETIOLOGY BASED ON THE EPIDEMIOLOGY OF PBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130787338\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MOLECULAR MIMICRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Retroviruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Propionibacterium acnes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chlamydophila (formerly Chlamydia pneumoniae)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - N. aromaticivorans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lactobacillus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHEMICAL EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTIMITOCHONDRIAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      T-CELL MITOCHONDRIAL RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      WHY TISSUE INJURY IN PBC IS CONFINED TO THE LIVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ROLE OF RETAINED BILE ACIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FETAL MICROCHIMERISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26933737\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3616|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/26/7599\" title=\"algorithm 1\">",
"      Pathogenesis of PBC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3616|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/39/43632\" title=\"diagnostic image 1\">",
"      Specific E2 antigen in PBC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3616|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/47/3825\" title=\"figure 1\">",
"      Bile acids in PBC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3616|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/48/12040\" title=\"picture 1A\">",
"      Primary biliary cirrhosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/16/27911\" title=\"picture 1B\">",
"      Primary biliary cirrhosis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/7/43127\" title=\"picture 2\">",
"      Primary biliary cirrhosis VIII - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/1/5143\" title=\"picture 3\">",
"      Foamy degeneration in PBC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_38_5738="Evaluation of acute pharyngitis in adults";
var content_f5_38_5738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of acute pharyngitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5738/contributors\">",
"     Anthony W Chow, MD, FRCPC, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5738/contributors\">",
"     Shira Doron, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5738/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5738/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/38/5738/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/38/5738/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/38/5738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pharyngitis is one of the most common conditions encountered in office practice, accounting for 12 million ambulatory visits in the United States annually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/1\">",
"     1",
"    </a>",
"    ]. The major treatable pathogen is group A streptococcus (GAS). Approximately 5 to 15 percent of sore throats in adults yield positive cultures for GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/2\">",
"     2",
"    </a>",
"    ], although this varies greatly from study to study, with reports ranging from 4.7 to 44.0 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Nevertheless, the vast majority of patients receive presumptive antibiotic therapy for pharyngitis.",
"   </p>",
"   <p>",
"    Overtreatment of acute pharyngitis represents one of the major causes of inappropriate use of antibiotics. In a large retrospective study, antibiotics were prescribed for 73 percent of adults presenting to primary care clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, 68 percent of the antibiotics chosen were more expensive and broader spectrum agents than those recommended in practice guidelines.",
"   </p>",
"   <p>",
"    In addition to GAS, other conditions that are important to remember in evaluating patients with sore throats are Epstein-Barr virus (EBV)-associated mononucleosis and the acute retroviral syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The microbiology, clinical presentation, differential diagnosis, and a diagnostic approach to acute pharyngitis in adults will be reviewed here. The treatment and complications of GAS pharyngitis and symptomatic management of pharyngitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38455?source=see_link\">",
"     \"Symptomatic treatment of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple pathogens can cause pharyngitis (",
"    <a class=\"graphic graphic_table graphicRef61935 \" href=\"UTD.htm?16/44/17100\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/7\">",
"     7",
"    </a>",
"    ]. The relative frequency of particular pathogens is uncertain, since most studies are old and include both children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The major causes of pharyngitis are viral agents (",
"    <a class=\"graphic graphic_table graphicRef61935 \" href=\"UTD.htm?16/44/17100\">",
"     table 1",
"    </a>",
"    ). Viruses associated with pharyngitis in adults include influenza, parainfluenza, coronavirus, rhinovirus, adenovirus, enterovirus, respiratory syncytial virus (RSV), metapneumovirus, herpes simplex virus (HSV), Epstein Barr virus (EBV), and the human immunodeficiency virus (HIV). Co-infections with streptococci and viruses may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important treatable agent is group A streptococcus (GAS). Other bacterial agents that may cause pharyngitis include Mycoplasma pneumoniae, Chlamydophila (formerly Chlamydia) pneumoniae, Neisseria gonorrhoeae, groups C and G streptococci, Arcanobacterium haemolyticum, Fusobacterium necrophorum (Fn), and Corynebacterium diphtheriae (",
"    <a class=\"graphic graphic_table graphicRef61935 \" href=\"UTD.htm?16/44/17100\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Identification of a particular microorganism, by culture or rapid antigen detection, does not prove causation of the pharyngitis since many organisms colonize the upper respiratory tract without causing disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10774877\">",
"    <span class=\"h1\">",
"     CAUSES AND ASSOCIATED CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pharyngitis typically complain of sore throat, particularly when swallowing. Fever is often present, and symptoms associated with fever (malaise, headache) may occur. Patients may note &ldquo;swollen glands&rdquo; or anterior neck pain related to lymphadenopathy. When throat symptoms are due to a viral upper respiratory infection (URI), accounting for pharyngitis in approximately 90 percent of symptomatic adults, associated symptoms may reflect other components of the URI, such as nasal congestion, coryza, hoarseness, sinus discomfort, ear pain, or cough, though such symptoms are not a result of pharyngitis itself. Fatigue is a prominent component when pharyngitis is due to infectious mononucleosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H5#H5\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with unusually severe signs and symptoms of pharyngitis, particularly if they have difficulty swallowing secretions, drooling, dysphonia, \"hot potato\" voice, or neck swelling, should be evaluated for rare but serious throat infections. Parapharyngeal space infections, peritonsillar abscess (\"quinsy\"), submandibular space infection (Ludwig's angina), and epiglottitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination will reveal pharyngeal erythema, often associated with tonsillar hypertrophy and purulent exudate. Anterior cervical lymph nodes are typically tender and enlarged. Palatal petechiae may be present.",
"   </p>",
"   <p>",
"    Significant asymmetry of the tonsils may indicate a peritonsillar abscess, particularly if the tonsil protrudes beyond the midline and causes uvular deviation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5322364\">",
"    <span class=\"h2\">",
"     Non-infectious causes of pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common non-infectious cause of inflammation of the pharynx is allergy. Patients with seasonal or environmental allergies often complain of sore throat. Smokers and those exposed to second-hand smoke may also have intermittent episodes of non-infectious pharyngitis. Poorly humidified air in the home or workplace, particularly in the winter, can be associated with pharyngitis as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Group A streptococcus (GAS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of GAS include the sudden onset of sore throat, tonsillar exudate, tender cervical adenitis, and fever. Cough and significant rhinorrhea are usually absent. The Centor criteria (exudate, cervical adenopathy, fever history, and lack of cough) provide a clinical prediction rule with reasonable negative predictive value in excluding streptococcal pharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical predictors and Centor criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Suppurative and nonsuppurative complications, although uncommon, can follow GAS pharyngitis. Suppurative complications refer to sinusitis and retropharyngeal and peritonsillar abscesses. The nonsuppurative complications are acute rheumatic fever and acute glomerulonephritis. Scarlet fever, another nonsuppurative complication, is much less common in adults and than in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link\">",
"     \"Complications of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non-group A streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pharyngitis caused by group C or group G beta hemolytic streptococci is not associated with acute rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/14\">",
"     14",
"    </a>",
"    ]. Antibiotic treatment for these infections may result in earlier symptomatic resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/15\">",
"     15",
"    </a>",
"    ], although one randomized trial in patients with non-GAS pharyngitis, with cultures positive for non-group A streptococcus in one-third, found only borderline effectiveness for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    treatment, compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/16\">",
"     16",
"    </a>",
"    ]. Group C streptococcus (GCS) is now considered a common cause of pharyngitis in adults and college students [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/17\">",
"     17",
"    </a>",
"    ]. Group G streptococcus has been linked to community outbreaks of pharyngitis in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/18\">",
"     18",
"    </a>",
"    ]. The role of antibiotics in the treatment of Group C or Group G pharyngitis is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=see_link\">",
"     \"Group C and group G streptococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is treatable, readily transmitted, and, at the outset of a season, epidemiologically important to recognize. The sore throat associated with influenza may be distinguished from streptococcal pharyngitis by several features: the presence of influenza cases in the community (epidemic), association with cough, and myalgias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fusobacterium necrophorum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 2005, several reports, primarily from Great Britain and Denmark, have documented the isolation of Fusobacterium necrophorum (Fn) from throat swabs of adolescents and young adults with nonstreptococcal sore throat [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Some studies also suggest a role for Fn in cases of recurrent or persistent sore throat [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fn is the causative agent of most cases of Lemierre syndrome, septic thrombophlebitis of the internal jugular vein, which often results in metastatic pulmonary infections. It is unclear how often Fn is a constituent of the normal oropharyngeal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Fn will not grow on the aerobic medium usually used for throat cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link\">",
"     \"Suppurative (septic) thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, the evidence for Fn as a primary pathogen in acute pharyngitis in adolescents and young adults without Lemmiere syndrome is suggestive but not yet conclusive. Data are not available on an immune response to Fn, analogous to that for streptococcal infection, in sore throat patients. Additionally, the prevalence of Fn may vary by geographic region. Although Fn was the most prevalent pathogen isolated from peritonsillar abscesses (PTA) in a large Danish study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/24\">",
"     24",
"    </a>",
"    ], this organism was recovered from only 3 of 295 PTA aspirates in Israel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further study is required to determine the role of Fn in acute pharyngitis, as well as the necessity for and efficacy of therapy. Some experts suggest that physicians should consider Fn infection in adolescents and young adults (ages 15 to 30) with a negative rapid test for streptococcus whose episode of pharyngitis is unusually prolonged and severe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Treatment for Fn pharyngitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link&amp;anchor=H27287700#H27287700\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\", section on 'Antibiotics for other organisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of Lemierre syndrome should be strongly considered in such patients with chills, high fever, and unilateral neck swelling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link&amp;anchor=H11#H11\">",
"     \"Suppurative (septic) thrombophlebitis\", section on 'Jugular vein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infectious mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) and cytomegalovirus (CMV) account for the majority of cases of the mononucleosis syndrome; HIV and other pathogens may cause similar symptoms. Mononucleosis is a systemic illness that is often associated with splenomegaly, lymphadenopathy, persistent fatigue, weight loss, and hepatitis. Pharyngitis and tonsillar exudate may be prominent; the diagnosis may not become apparent until the pharyngitis has persisted beyond expectations for other etiologies. CMV is less likely than EBV to be associated with pharyngitis. In addition to tender anterior cervical adenopathy, patients with EBV mononucleosis will often have enlarged tender posterior cervical nodes. Atypical lymphocytosis is often seen on complete blood count in infectious mononucleosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute retroviral syndrome often presents in a fashion suggesting EBV mononucleosis. It is important to establish the diagnosis of primary HIV infection, both for treatment of the individual patient and for public health concerns, as HIV transmission is most frequent in the two months following initial infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features of primary HIV include fever, nonexudative pharyngitis, weight loss, adenopathy, and splenomegaly; laboratory tests often show lymphopenia and increased transaminase levels.",
"   </p>",
"   <p>",
"    Newer rapid point-of-care (POC) tests detect both HIV antigen and antibody, thus permitting a POC diagnosis of acute HIV infection. Patients with this possible diagnosis should be promptly referred to an HIV specialist for evaluation and counseling on HIV transmission, since acute HIV infection is the time of most efficient HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/28\">",
"     28",
"    </a>",
"    ]. The diagnosis is established with an HIV viral load assay, which should show &ge;10,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neisseria gonorrhoeae",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. gonorrhoeae is a relatively rare cause of pharyngitis, but represents a treatable and transmissible pathogen that has important implications for contact tracing. Most cases are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link&amp;anchor=H7889046#H7889046\">",
"     \"Treatment of uncomplicated gonococcal infections\", section on 'Pharyngeal infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mycoplasma pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. pneumoniae may cause pharyngitis that is usually accompanied by acute bronchitis. Pharyngitis as a manifestation of mycoplasma infection occurs primarily in young, previously healthy adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chlamydophila pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. pneumoniae, similar to M. pneumoniae, also generally affects young, previously healthy adults. When C. pneumoniae causes pharyngitis, it is usually accompanied by other manifestations such as acute bronchitis or pneumonitis. Clinical laboratory methods for identification of C. pneumoniae are suboptimal and it is rare to make a definitive diagnosis in a timely manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Corynebacterium diphtheriae",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. diphtheriae, the etiologic agent of diphtheria, produces pharyngitis, malaise, and low grade fever. The onset of symptoms is typically gradual. The infection can begin with mild pharyngeal injection and erythema. The hallmark of diphtheria, the formation of a tightly adhering gray membrane that causes bleeding when dislodged, occurs in at least one-third of patients. Diphtheria should be considered in patients with compatible symptoms who have recently traveled to countries where the disease remains endemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11046?source=see_link\">",
"     \"Diagnosis and treatment of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94571825\">",
"    <span class=\"h2\">",
"     Arcanobacterium haemolyticum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arcanobacterium haemolyticum (formerly Corynebacterium haemolyticum) is a gram positive bacillus that is a relatively uncommon cause of acute pharyngitis and tonsillitis. Symptomatic infection with this organism may closely mimic acute streptococcal pharyngitis. Rarely A. haemolyticum causes more deeply invasive disease. Two features of pharyngeal infection with this organism are notable. It has a predilection for adolescents and young adults and it frequently provokes a generalized rash that may resemble that of scarlet fever [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/30\">",
"     30",
"    </a>",
"    ]. The organism is detected more readily on human-than sheep-blood agar plates and thus may not be identified in routine throat cultures. Thus the clinician should suspect A. haemolyticum infection in adolescents or young adults who have an acute pharyngitis and scarlatiniform rash but a negative culture or rapid streptococcal antigen test for GAS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link&amp;anchor=H27287700#H27287700\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\", section on 'Antibiotics for other organisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Other bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6386158\">",
"    <span class=\"h2\">",
"     HSV type 1 and HSV type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV type 1 has been reported to cause 5 to 10 percent of cases of acute pharyngitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tonsillitis in college students [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/8,9,31\">",
"     8,9,31",
"    </a>",
"    ]. Because only a small minority of these patents has lesions of the anterior mouth or lips, they cannot be easily distinguished from other causes of acute pharyngitis. Rare cases of pharyngeal HSV type 2 infection may occur secondary to orogenital contact [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10775090\">",
"    <span class=\"h1\">",
"     RATIONALE FOR IDENTIFYING GAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of pharyngitis in adults are due to viral infection and are self-limited. Determining an optimal diagnostic and management strategy for adults with pharyngitis involves assessing the likelihood of a bacterial etiology and balancing the costs of the evaluation and drugs, the risks of undertreatment of group A streptococcus (GAS) (including transmission, discomfort, and poststreptococcal sequelae), and the risks of overtreatment (drug resistance, antibiotic side effects, and allergic reactions).",
"   </p>",
"   <p>",
"    There are four reasons to treat streptococcal pharyngitis with antibiotics, but these are less compelling in adults than in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To prevent poststreptococcal sequelae &mdash; Acute rheumatic fever is rare in North America, but a significant problem in developing countries. (See",
"      <a class=\"local\" href=\"#H10775139\">",
"       'Poststreptococcal sequelae'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      To prevent suppurative complications &mdash; Peritonsillar abscess, sinusitis, and retropharyngeal abscess. Peritonsillar abscess typically occurs in adolescents and young adults. However, many patients do not present for care until after this complication has developed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/12\">",
"       12",
"      </a>",
"      ]. Retropharyngeal abscess occurs most commonly in the first few years of life, and sinusitis is a very rare complication of GAS pharyngitis.",
"     </li>",
"     <li>",
"      To reduce symptoms &mdash; There is a modest (approximately one day) reduction in symptoms with early antibiotic treatment. A meta-analysis found that throat soreness and fever were reduced by about one-half at day three for patients treated with antibiotics, compared to those given placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/33\">",
"       33",
"      </a>",
"      ]. For patients with GAS and severe symptoms (&ge;3 Centor criteria), symptoms resolved 2.5 days earlier with antibiotic therapy in one randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical predictors and Centor criteria'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      To prevent transmission &mdash; While this is important in pediatrics, due to extensive exposures, it is considered somewhat less so in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"       \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link\">",
"       \"Complications of streptococcal tonsillopharyngitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10775139\">",
"    <span class=\"h2\">",
"     Poststreptococcal sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rheumatic fever (ARF), an important complication of acute streptococcal pharyngitis, has become rare in most developed countries. However, beginning in early 1985, an epidemic of the disease occurred in Salt Lake City, Utah, and the surrounding intermountain area, concomitant with the appearance of a highly rheumatogenic GAS strain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/34\">",
"     34",
"    </a>",
"    ]. By the year 2000, more than 500 cases had been diagnosed. Smaller clusters of ARF, ranging from 15 to 40 cases, were reported during approximately the same time period in other US communities. In contrast, acute rheumatic fever and rheumatic heart disease are estimated to affect 20 million people in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review found that antibiotic treatment of pharyngitis, compared to placebo, reduced the incidence of acute rheumatic fever by about 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/33\">",
"     33",
"    </a>",
"    ]. 2009 guidelines for the prevention of rheumatic fever have been issued by the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link\">",
"     \"Treatment and prevention of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other nonsuppurative sequela of GAS pharyngitis is poststreptococcal glomerulonephritis (PSGN). This complication is exceedingly rare in adults in developed countries. Unlike ARF, PSGN may follow either throat or skin infection. Moreover, there is no firm evidence that treatment of the antecedent streptococcal throat infection can prevent PSGN [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10775535\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF GROUP A STREPTOCOCCUS (GAS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on physical examination in patients with pharyngitis will rarely distinguish the etiology. With rare exception, none of the agents of acute pharyngitis presents a unique clinical picture, complicating the ability of clinicians to distinguish among the pathogens. The major goal for the evaluation of patients with pharyngitis is to identify those with GAS pharyngitis in order to prescribe antibiotics to these patients and not to treat others inappropriately.",
"   </p>",
"   <p>",
"    Algorithms have been proposed that variably rely upon a clinical prognostic score, throat cultures, rapid antigen testing, or combinations of these. Since clinical features do not reliably distinguish GAS from a viral pharyngitis, in the absence of other symptoms of a viral upper respiratory infection (URI), a throat swab for microbiologic testing (by antigen testing, DNA probe, or culture) is necessary to determine if GAS is present in patients with sore throat and at least two signs or symptoms of pharyngitis, as specified by the Centor criteria (tonsillar exudates, tender anterior cervical adenopathy, fever history, absence of cough) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical predictors and Centor criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Laboratory policies regarding throat cultures vary; some laboratories will only look for GAS while others identify all potential pathogens including N. meningitidis when a \"throat culture\" is requested. Throat cultures may incidentally grow Neisseria meningitidis, which rarely, if ever, causes symptoms of pharyngitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to detect GAS since antibiotic therapy can prevent acute rheumatic fever, slightly shorten the acute illness, and prevent suppurative sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/33\">",
"     33",
"    </a>",
"    ]. Identification of several nonbacterial pathogens associated with pharyngitis may also be important. Establishing the diagnosis of primary HIV infection allows initiation of antiretroviral therapy; diagnosing influenza can lead to treatment and initiation of infection control procedures; and confirming infectious mononucleosis is helpful for prognostic purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10775592\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pharyngitis should have a physical examination focusing on the head and neck, chest, and skin. An abdominal examination to look for splenomegaly is indicated when history and significant adenopathy suggest possible infectious mononucleosis. Findings in patients with pharyngitis may include fever, pharyngeal erythema, palatal petechiae, cervical adenitis, tonsillar hypertrophy, and purulent exudate. Abnormal findings restricted to the throat and related lymph nodes are consistent with streptococcal pharyngitis, but may also be found in patients with other etiologies for pharyngitis, including viral infection.",
"   </p>",
"   <p>",
"    Examination may reveal findings suggesting other components of a viral upper respiratory infection, such as sinus tenderness or pulmonary rhonchi. Diffuse adenitis, splenomegaly, and skin rash suggest infectious mononucleosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H5#H5\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical predictors and Centor criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians, even those with extensive clinical experience, are not able to reliably predict which patients will have a positive throat culture for GAS; sensitivity and specificity estimates range from 55 to 74 percent and 58 to 76 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical decision rules, based upon a constellation of symptoms and signs, have been developed to try to improve the accuracy of prediction of GAS infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/13,38,39\">",
"     13,38,39",
"    </a>",
"    ]. The Centor criteria are widely used and accepted and are endorsed by the NICE Guidance that establishes standards of care for the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/13,40\">",
"     13,40",
"    </a>",
"    ]. These criteria are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tonsillar exudates",
"     </li>",
"     <li>",
"      Tender anterior cervical adenopathy",
"     </li>",
"     <li>",
"      Fever by history",
"     </li>",
"     <li>",
"      Absence of cough",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have evaluated the ability of these criteria to predict the presence of GAS infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the initial model for these criteria, based upon correlation with cultures in patients presenting to an emergency room, the positive predictive value for the presence of GAS in the pharynx was 40 to 60 percent for patients who met three or four criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/13\">",
"       13",
"      </a>",
"      ]. The absence of three or four of the criteria has a higher negative predictive value of 80 percent.",
"     </li>",
"     <li>",
"      In a prospective study of adults with acute pharyngitis the sensitivity of this prediction rule in patients with three or four criteria was 77 percent when compared to throat cultures, but the specificity was only 44 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a larger database, based upon 140,000 individuals 15 years or older presenting with sore throat symptoms to a retail health chain in the US, the rate of confirmation of GAS (by either rapid streptococcal antigen testing or culture) for patients meeting one, two, three, or four criteria were 12, 21, 38, and 57 percent respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definitive criteria for initiating antibiotics remain controversial. Dependence upon clinical criteria alone leads to overtreatment of 50 percent, if the intended treatment goal is eradication of infection with group A streptococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/2,6,37\">",
"     2,6,37",
"    </a>",
"    ]. One study suggests that incorporating local recent incidence data for group A streptococcus (percent of positive cultures or rapid tests for strep) could change the threshold with which to initiate antibiotics and potentially improve the appropriateness of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/43\">",
"     43",
"    </a>",
"    ]. However, such local incidence data are not generally available in a timely way.",
"   </p>",
"   <p>",
"    Strategies have been developed that incorporate throat culture or a positive rapid antigen detection test (RADT) for streptococcus to determine who should be treated with antibiotics for GAS. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'RADT or RADT with back-up testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throat cultures have been the \"gold standard\" for diagnosing GAS pharyngitis and, in unusual circumstances, can be used to isolate other pathogens, such as N. gonorrhoeae. However, N. gonorrhoeae may not grow in routine culture. Thus, if this infection is suspected, the laboratory should be alerted so as to properly plate the specimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cultures take 24 to 48 hours to grow and cannot immediately be used to decide which patients merit antibiotic therapy. Thus, the rapid antigen detection test (RADT) has assumed greater importance in algorithms for managing acute pharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/2,3,37\">",
"     2,3,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Rapid antigen detection test'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Specimen collection and transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key to optimizing detection of GAS in clinical specimens is appropriate collection and transport of the sample [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specimens should be obtained prior to the initiation of antimicrobial therapy. Even a single dose of antibiotics may be sufficient to render the culture or rapid antigen test negative [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Specimens should be obtained by vigorous swabbing of both tonsils (or tonsillar fossae in patients without tonsils) and the posterior pharynx. The tongue, buccal mucosa, and hard palate are",
"      <strong>",
"       not",
"      </strong>",
"      satisfactory sites for culture and should be avoided. The importance of obtaining an adequate specimen cannot be overstated, as the sensitivity of both culture and rapid antigen detection testing correlate with inoculum size [",
"      <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/47\">",
"       47",
"      </a>",
"      ]. Although double testing for both rapid test and culture is not recommended for most adults, if such a strategy is chosen, two separate samples should be used; the sample obtained for the rapid test should not be then sent for routine culture. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'RADT or RADT with back-up testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      GAS are relatively resistant to desiccation. The organism remains viable on dry swabs for 48 to 72 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Rapid antigen detection test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid antigen detection tests (RADTs) for streptococcus, sometimes referred to as rapid streptococcal antigen tests (RSATs), are based upon enzyme or acid extraction of antigen from throat swabs. Most tests currently in use employ enzyme linked immunoabsorbent assay (ELISA) to detect antigen-antibody complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. Sensitivity for the streptococcal RADT ranges from 70 to 90 percent and specificity from 90 to 100 percent in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/33,53-55\">",
"     33,53-55",
"    </a>",
"    ]. Some studies suggest that the sensitivity of optical immunoassay (OIA) rapid testing may equal that of culture on blood agar plate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/53\">",
"     53",
"    </a>",
"    ]. Unfortunately, at this writing, OIA is no longer commercially available.",
"   </p>",
"   <p>",
"    The performance of a particular RADT for the diagnosis of GAS pharyngitis is also a function of the clinical characteristics of the illness in patients selected for testing. This factor is referred to as \"spectrum bias\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/56\">",
"     56",
"    </a>",
"    ]. In three studies, the sensitivity of the RADT for streptococcus increased concomitant with the number of Centor criteria present [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive RADT is useful in establishing the diagnosis of GAS pharyngitis, but a negative test does not rule out GAS. The RADT provides a same visit result and permits rapid institution of therapy. It does not identify non-group A beta hemolytic streptococci.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Throat culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throat culture is the time-honored method to establish the microbial cause of acute pharyngitis. Sensitivity can be negatively impacted by suboptimal methods of specimen collection and laboratory processing as routinely performed in clinical practice. The specimen should be obtained under direct visualization and plated as soon as possible on sheep's blood agar with low dextrose content. Growth of GAS does not distinguish between acute pharyngeal infection and asymptomatic carriage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With proper techniques in adults, the sensitivity should be approximately 90 percent and specificity should be 95 to 99 percent. The figure given for sensitivity is based on double swabs, which show discordant results in 9 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/62\">",
"     62",
"    </a>",
"    ]. The performance in practice, however, is often significantly lower than these figures.",
"   </p>",
"   <p>",
"    The utility of throat cultures in adults has been questioned, both due to problems with sensitivity and the time delay in obtaining actionable results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34026401\">",
"    <span class=\"h3\">",
"     DNA probes",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA probe tests use nucleic acid hybridization for the qualitative detection of group A Streptococcal RNA directly from throat swabs. Compared to throat culture, considered the gold standard, the sensitivity, specificity, positive, and negative predictive values of the streptococcal DNA probe was 94.8, 100, 100, and 96.9 percent respectively; analogous performance characteristics for RADT were 86.1, 97.1, 93.7, and 93.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/63\">",
"     63",
"    </a>",
"    ]. Due to their high sensitivity and specificity, DNA probes are used by some laboratories as an alternative to culture to confirm findings when RADT is negative; DNA probe can also be used as a stand-alone test. Turn-around time is 24 hours as compared with up to 72 hours for culture, which allows for quicker diagnosis, but does not support a same visit treatment decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most widely used antibody assays for group A Streptoccocus are antistreptolysin O (ASO) and anti-deoxyribonuclease B. Although serology is critical for the diagnosis of acute rheumatic fever, it is not helpful or relevant for management of streptococcal pharyngitis because antibiotic treatment decisions need to be made before the titer rises to diagnostic levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Evaluation and treatment strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple treatment strategies have been designed that incorporate varied combinations of empiric therapy for specified clinical criteria and treatment based on test results from rapid antigen tests (RADT) and throat culture. Determining the optimal strategy involves limiting the use of unnecessary antibiotics and increasing the accuracy of GAS identification, while factoring in the convenience of immediate treatment, need for telephone follow-up once culture or DNA probe results return, and relative costs.",
"   </p>",
"   <p>",
"    Several decision analyses have been applied to these strategies. A definitive optimal approach to the treatment of adult pharyngitis, based on results of a randomized controlled trial, has not been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although published treatment strategies have recommended empiric antibiotic therapy for patients who meet three or all four Centor clinical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/2,64\">",
"     2,64",
"    </a>",
"    ], this approach may lead to high rates of unnecessary antibiotic exposure. In one study, for example, empiric antibiotic treatment in patients who met three or four Centor criteria resulted in appropriate antibiotic therapy for 59 percent of patients, antibiotic overuse for 32 percent and antibiotic underuse in 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/57,65\">",
"     57,65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical predictors and Centor criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America (IDSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/37\">",
"     37",
"    </a>",
"    ] and other authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/14,41,65\">",
"     14,41,65",
"    </a>",
"    ] find these rates unacceptable and recommend treatment be based upon positive RADT or culture results. In unusual circumstances, clinician judgment may reasonably supersede the caveat not to treat based upon clinical presentation alone. Examples may include a febrile mother with exudative tonsillitis whose two children have documented streptococcal pharyngitis, acute pharyngitis in a patient with a history of rheumatic heart disease, or the presence of a community-wide outbreak of rheumatic fever.",
"   </p>",
"   <p>",
"    Clinical criteria are well accepted for determining which patients do",
"    <strong>",
"     not",
"    </strong>",
"    need either treatment or further evaluation. The approaches discussed below advise that patients with fewer than two Centor criteria receive neither antibiotic treatment nor diagnostic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     RADT or RADT with back-up testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of two studies, evaluating diagnostic strategies for adults with acute pharyngitis, differed in their findings as to whether treatment based on systematic culture or RADT was the optimal strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/41,57\">",
"     41,57",
"    </a>",
"    ]. These studies differed in the prevalence of GAS (21.9 and 37.6 percent) and in the sensitivity of the RADT employed (77 and 91 percent). Both of these studies employed OIA, a technology which is not currently available. Similar large, high-quality studies of ELISA-based RADTs in adults have not been reported. However, in an analysis of 1848 children with acute pharyngitis presenting to six community pediatric offices in the Chicago area, a CLIA-waived non-OIA RADT (Quidel QuickVue) had a sensitivity of 70 percent and a specificity of 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical criteria are well accepted for determining which patients do",
"    <strong>",
"     not",
"    </strong>",
"    need either antibiotic treatment or further evaluation. Adults with fewer than two Centor criteria (tonsillar exudates, tender anterior cervical adenopathy, history of fever, absence of cough) should not receive either antibiotic treatment or diagnostic testing. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Clinical predictors and Centor criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most authorities favor evaluation using a sensitive RADT without reflex throat culture or DNA probe for negative results in adults with two or more Centor criteria. This approach is in line with guidelines of IDSA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/37\">",
"     37",
"    </a>",
"    ], AHA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/14\">",
"     14",
"    </a>",
"    ], and CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. According to the 2012 IDSA Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis, &ldquo;Routine use of back-up throat cultures for those with a negative RADT is not necessary for adults in usual circumstances&hellip;. Physicians who wish to ensure they are achieving maximal sensitivity in diagnosis may continue to use conventional throat culture or to back-up negative RADTs with a culture.&rdquo; The authors concur but would consider &ldquo;adults&rdquo; to be persons 18 years of age or older who are not living in a college dormitory setting. Students older than 18 who reside in a college dormitory are likely to be at higher risk for streptococcal pharyngitis and should be approached like those 18 and younger. Positive RADTs do not need to be backed up with culture or DNA probe because they are highly specific. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The omission of a backup culture means that some adults with pharyngeal GAS will not be treated. However, acute pharyngitis in otherwise healthy adults is largely a benign and self-limited illness, and the risk of acute rheumatic fever in developed countries is exceptionally low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/37\">",
"     37",
"    </a>",
"    ]. Some experts advocate culture for rapid-test negative patients because culture is more sensitive than antigen testing and will also detect groups C and G organisms. Antibiotic treatment based on results of throat culture or DNA probe is a reasonable option. However, in one study in which DNA probes were performed for over 15,000 symptomatic adults with a negative RADT, the RADT was falsely negative in 6 percent, but the DNA probe changed management for only 3 percent of patients, at a cost of over 1.75 million dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric therapy based on symptoms is generally not recommended.",
"   </p>",
"   <p>",
"    A study of clinical practice in adult primary care clinics in Boston found that clinicians were adherent to",
"    <strong>",
"     no",
"    </strong>",
"    published test strategy in 66 percent of visits [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/66\">",
"     66",
"    </a>",
"    ]. For the most part, non-adherence resulted from unnecessary testing or treatment for patients who did not have two or more Centor criteria and were therefore at low risk for streptococcal pharyngitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children have a much higher incidence of streptococcal pharyngitis and a greater risk of acute rheumatic fever than do adults. Also, preventing transmission is an important issue in children. Because RADTs are generally less sensitive than throat cultures, a back-up throat culture or DNA probe is recommended in children with a negative RADT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/14,37\">",
"     14,37",
"    </a>",
"    ]. The back-up throat culture or DNA probe strategy for adults might be favored in cases where prevention of transmission is particularly important (eg, adults in close contact with young children) or in the presence of endemic or epidemic rheumatic fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     NEGATIVE EVALUATION FOR GAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the vast majority of patients with a negative evaluation for GAS, the pharyngitis will resolve without sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?5/38/5738/abstract/2\">",
"     2",
"    </a>",
"    ] and no further diagnostic measures are required. Symptomatic treatment should be offered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38455?source=see_link\">",
"     \"Symptomatic treatment of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific diagnoses may be suggested based on history and physical examination findings, as follows (see",
"    <a class=\"local\" href=\"#H10774877\">",
"     'Causes and associated clinical features'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of HIV risk factors should be sought since primary HIV is under recognized in the acute clinical setting and early antiretroviral therapy is warranted if a diagnosis is made.",
"     </li>",
"     <li>",
"      Influenza is usually recognized clinically by the presence of an epidemic in the community and typical symptoms including fever, cough, and myalgias.",
"     </li>",
"     <li>",
"      Gonococcal pharyngitis can be considered in selected patients and a throat culture for this pathogen can be obtained.",
"     </li>",
"     <li>",
"      Diphtheria should be entertained in those patients with a membrane, as well as in patients who have recently traveled to areas in which this disease is still endemic.",
"     </li>",
"     <li>",
"      EBV mononucleosis should be considered in those with persisting symptoms and systemic involvement.",
"     </li>",
"     <li>",
"      It is rare to need to diagnose either M. pneumoniae or C. pneumoniae as causes of pharyngitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/57/914?source=see_link\">",
"       \"Patient information: Sore throat in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=see_link\">",
"       \"Patient information: Sore throat in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group A streptococcus (GAS), the major treatable pathogen for acute pharyngitis, is the cause of pharyngitis in only approximately 10 to 15 percent of adults who seek medical care. However, antibiotics are prescribed for more than 70 percent of adults who present with pharyngitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many pathogens cause pharyngitis, but with rare exception, few present a unique clinical picture. Clinical features of GAS include sudden onset of sore throat, tonsillar exudate, tender cervical adenopathy, and fever. Influenza is suspected when present in the community, and sore throat is accompanied by myalgias, cough, and high fever. (See",
"      <a class=\"local\" href=\"#H10774877\">",
"       'Causes and associated clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The number of Centor clinical criteria present (tonsillar exudates, tender anterior cervical adenopathy, fever history, absence of cough) correlate with the likelihood of acute GAS pharyngitis in an adult patient. The criteria, however, have a higher negative than positive predictive value, and they are most useful in identifying patients in whom neither microbiologic tests nor antimicrobial therapy are necessary. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical predictors and Centor criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three diagnostic tests for GAS are throat culture, DNA probe, and rapid antigen detection test (RDAT) for streptococcus. Serologic tests are useful in the diagnosis of streptococcal sequelae, such as rheumatic fever, but are not helpful in the patient with pharyngitis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple treatment strategies have been proposed, such as empiric therapy on the basis of clinical criteria and treatment following test results from RADT and throat culture or DNA probe. A definitive approach to the treatment of adult pharyngitis, based on results of a randomized controlled trial, has not been identified. (See",
"      <a class=\"local\" href=\"#H10775090\">",
"       'Rationale for identifying GAS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with fewer than two Centor criteria (tonsillar exudates, tender anterior cervical adenopathy, fever history, absence of cough) should not receive either antibiotic treatment or diagnostic testing. Most authorities, as well as practice guidelines published by the IDSA and American Heart Association favor evaluation using a sensitive RADT, without reflex throat culture for negative results, in adult patients with two or more Centor criteria. Antibiotic treatment based on results of throat culture or DNA probe is a reasonable option. Empiric therapy based on symptoms is generally not recommended. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Evaluation and treatment strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17204048\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Alan Bisno and Dr. Paola Lichtenberger, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/1\">",
"      Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl Health Stat Report 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/2\">",
"      Snow V, Mottur-Pilson C, Cooper RJ, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults. Ann Intern Med 2001; 134:506.",
"     </a>",
"    </li>",
"    <li>",
"     Peter GS, Bisno AL. Group A streptococcal pharyngitis in adults: diagnosis and management. In: Streptococcal pharyngitis issues in infectious diseases, Pechera JC, Kaplan EL.  (Eds), Karger, Basel 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/4\">",
"      Poses RM, Cebul RD, Collins M, Fager SS. The accuracy of experienced physicians' probability estimates for patients with sore throats. Implications for decision making. JAMA 1985; 254:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/5\">",
"      Woods WA, Carter CT, Stack M, et al. Group A streptococcal pharyngitis in adults 30 to 65 years of age. South Med J 1999; 92:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/6\">",
"      Linder JA, Stafford RS. Antibiotic treatment of adults with sore throat by community primary care physicians: a national survey, 1989-1999. JAMA 2001; 286:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/7\">",
"      Alcaide ML, Bisno AL. Pharyngitis and epiglottitis. Infect Dis Clin North Am 2007; 21:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/8\">",
"      EVANS AS, DICK EC. ACUTE PHARYNGITIS AND TONSILLITIS IN UNIVERSITY OF WISCONSIN STUDENTS. JAMA 1964; 190:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/9\">",
"      Glezen WP, Clyde WA Jr, Senior RJ, et al. Group A streptococci, mycoplasmas, and viruses associated with acute pharyngitis. JAMA 1967; 202:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/10\">",
"      Monto AS, Ullman BM. Acute respiratory illness in an American community. The Tecumseh study. JAMA 1974; 227:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/11\">",
"      Huovinen P, Lahtonen R, Ziegler T, et al. Pharyngitis in adults: the presence and coexistence of viruses and bacterial organisms. Ann Intern Med 1989; 110:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/12\">",
"      Cooper RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med 2001; 134:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/13\">",
"      Centor RM, Witherspoon JM, Dalton HP, et al. The diagnosis of strep throat in adults in the emergency room. Med Decis Making 1981; 1:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/14\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/15\">",
"      Zwart S, Sachs AP, Ruijs GJ, et al. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. BMJ 2000; 320:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/16\">",
"      Petersen K, Phillips RS, Soukup J, et al. The effect of erythromycin on resolution of symptoms among adults with pharyngitis not caused by group A streptococcus. J Gen Intern Med 1997; 12:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/17\">",
"      Turner JC, Hayden FG, Lobo MC, et al. Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students. J Clin Microbiol 1997; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/18\">",
"      Gerber MA, Randolph MF, Martin NJ, et al. Community-wide outbreak of group G streptococcal pharyngitis. Pediatrics 1991; 87:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/19\">",
"      Amess JA, O'Neill W, Giollariabhaigh CN, Dytrych JK. A six-month audit of the isolation of Fusobacterium necrophorum from patients with sore throat in a district general hospital. Br J Biomed Sci 2007; 64:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/20\">",
"      Batty A, Wren MW. Prevalence of Fusobacterium necrophorum and other upper respiratory tract pathogens isolated from throat swabs. Br J Biomed Sci 2005; 62:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/21\">",
"      Jensen A, Hagelskjaer Kristensen L, Prag J. Detection of Fusobacterium necrophorum subsp. funduliforme in tonsillitis in young adults by real-time PCR. Clin Microbiol Infect 2007; 13:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/22\">",
"      Batty A, Wren MW, Gal M. Fusobacterium necrophorum as the cause of recurrent sore throat: comparison of isolates from persistent sore throat syndrome and Lemierre's disease. J Infect 2005; 51:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/23\">",
"      Riordan T. Human infection with Fusobacterium necrophorum (Necrobacillosis), with a focus on Lemierre's syndrome. Clin Microbiol Rev 2007; 20:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/24\">",
"      Ehlers Klug T, Rusan M, Fuursted K, Ovesen T. Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark. Clin Infect Dis 2009; 49:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/25\">",
"      Gavriel H, Vaiman M, Kessler A, Eviatar E. Microbiology of peritonsillar abscess as an indication for tonsillectomy. Medicine (Baltimore) 2008; 87:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/26\">",
"      Centor RM, Samlowski R. Avoiding sore throat morbidity and mortality: when is it not \"just a sore throat?\". Am Fam Physician 2011; 83:26, 28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/27\">",
"      Centor RM. Expand the pharyngitis paradigm for adolescents and young adults. Ann Intern Med 2009; 151:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/28\">",
"      Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/29\">",
"      Morris SR, Klausner JD, Buchbinder SP, et al. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study. Clin Infect Dis 2006; 43:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/30\">",
"      Miller RA, Brancato F, Holmes KK. Corynebacterium hemolyticum as a cause of pharyngitis and scarlatiniform rash in young adults. Ann Intern Med 1986; 105:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/31\">",
"      McMillan JA, Weiner LB, Higgins AM, Lamparella VJ. Pharyngitis associated with herpes simplex virus in college students. Pediatr Infect Dis J 1993; 12:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/32\">",
"      Tustin AW, Kaiser AB. Life-threatening pharyngitis caused by herpes simplex virus, type 2. Sex Transm Dis 1979; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/33\">",
"      Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2006; :CD000023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/34\">",
"      Veasy LG, Tani LY, Daly JA, et al. Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics 2004; 113:e168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/35\">",
"      Lee GM, Wessels MR. Changing epidemiology of acute rheumatic fever in the United States. Clin Infect Dis 2006; 42:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/36\">",
"      Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/37\">",
"      Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/38\">",
"      Dobbs F. A scoring system for predicting group A streptococcal throat infection. Br J Gen Pract 1996; 46:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/39\">",
"      McIsaac WJ, White D, Tannenbaum D, Low DE. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ 1998; 158:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/40\">",
"      Tan T, Little P, Stokes T, Guideline Development Group. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ 2008; 337:a437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/41\">",
"      McIsaac WJ, Kellner JD, Aufricht P, et al. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA 2004; 291:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/42\">",
"      Fine AM, Nizet V, Mandl KD. Large-scale validation of the Centor and McIsaac scores to predict group A streptococcal pharyngitis. Arch Intern Med 2012; 172:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/43\">",
"      Fine AM, Nizet V, Mandl KD. Improved diagnostic accuracy of group A streptococcal pharyngitis with use of real-time biosurveillance. Ann Intern Med 2011; 155:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/44\">",
"      Carroll K, Reimer L. Microbiology and laboratory diagnosis of upper respiratory tract infections. Clin Infect Dis 1996; 23:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/45\">",
"      Snellman LW, Stang HJ, Stang JM, et al. Duration of positive throat cultures for group A streptococci after initiation of antibiotic therapy. Pediatrics 1993; 91:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/46\">",
"      Gerber MA, Randolph MF, DeMeo KK. Streptococcal antigen in the pharynx after initiation of antibiotic therapy. Pediatr Infect Dis J 1987; 6:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/47\">",
"      Kurtz B, Kurtz M, Roe M, Todd J. Importance of inoculum size and sampling effect in rapid antigen detection for diagnosis of Streptococcus pyogenes pharyngitis. J Clin Microbiol 2000; 38:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/48\">",
"      Dagnelie CF, Bartelink ML, van der Graaf Y, et al. Towards a better diagnosis of throat infections (with group A beta-haemolytic streptococcus) in general practice. Br J Gen Pract 1998; 48:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/49\">",
"      Roddey OF Jr, Clegg HW, Martin ES, et al. Comparison of an optical immunoassay technique with two culture methods for the detection of group A streptococci in a pediatric office. J Pediatr 1995; 126:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/50\">",
"      Gerber MA, Tanz RR, Kabat W, et al. Optical immunoassay test for group A beta-hemolytic streptococcal pharyngitis. An office-based, multicenter investigation. JAMA 1997; 277:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/51\">",
"      Stewart MH, Siff JE, Cydulka RK. Evaluation of the patient with sore throat, earache, and sinusitis: an evidence based approach. Emerg Med Clin North Am 1999; 17:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/52\">",
"      Daly JA, Korgenski EK, Munson AC, Llausas-Magana E. Optical immunoassay for streptococcal pharyngitis: evaluation of accuracy with routine and mucoid strains associated with acute rheumatic fever outbreak in the intermountain area of the United States. J Clin Microbiol 1994; 32:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/53\">",
"      Gerber MA, Shulman ST. Rapid diagnosis of pharyngitis caused by group A streptococci. Clin Microbiol Rev 2004; 17:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/54\">",
"      Gieseker KE, Mackenzie T, Roe MH, Todd JK. Comparison of two rapid Streptococcus pyogenes diagnostic tests with a rigorous culture standard. Pediatr Infect Dis J 2002; 21:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/55\">",
"      Nakhoul GN, Hickner J. Management of Adults with Acute Streptococcal Pharyngitis: Minimal Value for Backup Strep Testing and Overuse of Antibiotics. J Gen Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/56\">",
"      Dimatteo LA, Lowenstein SR, Brimhall B, et al. The relationship between the clinical features of pharyngitis and the sensitivity of a rapid antigen test: evidence of spectrum bias. Ann Emerg Med 2001; 38:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/57\">",
"      Humair JP, Revaz SA, Bovier P, Stalder H. Management of acute pharyngitis in adults: reliability of rapid streptococcal tests and clinical findings. Arch Intern Med 2006; 166:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/58\">",
"      Tanz RR, Gerber MA, Kabat W, et al. Performance of a rapid antigen-detection test and throat culture in community pediatric offices: implications for management of pharyngitis. Pediatrics 2009; 123:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/59\">",
"      Kaplan EL, Top FH Jr, Dudding BA, Wannamaker LW. Diagnosis of streptococcal pharyngitis: differentiation of active infection from the carrier state in the symptomatic child. J Infect Dis 1971; 123:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/60\">",
"      Kellogg JA, Manzella JP. Detection of group A streptococci in the laboratory or physician's office. Culture vs antibody methods. JAMA 1986; 255:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/61\">",
"      Brien JH, Bass JW. Streptococcal pharyngitis: optimal site for throat culture. J Pediatr 1985; 106:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/62\">",
"      Halfon ST, Davies AM, Kaplan O, et al. Primary prevention of rheumatic fever in Jerusalem schoolchildren. 2. Identification of beta-hemolytic streptococci. Isr J Med Sci 1968; 4:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/63\">",
"      Chapin KC, Blake P, Wilson CD. Performance characteristics and utilization of rapid antigen test, DNA probe, and culture for detection of group a streptococci in an acute care clinic. J Clin Microbiol 2002; 40:4207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/64\">",
"      Centor RM, Allison JJ, Cohen SJ. Pharyngitis management: defining the controversy. J Gen Intern Med 2007; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/65\">",
"      Bisno AL, Peter GS, Kaplan EL. Diagnosis of strep throat in adults: are clinical criteria really good enough? Clin Infect Dis 2002; 35:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/38/5738/abstract/66\">",
"      Linder JA, Chan JC, Bates DW. Evaluation and treatment of pharyngitis in primary care practice: the difference between guidelines is largely academic. Arch Intern Med 2006; 166:1374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6867 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-0E8DCFA2F5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5738=[""].join("\n");
var outline_f5_38_5738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10774877\">",
"      CAUSES AND ASSOCIATED CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5322364\">",
"      Non-infectious causes of pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Group A streptococcus (GAS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non-group A streptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fusobacterium necrophorum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infectious mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neisseria gonorrhoeae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mycoplasma pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chlamydophila pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Corynebacterium diphtheriae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94571825\">",
"      Arcanobacterium haemolyticum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6386158\">",
"      HSV type 1 and HSV type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10775090\">",
"      RATIONALE FOR IDENTIFYING GAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10775139\">",
"      Poststreptococcal sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10775535\">",
"      DIAGNOSIS OF GROUP A STREPTOCOCCUS (GAS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10775592\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical predictors and Centor criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Specimen collection and transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Rapid antigen detection test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Throat culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34026401\">",
"      - DNA probes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Evaluation and treatment strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - RADT or RADT with back-up testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      NEGATIVE EVALUATION FOR GAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17204048\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6867\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6867|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/44/17100\" title=\"table 1\">",
"      Causes of acute pharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11046?source=related_link\">",
"      Diagnosis and treatment of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=related_link\">",
"      Group C and group G streptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=related_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/57/914?source=related_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38455?source=related_link\">",
"      Symptomatic treatment of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=related_link\">",
"      Treatment and prevention of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_38_5739="Antibody screening for celiac";
var content_f5_38_5739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Positive predictive value of serum tests for celiac disease based upon 4615 adults in Northern Italy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Serum test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probability*, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA antiendomysium",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG antigliadin",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA antigliadin",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG and IgA antigliadin",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Indicates probability that the disease is present when the test is positive.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Pittschieler K, Ladinser B. Coeliac disease: screened by a new strategy. Acta Paediatr 1996; 412(Suppl):42.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5739=[""].join("\n");
var outline_f5_38_5739=null;
var title_f5_38_5740="Fetal neutrophil count by GA";
var content_f5_38_5740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fetal neutrophil count, 10",
"    <sup>",
"     9",
"    </sup>",
"    /L",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        GA, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.16",
"       </td>",
"       <td>",
"        0.42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"       <td>",
"        0.19",
"       </td>",
"       <td>",
"        0.47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"       <td>",
"        0.23",
"       </td>",
"       <td>",
"        0.55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        0.17",
"       </td>",
"       <td>",
"        0.43",
"       </td>",
"       <td>",
"        0.94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0.27",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"       <td>",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        0.44",
"       </td>",
"       <td>",
"        0.96",
"       </td>",
"       <td>",
"        1.98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        0.74",
"       </td>",
"       <td>",
"        1.55",
"       </td>",
"       <td>",
"        3.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        1.28",
"       </td>",
"       <td>",
"        2.60",
"       </td>",
"       <td>",
"        5.19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        2.28",
"       </td>",
"       <td>",
"        4.59",
"       </td>",
"       <td>",
"        9.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        4.23",
"       </td>",
"       <td>",
"        8.53",
"       </td>",
"       <td>",
"        17.09",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     GA = gestational age",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5740=[""].join("\n");
var outline_f5_38_5740=null;
var title_f5_38_5741="GRADE criteria";
var content_f5_38_5741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    GRADE criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade of recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clarity of risk/benefit",
"       </td>",
"       <td class=\"subtitle1\">",
"        Quality of supporting evidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Implications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          1A.",
"         </strong>",
"        </p>",
"        <p>",
"         Strong recommendation",
"        </p>",
"        <p>",
"         High quality evidence",
"        </p>",
"       </td>",
"       <td>",
"        Benefits clearly outweigh risk and burdens, or vice versa.",
"       </td>",
"       <td>",
"        Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.",
"       </td>",
"       <td>",
"        Strong recommendation, can apply to most patients in most circumstances without reservation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          1B.",
"         </strong>",
"        </p>",
"        <p>",
"         Strong recommendation",
"        </p>",
"        <p>",
"         Moderate quality evidence",
"        </p>",
"       </td>",
"       <td>",
"        Benefits clearly outweigh risk and burdens, or vice versa.",
"       </td>",
"       <td>",
"        Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.",
"       </td>",
"       <td>",
"        Strong recommendation, likely to apply to most patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          1C.",
"         </strong>",
"        </p>",
"        <p>",
"         Strong recommendation",
"        </p>",
"        <p>",
"         Low quality evidence",
"        </p>",
"       </td>",
"       <td>",
"        Benefits appear to outweigh risk and burdens, or vice versa.",
"       </td>",
"       <td>",
"        Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.",
"       </td>",
"       <td>",
"        Relatively strong recommendation; might change when higher quality evidence becomes available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          2A.",
"         </strong>",
"        </p>",
"        <p>",
"         Weak recommendation",
"        </p>",
"        <p>",
"         High quality evidence",
"        </p>",
"       </td>",
"       <td>",
"        Benefits closely balanced with risks and burdens.",
"       </td>",
"       <td>",
"        Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.",
"       </td>",
"       <td>",
"        Weak recommendation, best action may differ depending on circumstances or patients or societal values.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          2B.",
"         </strong>",
"        </p>",
"        <p>",
"         Weak recommendation",
"        </p>",
"        <p>",
"         Moderate quality evidence",
"        </p>",
"       </td>",
"       <td>",
"        Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens.",
"       </td>",
"       <td>",
"        Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.",
"       </td>",
"       <td>",
"        Weak recommendation, alternative approaches likely to be better for some patients under some circumstances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          2C.",
"         </strong>",
"        </p>",
"        <p>",
"         Weak recommendation",
"        </p>",
"        <p>",
"         Low quality evidence",
"        </p>",
"       </td>",
"       <td>",
"        Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens.",
"       </td>",
"       <td>",
"        Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.",
"       </td>",
"       <td>",
"        Very weak recommendation; other alternatives may be equally reasonable.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5741=[""].join("\n");
var outline_f5_38_5741=null;
var title_f5_38_5742="Womens health initiative risk of heart disease";
var content_f5_38_5742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Women's Health Initiative: Risk of heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 372px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of cumulative hazard rates of CHD. In the Women's Health Initiative, combined estrogen-progestin therapy was associated with a significant increase in coronary events. CHD included nonfatal myocardial infarction and death due to CHD. The overall hazard ratio for CHD was 1.24 (nominal 95% CI, 1.00-1.54).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5742=[""].join("\n");
var outline_f5_38_5742=null;
var title_f5_38_5743="MDI with counter";
var content_f5_38_5743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metered dose inhaler with counter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some MDIs are now manufactured with built-in dose counters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_38_5743=[""].join("\n");
var outline_f5_38_5743=null;
